Index for Years 1970, 1971, and 1972

Volumes 54, 55, and 56

Note: The volume year is in *italic* type. Page numbers of symposium and article titles are in **boldface** type.

SYMPOSIUM TITLES

1970

January	MODERN CHALLENGES IN MEDICINE
March	DIFFICULT MEDICAL PROBLEMS
May	NEW DEVELOPMENTS IN MEDICINE
July	SOPHISTICATED DIAGNOSTIC PROCEDURES
September	EFFICACY OF ANTIMICROBIAL AND ANTIFUNGAL AGENTS
November	CURRENT CONCEPTS IN CLINICAL NUTRITION

1971

January	DISEASES OF THE KIDNEY
March	TREATMENT OF COMMON MEDICAL DISORDERS
May	MEDICAL ASPECTS OF CANCER
July	DIABETES MELLITUS
September	INTENSIVE CARE UNITS
November	MODERN CONCEPTS IN RENAL DISEASE

1972

January	HEMORRHAGIC DISORDERS
March	CLINICAL IMMUNOLOGY
May	THERAPEUTIC PROBLEMS
July	ENDOCRINE DISORDERS
September	VENEREAL DISEASES
November	CLINICAL NEUROLOGY

ABDOMEN, acute, ketoacidosis and, *1971*: July, 1041
Abetalipoproteinemia, jejunal biopsy in, *1970*: July, 856
Abortion, therapeutic, in diabetics, *1971*: July, 972
Abruptio placentae, disseminated intravascular coagulation and, *1972*: Jan., 181
Abscess, liver, prolonged fever and, *1970*: March, 384
lung, penicillins in, *1970*:Sept., 1088
staphylococcal, intravenous hyperalimentation for, *1970*: May, 585
subphrenic, and prolonged fever, *1970*: March, 385
Absorption, disorders of. See *Malabsorption*.
Acanthocytosis, jejunal biopsy in, *1970*: July, 856
Acanthosis nigricans, *1972*: July, 1042
Acetazolamide, thrombocytopenia induced by, *1972*: Jan., 66
Acetylsalicylic acid, blood glucose level and, *1971*: July, 927
platelet function and, *1972*: Jan., 40
surgical bleeding and, *1972*: Jan., 210
Achalasia, esophageal. See under *Esophagus*.
staphylococcal abscess and, intravenous hyperalimentation for, *1970*: May, 585
Achromobacter infections, choice of therapy for, *1970*: Sept., 1162
Acid(s), production and excretion, *1970*: Nov., 1543–1554
Acid-base balance, cardiac arrhythmias and, *1971*: Sept., 1198
evaluation of, *1970*: Nov., 1543
Acid-peptic disease. See also *Peptic ulcer*.
diet in, *1970*: Nov., 1357–1359
hyperparathyroidism and, *1970*: Jan., 132
Acidemia, methylmalonic, dietary control, *1970*: Nov., 1444
fibroblast cultures in, *1970*: May, 705
Acidosis, complicating acute renal failure, *1971*: Jan., 128
diabetic. See *Ketoacidosis*.
in chronic renal failure, management, *1971*: Jan., 142
lactic, coma of, diabetes and, *1971*: July, 914
intensive care for, *1971*: Sept., 1321
metabolic, *1970*: Nov., 1548–1550
renal tubular, dietary control, *1970*: Nov., 1442
cirrhosis and, *1971*: March, 369
in chronic renal failure, *1971*: March, 347
treatment, *1971*: March, 339
Aciduria, orotic, hereditary, dietary control, *1970*: Nov., 1443
xanthurenic, management, *1970*: Nov., 1445
Acne vulgaris, tetracyclines for, *1970*: Sept., 1181
Acromegaly, body compositional studies in, *1970*: Nov., 1475
diabetes and, *1970*: Nov., 1477
glucose intolerance and, *1971*: July, 1058
Acromegaly *(Continued)*
hypertension and, *1971*: Jan., 24
radioimmunoassay of gonadal hormones in, *1970*: July, 1056
ACTH. See *Corticotropin*.
Actinobacillus mallei infections, choice of therapy for, *1970*: Sept., 1163
Activity, caloric requirements and, *1970*: Nov., 1578
limitation of, in chronic heart failure, *1970*: March, 324
Addiction, to drugs, malnutrition and, *1970*: Nov., **1567–1575**
Addison's disease, metabolic and nutritional aspects, *1970*: Nov., 1475, 1486–1488
ADH. See *Hormone(s), antidiuretic*.
Adipose tissue, cell size and number, *1970*: Nov., 1536–1537
insulin response, *1971*: July, 826
metabolism, cell size and, *1970*: Nov., 1538
physiologic studies of, *1970*: May, 749
Adolescents, diabetes mellitus in, *1971*: July, **975–987**
Adoptive immunity, *1972*: March, 465
Adrenal glands, cortex, hypertension and, *1971*: Jan., 31–32
steroids, See *Corticosteroids*.
disorders, neurologic complications, *1972*: July, 1033–1034
pigmentary disturbances, *1972*: July, 1046
hyperplasia, congenital, hypertension and, *1971*: Jan., 40–42
hypertension and, *1971*: Jan., 27–42
hypofunction, hypoglycemia and, *1970*: March, 533
insufficiency, acute, intensive care for, *1971*: Sept., 1324–1326
nutritional disturbances in, *1970*: Nov., 1486–1488
Adrenalectomy, for metastatic breast cancer, *1972*: May, 659
Adrenalin. See *Epinephrine*.
Adrenergic receptors, blockers of, blood glucose level and, *1971*: July, 927
cardiac arrhythmias and, *1971*: March, 289
for angina pectoris, *1971*: March, 428; *1972*: May, 602–603
Adrenocortical carcinoma, treatment with o,p'-DDD, *1972*: July, **999–1012**
Adrenocortical disease, lipid disturbances in, *1972*: July, 1017
Adrenocortical insufficiency, chronic, metabolic and nutritional aspects, *1970*: Nov., 1475, 1486–1488
Adrenocorticoids. See *Corticosteroids*.
Adrenocorticotropic hormone. See *Corticotropin*.
Adrenocorticotropin. See *Corticotropin*.
Adriamycin, in cancer therapy, *1971*: May, 698
thrombocytopenia induced by, *1972*: Jan., 66
Aerosol therapy, for status asthmaticus, *1970*: March, 500

AFC. See *Antibody-forming cell.*
AFP. See *Alpha-fetoprotein.*
Ag. See *Antigen.*
Agammaglobulinemia, alymphocytic (Swiss type), *1970*: March, 288
bone marrow transplantation in, *1972*: March, 445
immunologic aspects, *1972*: March, 296, 325–327
sex-linked recessive (Bruton type), *1970*: March, 285
with thymoma, *1970*: March, 297
Age, as factor in diabetes mellitus, *1971*: July, **835–846**
body fat and, *1970*: Nov., 1369
Aged persons, nutrition in, *1970*: Nov., **1589–1597**
AGS. See *Anti-immunoglobulin serum.*
Airway, artificial, *1971*: March, 451
maintenance, for intensive care, *1971*: Sept., 1219–1223
obstruction, *1971*: March, **445–456**
Akineton. See *Biperiden.*
Alcaligenes infections, choice of therapy for, *1970*: Sept., 1162
Alcohol metabolism, *1970*: Nov., 1568
Alcoholism, hepatitis and, *1971*: March, 386
hypoglycemia and, *1970*: March, 535
liver disease in, nutritional management, *1970*: March, 468–496; Nov., 1464
treatment, *1971*: March, 386
malnutrition and, *1970*: Nov., **1567–1575**
myopathy of, *1970*: May, **723–730**; *1972*: Nov., 1243
pancreatitis and, *1970*: March, 480
polyneuritis of, *1972*: Nov., 1305
tremor of, *1972*: Nov., 1369
Aldomet. See *Methyldopa.*
Aldosterone, sodium-retaining effects, *1971*: Nov., 1510
Aldosteronism, primary, hypertension and, *1971*: Jan., 36
ALG. See *Antilymphocyte globulin.*
Alimentation, intravenous, *1970*: Nov., 1377–1381
Alkaline phosphatase, urinary, *1971*: Nov., 1493
Alkalis, production and excretion, *1970*: Nov., **1543–1554**
Alkaloids, for carcinoma, *1971*: May, 606, 693
for parkinsonism, *1972*: Nov., 1390
Alkalosis, diuretic-induced, *1971*: March, 365
metabolic, *1970*: Nov., 1550–1553
Alkylating agents, experimental use, *1971*: May, 677
in carcinoma, *1971*: May, 606, 688–691
in dermatologic disorders, *1972*: May, 733
thrombocytopenia induced by, *1972*: Jan., 66
Allergic encephalomyelitis, experimental, immunologic mechanisms in, *1972*: March, 516–518
Allergy. See also specific allergens.
immunologic aspects, *1972*: March, 399
prolonged fever and, *1970*: March, 391
Allergy *(Continued)*
to antibiotics, *1970*: Jan., **59–73.** See also *Antibiotics, allergy to;* and specific antibiotics.
to insulin, *1971*: July, 874
Allogeneic leukocyte, lymphocyte response in vitro, *1972*: March, 294–295
Allopurinol (Zyloprim), for gout, *1970*: March, 440
for nephrolithiasis in gout, *1970*: March, 435
Alpha cells of pancreas. See *Pancreas, islet cells.*
Alpha-fetoprotein, in malignant diseases, *1970*: May, **797–803**
Alpha-fetoprotein antigen, *1971*: May, 772
Alpha-methyldopa, for essential hypertension, *1971*: Jan., 16
ALS. See *Antilymphocyte serum.*
Alveolar-capillary block, vs. intractable heart disease, *1970*: March, 314
Alveolar-capillary block syndrome, hypoxia due to, *1970*: May, 619
Alveolar proteinosis, bronchopulmonary lavage for, *1970*: May, 762
Alzheimer's disease, *1972*: Nov., 1407, 1408
Amantadine (Symmetrel), for parkinsonism, *1970*: May, 784; *1972*: Nov., 1389
Amaurosis fugax, cerebrovascular disease and, *1970*: March, 353
Amenorrhea, investigation and classification, *1972*: July, **931–936**
oral contraception and, *1970*: Jan., 167
American Board of Internal Medicine training requirements in medical oncology, *1971*: May, 651
Amethopterin. See *Methotrexate.*
Amines, vasoactive, in acute inflammatory reactions, *1972*: March, 544
Amino acids, metabolism, disorders, dietary control of, *1970*: Nov., 1433–1438
in liver disease, *1970*: Nov., 1456
sulfur-containing, disorders, nutritional management, *1970*: Nov., 1437–1438
Aminoglycosides, allergic reactions to, incidence of, *1970*: Jan., 63
Aminophylline, as bronchodilator, *1971*: March, 450
for status asthmaticus, *1970*: March, 498
Amitriptyline (Elavil), in parkinsonism, *1972*: Nov., 1388
Amnesia, global, transient, cerebrovascular disease and, *1970*: March, 354
Amphetamines, for parkinsonism, *1972*: Nov., 1387
Ampicillin, *1970*: Sept., **1145–1159**
clinical indications, *1970*: Sept., 1148–1154
for urinary tract infection, *1971*: Nov., 1450
in patients with renal disease, *1970*: Sept., 1146, 1154
pediatric use, *1970*: Sept., 1154
serum protein-binding, *1970*: Sept., 1117
spectrum of activity, *1970*: Sept., 1129, 1148

Ampicillin *(Continued)*
toxic reactions, *1970*: Sept., 1154
Ampulla of Vater, retrograde cannulation of, *1972*: May, **781–788**
Amputation, in diabetic vascular disease, *1971*: July, 1052
Amyloidosis, jejunal biopsy in, *1970*: July, 855, 857
multiple myeloma and, *1971*: May, 708
neuropathy of, *1972*: Nov., 1314
primary systemic, immunologic aspects, *1972*: March, 385–386
Amylopectin sulfate, in peptic ulcer disease, *1971*: March, 312
Amyotrophy, diabetic, *1971*: July, 1005
Analgesics, blood glucose level and, *1971*: July, 927
in hemophilia, *1972*: Jan., 113
Anaphylactoid purpura, glomerulonephritis in, *1971*: Nov., 1409
Anaphylactoid reaction, to antibiotics, *1970*: Jan., 61, 62
to penicillins, *1970*: Sept., 1094
to vancomycin, *1970*: Sept., 1281
Anaphylaxis, slow-reacting substance of, *1972*: March, 548
Androgen(s), in cancer therapy, *1971*: May, 684–693; *1972*: May, 658
in postmenopausal and senile osteoporosis, *1972*: July, 992
Anemia, asplastic, chloramphenicol-induced, *1970*: Sept., 1190
platelet transfusion for, *1972*: Jan., 86
Biermer's. See *Anemia, pernicious.*
chronic renal failure and, *1971*: March, 348
complicating home hemodialysis, *1971*: Nov., 1485
complicating renal failure, acute, *1971*: Jan., 129
chronic, *1971*: Jan., 148–149
copper-deficiency, *1970*: Nov., 1512
erythropoietin and, *1970*: Jan., 175–177
hemolytic, due to penicillins, *1970*: Sept., 1094
uremic syndrome and, *1971*: Nov., 1412
in uremia, *1970*: March, 419
iron-deficiency, *1970*: July, **903–915**; Nov., **1406–1412**. See also *Iron, deficiency.*
nutritional, recent advances in, *1970*: May, **631–645**
of renal failure, *1971*: Jan., **3–9**
pernicious, immunity and, *1970*: May, 640
in infancy, dietary management, *1970*: Nov., 1445
juvenile, *1970*: May, 641
vs. thrombocytopenic purpura, *1972*: Jan., 48, 49
red cell 2,3-diphosphoglycerate and, *1970*: May, 736
Anesthetics, carbohydrate metabolism and, *1971*: July, 940
Aneurysm, abdominal, ruptured, intensive care for, *1971*: Sept., 1208
Angiitis, hypersensitivity, glomerulonephritis in, *1971*: Nov., 1409
Angina pectoris, anticoagulants and, *1972*: Jan., 247
coronary arteriography in selection of treatment, *1970*: July, 989–991
intractable, *1970*: March, **333–348**
severe, treatment of, *1972*: May, **599–609**
stable, diagnosis and treatment, *1971*: March, **420–433**
Angioma, recurrent headache with, *1972*: Nov., 1263
Ankylosing spondylitis, nonspecific urethritis and, *1972*: Sept., 1199
Anoxia, cardiac arrest and, *1971*: Sept., 1158
Antacids, in peptic ulcer disease, *1971*: March, 310
Antazoline, blood glucose level and, *1971*: July, 927
Anti-anxiety drugs, in medical practice, *1971*: March, **485–494**
Anti-arrhythmic drugs, *1971*: Sept., 1201
Antibiotics. See also specific drugs.
administration, in patients with renal failure, *1971*: Jan., 130
allergy to, *1970*: Jan., **59–73**
alternate drugs, *1970*: Jan., 69
corticosteroids and antihistamines for, *1970*: Jan., 71
desensitization and, *1970*: Jan., 70
incidence of, *1970*: Jan., 62–64
mechanism of, *1970*: Jan., 64–66
prevention of reactions, *1970*: Jan., 66–68
treatment of reactions, *1970*: Jan., 68–69
alternate, history of allergic reaction and, *1970*: Jan., 69
anticoagulants and, *1972*: Jan., 256
antitumor, *1971*: May, 606
contaminants of, reactions and, *1970*: Jan., 64
empiric therapy with, *1970*: Sept., 1167
for diarrheal disease in children, *1970*: March, 450
for status asthmaticus, *1970*: March, 500
for urinary tract infection, *1970*: March, 402
in cancer therapy, dosage and side-effects, *1971*: May, 689, 693
in dermatologic disorders, *1972*: May, 734
resistance of gonococcus to, *1972*: Sept., **1133–1144**
superinfections, *1970*: Sept., 1170
microbial, *1971*: March, **471–483**
thrombocytopenia induced by, *1972*: Jan., 66
Antibody, circulating humoral, in cancer, *1972*: March, **481–499**
in virus infections, *1972*: March, 355–360
local presentation and immunity, *1972*: March, 394
penicillin allergy and, *1970*: July, 999
production, B lymphocytes in, *1972*: March, 293

Antibody (*Continued*)
production, nutrition and, *1970*: Nov., 1497
tumor-specific, disappearance with metastases, *1972*: March, 492
tests for, *1972*: March, 484–490
Antibody-forming cell (AFC), *1972*: March, 306, 310–314
development, *1972*: March, 321
Anticholinergics, in parkinsonism, *1972*: Nov., 1389
in peptic ulcer disease, *1971*: March, 311
Anticoagulants, Arvin and Reptilase, *1972*: Jan., 182
circulating, *1972*: Jan., **145–151**
current status of, *1972*: Jan., **235–253**
for occlusive cerebrovascular disease, *1972*: Nov., 1294
for transient ischemic attacks, *1970*: March, 356
oral, and coagulation factor deficiencies, *1970*: July, 898
overdosage, hemorrhage and, *1972*: Jan., **263–273**
prophylactic, pulmonary embolism and, *1970*: March, 366
therapy, drugs affecting, *1972*: Jan., **255–262**
Anticonvulsants, thrombocytopenia induced by, *1972*: Jan., 66
Antidepressants, in medical practice, *1971*: March, **485–494**
tricyclic, in parkinsonism, *1972*: Nov., 1388
Antidiuretic hormone, renal response, defect in, *1970*: Nov., 1441
Antifibrinolytic agents, for hemophilia, *1972*: Jan., 111
Antifungal agents, efficacy, *1970*: Sept., **1329–1345**
Antigen(s), Australia, viral hepatitis and, *1970*: May, **805–817**
carcinoma, cell-mediated immune reactions to, *1971*: May, 772–777
differentiation of, *1972*: March, 312
fetal, *1971*: May, 771
hepatitis-associated, chronic hepatitis and, *1971*: March, 383
HL-A, in clinical transplantation, *1972*: March, 341, **403–417**
lymphocyte response in vitro, *1972*: March, 295–297, 309
tests for. See under specific antigens and tests.
transplantation, *1970*: Jan., 45–53; *1972*: March, 341
detection of, *1970*: Jan., 46–52
immunologic tolerance and, *1970*: Jan., 54–55
inheritance of, *1970*: Jan., 52–53
nature and function, *1971*: Jan., 193
tumor-specific, *1971*: May, 763–777; *1972*: May, 801
tests for, *1972*: March, 484–490
Antigen-antibody complexes, composition of, *1972*: March, 530
Antigen-reactive cell (ARC), *1972*: March, 306, 310–314
test for, *1972*: March, 297
Antihemophilic factor (VIII), antibodies to, *1972*: Jan., 145–148
coagulation and, *1972*: Jan., 100
concentrates, for hemophilia, *1972*: Jan., 106–110
von Willebrand's disease and, *1972*: Jan., 278–279
Antihistamines, for allergy to antibiotics, *1970*: Jan., 71
for parkinsonism, *1972*: Nov., 1390
Antihypertensive drugs, *1971*: March, 320–324; *1972*: May, **633–644**
Anti-immunoglobulin serum (AGS), lymphocyte response in vitro, *1972*: March, 294, 297
Antilymphocyte globulin (ALG), after kidney transplants, *1970*: Jan., 87
clinical application, *1972*: March, **419–432**, 457
in bone marrow transplantation, *1972*: March, 435, 436
in kidney transplantation, *1972*: March, 424–427
Antilymphocyte serum (ALS), after kidney transplants, *1970*: Jan., 87
clinical aspects, *1972*: March, 419, 457
Antimetabolites, in carcinoma, *1971*: May, 607
dosage and side-effects, *1971*: May, 688, 691
Antimicrobic drugs, as cause of suprainfection, *1971*: March, **471–483**
choice of therapy for various organisms, *1970*: Sept., 1162
efficacy, symposium on, *1970*: Sept., **1075–1350**
for urinary tract infection, effect of pH on, *1971*: Nov., 1448
Antipurine drugs, thrombocytopenia induced by, *1972*: Jan., 66
Antipyrimadines, thrombocytopenia induced by, *1972*: Jan., 66
Antirheumatic drugs, thrombocytopenia induced by, *1972*: Jan., 66
Anuria, in obstructive uropathy, *1971*: Nov., 1418
Anxiety, depression and, drug therapy in medical practice, *1971*: March, **485–494**
Aorta, coarctation of, cardiac catheterization in, *1970*: July, 978
insufficiency of, cardiac catheterization in, *1970*: July, 977
Aortic valve, disease of, coronary arteriography in, *1970*: July, 988
stenosis of, cardiac catheterization in, *1970*: July, 974
Aplastic anemia, chloramphenicol-induced, *1970*: Sept., 1190
platelet transfusion for, *1972*: Jan., 86
Apomorphine, for parkinsonism, *1972*: Nov., 1388
Apoproteins, in plasma lipid transport, *1970*: Nov., 1384
Appetite, regulating mechanism, obesity and, *1972*: July, 1024
Apresoline. See *Hydralazine*.
Arabinosylcytosine. See *Cytosine arabinoside*.

Arbovirus, renal disease and, *1971*: Jan., 92
Arbovirus encephalitis, *1972*: Nov., 1393–1398
ARC. See *Antigen-reactive cells.*
Arfonad. See *Trimethaphan camphorsulfonate.*
Armed Forces, venereal disease in, *1972*: Sept., **1087–1100**
Arrhythmia(s), adrenergic blocking agents and, *1971*: March, 289
  after myocardial infarction, *1971*: March, 273–293
  atrial, paroxysmal, *1972*: May, **611–614**
  causes, *1971*: Sept., 1198
  chronic, complicating heart failure, *1970*: March, 318, 323
  electrolyte imbalance and, *1971*: Sept., 1197
  management, in intensive care unit, *1971*: Sept., **1196–1202**
  procainamide for, *1971*: March, 439
  propranolol for, *1971*: March, 275, 287, 441
  quinidine for, *1971*: March, 438
  therapy for, *1971*: Sept., 1200
    basic considerations, *1971*: March, **435–444**
  ventricular, in ambulatory patients, *1972*: May, **615–624**
Artane. See *Trihexyphenidyl.*
Arteriography, coronary, indications for, *1970*: July, **979–995**
  of pancreas, *1970*: March, 485
  pulmonary, in pulmonary embolism, *1970*: March, 365
  renal, in renovascular hypertension, *1971*: Nov., 1432
Arteriosclerosis, cerebral, pathogenesis of, *1970*: March, 352
Arteritis, temporal, *1972*: Nov., 1264
Artery(ies), peripheral, disease, anticoagulants and, *1972*: Jan., 247
  renal, stenosis, hypertension of, diagnosis, *1971*: Nov., **1429–1438**
Arthritis, gonococcal, *1972*: Sept. 1122–1123
    penicillins for, *1970*: Sept., 1090
  nonspecific urethritis and, *1972*: Sept., 1198
  rheumatoid, Arthus reaction and, *1972*: March, 535
    as immune complex disease, *1972*: March, **529–539**
    virus and, *1972*: March, 367
  rubella virus and, *1972*: March, 364
  septic, oxacillin and cloxacillin for, *1970*: Sept., 1134
Arthropathy, neurogenic, diabetes mellitus and, *1971*: July, 1004
Arthus reaction, mechanism of, *1972*: March, 530–531
  rheumatoid arthritis and, *1972*: March, 535
Arvin, blood defibrination by, *1972*: Jan., 182
Ascites, in liver disease, dietary control, *1970*: Nov., 1466
Ascites *(Continued)*
  intensive care for, *1971*: Sept., 1295
  tense, treatment, *1971*: March, 370
Ascorbic acid deficiency, osteoporosis and, *1970*: Jan., 145
L-Asparaginase, in cancer therapy, *1971*: May, 684–693
  in leukemia, *1971*: May, 586, 590
  neurological complications, *1971*: May, 642
  thrombocytopenia induced by, *1972*: Jan., 66
Aspiration, of joints, in hemophilia, *1972*: Jan., 111–112
Aspiration pneumonia, penicillins for, *1970*: Sept., 1088
Aspirin, blood glucose level and, *1971*: July, 927
  platelet function and, *1972*: Jan., 40
  surgical bleeding and, *1972*: Jan., 210
Asterixis, *1972*: Nov., 1370
Asthma, acute, vs. intractable heart failure, *1970*: March, 312
  bronchial, airway obstruction in, *1971*: March, 446
    bronchopulmonary lavage for, *1970*: May, 765
  status asthmaticus, *1970*: March, **493–509**
Ataractic drugs, in medical practice, *1971*: March, **485–494**
Ataxia-telangiectasia, *1970*: March, 293
  immunologic aspects, *1972*: March, 326
Atelectasis, intensive care management, *1971*: Sept., 1303–1306
  right-to-left shunt due to, *1970*: May, 626
Atherogenesis, cerebral, *1970*: March, 352
Atherosclerosis, cerebral, diabetes mellitus and, *1971*: July, 1005
  dietary management, *1970*: Nov., 1449–1452
  hyperlipidemia in, dietary and drug therapy, *1970*: May, **657–669**
  lipid alterations in, *1970*: Nov., 1450
Athetosis, *1972*: Nov., 1327–1328
Atrial fibrillation, chronic, *1970*: March, 325
  paroxysmal, *1972*: May, **611–614**
Atrium, septal defects, cardiac catheterization in, *1970*: July, 975–976
Atromid S. See *Clofibrate.*
Atropine, for cardiac arrhythmia, *1971*: March, 277
  for parkinsonism, *1972*: Nov., 1390
Australia antigen, viral hepatitis and, *1970*: May, **805–817**
Autoimmune disorders, *1972*: March, 328–330
  antilymphocyte globulin for, *1972*: March, 428
  myasthenia gravis and, *1972*: March, 522
  neurologic disorders and, *1972*: March, 515
Autoimmunity, exophthalmic goiter and, *1970*: Jan., 120–123
  idiopathic thrombocytopenic purpura and, *1972*: Jan., 53–54
  skin disease and, *1970*: Jan., **95–105**

Autoimmunity *(Continued)*
thyroid disease and, *1970*: Jan., 120
Automated medical history, *1970*: July, 828
Automated personality assessment, *1970*: July, **835–849**
Azaribine (Triazure), in dermatologic disorders, *1972*: May, 733
Azathioprine (Imuran), after kidney transplants, *1970*: Jan., 84
in dermatologic disorders, *1972*: May, 732
myoglobinuria and, *1972*: Nov., 1243–1244
thrombocytopenia induced by, *1972*: Jan., 66
Azotemia, dietary control, *1970*: Nov., 1453
during tetracycline therapy, *1970*: Sept., 1182

B LYMPHOCYTE. See *Lymphocyte, thymus-independent.*
Bacilluria, chronic, tetracyclines for, *1970*: Sept., 1180
Bacitracin, *1970*: Sept., 1291–1292
Bacteremia, gram-negative, diabetes and, *1971*: July, 934
gentamicin for, *1970*: Sept., 1312
oxacillin and cloxacillin for, *1970*: Sept., 1133
Bacteria, diarrhea and, *1970*: March, 445–446
gram-negative antibacterials for, *1970*: Sept., 1167
infections, in carcinoma, *1971*: May, 733–738
Bacterial endocarditis. See under *Endocarditis.*
Bacteriuria, diagnosis and treatment, *1971*: Nov., **1439–1456**
in children, long-term sulfonamide therapy for, *1970*: Sept., 1080
in diabetics, *1971*: July, 933
during pregnancy, *1971*: July, 966
Bacteroides infections, ampicillin for, *1970*: Sept., 1153
tetracyclines for, *1970*: Sept., 1179
Balanoposthitis, candidal, nystatin for, *1970*: Sept., 1336
Barbiturates, blood glucose level and, *1971*: July, 927
metabolism, *1970*: Nov., 1569
Basement membrane, capillary, in diabetes mellitus, *1971*: July, **847–860**, 894
glomerular, antibody reactive to, ALG therapy and, *1972*: March, 422
diabetes and, *1971*: July, 895
Basilar artery insufficiency, *1972*: Nov., 1264
Basilar artery migraine, *1972*: Nov., 1262
BCNU, in cancer therapy, *1971*: May, 684–693, 697
Behavior therapy, for obesity, *1970*: May, 752
Behçet syndrome, vs. herpes genitalis, *1972*: Sept., 1184, 1185
Benadryl. See *Diphenhydramine.*
Benemid. See *Probenecid.*
Benzathine penicillin, hypersensitivity reactions, *1970*: Sept., 1094
Benzatropine methanesulfonate (Cogentin), for parkinsonism, *1972*: Nov., 1390
Benziodarone, anticoagulants and, *1972*: Jan., 258
Benzylpenicillin. See *Penicillin G.*
Benzylpenicilloyl-polylysine, in skin test of penicillin allergy, *1970*: July, 1001, 1004; Sept., 1097
Beta-lipoproteins, plasma transport, *1970*: Nov., 1385
BF. See *Blastogenic factor.*
Bicarbonate therapy, in diabetic ketoacidosis, *1971*: July, 907
Biermer's anemia. See *Anemia, pernicious.*
Biguanides, in diabetes mellitus, *1971*: March, 300
Biliary tract, diseases, pancreatitis and, *1970*: March, 480
Binswanger's encephalopathy, *1972*: Nov., 1411
Biopsy, bone marrow, in iron deficiency states, *1970*: Nov., 1405
jejunal, *1970*: July, **851–862**
lung, transbronchoscopic, *1970*: July, **951–959**
transthoracic (needle), *1970*: July, **961–971**
muscle, in diagnosis of diabetes mellitus, *1971*: March, 297
renal, during pregnancy, *1971*: Jan., 48
thyroid, in Hashimoto's thyroiditis, *1972*: July, 894
Biperiden (Akineton), in parkinsonism, *1972*: Nov., 1390
Birth weight, low, cerebral palsy and, *1972*: Nov., 1273
Bishydroxycoumarin, blood glucose level and, *1971*: July, 927
Blastogenic factor (BF), *1972*: March, 340
Bleeding. See *Hemorrhage.*
Bleeding time test, *1970*: July, 890; *1972*: Jan., 35
in von Willebrand's disease, *1972*: Jan., 276–277
Bleomycin, *1972*: May, 734
in cancer therapy, *1971*: May, 698
thrombocytopenia induced by, *1972*: Jan., 66
Blister, diabetes mellitus and, *1971*: July, 1027
Blocking agents. See *Adrenergic receptors, blockers of.*
Blood, cells. See also under names of cells.
differentiation of, erythropoietin and, *1970*: Jan., 174
kinetics of, *1971*: May, 576
coagulation. See *Coagulation.*
dyscrasias, due to chloramphenicol, *1970*: Sept., 1189, 1190
elements. See under specific names.
examination, iron-deficiency anemia and, *1970*: July, 904
flow, peripheral, monitoring for intensive care, *1971*: Sept., 1210

Blood *(Continued)*
gases, in cardiogenic shock, *1971*: Sept., 1187–1189
in pulmonary embolism, *1970*: March, 365
in status asthmaticus, *1970*: March, 495–497
measurement, clinical interpretation of, *1970*: May, **617–629**
glucose. See also *Glucose*.
control in diabetes mellitus, *1971*: March, 298
determinations, in capillary vs. venous blood, *1971*: July, 795
drugs lowering, *1971*: July, 927
lipids. See *Lipids*.
platelet-rich, for transfusion, *1972*: Jan., 82
platelets. See *Platelets*.
pressure, arterial, in cardiogenic shock, *1971*: Sept., 1186
monitoring for intensive care, *1971*: Sept., 1141–1143
central venous, in cardiogenic shock, *1971*: Sept., 1186
in myocardial infarction, *1970*: Jan., 238–239
monitoring for intensive care, *1971*: Sept., 1143–1145
diabetes mellitus and, *1971*: July, 1046
high. See *Hypertension*.
low. See *Hypotension*.
monitoring, equipment for, *1971*: Sept., 1113
reduction of, hazards in, *1971*: March, 317
storage, oxygen affinity and, *1970*: May, 739
tests, in study of Burkitt's lymphoma, *1971*: May, 764–765
nuclear medicine in, *1971*: May, 555
urea nitrogen, glomerular filtration rate and, *1971*: March, 343
venous oxygen saturation, monitoring for intensive care, *1971*: Sept., 1149
vessels, major, injury to, intensive care for, *1971*: Sept., 1208
volume, monitoring, for intensive care, *1971*: Sept., 1145
Blood-tissue barrier, in acute inflammatory reactions, *1972*: March, 542
Body composition, as measure of energy stores, *1970*: Nov., 1367
measurement, *1970*: Nov., 1371
Body fluids. See *Fluids*.
Body image disturbances, in obesity, *1970*: May, 751
Body temperature, as sign of hypothyroidism, *1972*: July, 874
in central nervous system disease, *1971*: Sept., 1245
monitoring, equipment for, *1971*: Sept., 1116
for intensive care, *1971*: Sept., 1152
Body weight. See also *Obesity*.
in diabetes mellitus, management, *1971*: March, 299
Body weight *(Continued)*
monitoring, for intensive care, *1971*: Sept., 1150–1152
Bone, changes, in hyperparathyroidism, *1970*: Jan., 134–135
density, determination of, in metabolic bone disease, *1970*: July, 1067–1069
disorders, complicating chronic renal failure, *1971*: Jan., 144–146
metabolic, tests for, *1970*: July, **1061–1070**
renal insufficiency and, *1972*: July, 962, 964–965
lesions, chronic renal failure and, *1971*: March, 349
maturation, delays in, hypothyroidism and, *1972*: July, 874
metabolism, fluoride and, *1970*: Nov., 1559
osteoporosis and, *1970*: Jan., **141–152**
metastases, from breast cancer, *1972*: May, 655
Bone marrow, biopsy, in iron deficiency states, *1970*: Nov., 1405
depression, due to chloramphenicol, *1970*: Sept., 1190
examination, for iron, *1970*: July, 910
scanning, *1971*: May, 548
radioactive colloids in, *1971*: May, 556
transplantation, *1972*: March, **433–451**
antilymphocyte globulin therapy with, *1972*: March, 428
donor selection, *1972*: March, 434
mixed leukocyte culture in, *1972*: March, 342
rejection in, *1972*: March, 434–436
selective depletion of immunocompetent cells, *1972*: March, 461–462
Borrelia infections, tetracyclines for, *1970*: Sept., 1179
Bowel. See also *Intestines*.
compromise, management, *1971*: Sept., 1215
congenital atresia of, intravenous hyperalimentation for, *1970*: May, 587
resection, mesenteric vein thrombosis with, intravenous hyperalimentation for, *1970*: May, 585
short, medium-chain triglycerides in, *1970*: Nov., 1375
BPPL. See *Benzyl penicilloylpolylysine*.
Brachial neuritis, acute, *1972*: Nov., 1312
Brain, dopamine deficiency, in parkinsonism, *1972*: Nov., 1377
function, nutrition and, *1970*: Nov., 1421–1428
growth fetal, critical periods in, *1970*: Nov., 1419
measurement, *1970*: Nov., 1420
physicochemical, *1970*: Nov., 1414–1421
lesions, location and clinical signs, *1971*: Sept., 1234–1245
metastases, *1971*: May, 625–631
physicochemical changes, *1970*: Nov., 1419–1421
scanning, *1971*: May, 547

Brain *(Continued)*
tumor, headache of, *1972*: Nov., 1264
weight, malnutrition and, *1970*: Nov., 1419
Branched-chain ketonuria. See *Maple syrup urine disease.*
Breast carcinoma, combination chemotherapy, *1971*: May, 696
metastatic, *1972*: May, **651–664**
screening patients for second tumor, *1971*: May, **527–544**
thermography in, *1970*: May, 606–611
viruses and, *1972*: March, 366
Breast-feeding, importance in undernourished populations, *1970*: Nov., 1427
Breathing. See also *Respiration.*
disturbances, brain lesions and, *1971*: Sept., 1238
Bretylium tosylate, for cardiac arrhythmias, *1971*: March, 442
Bricker hypothesis, *1971*: March, 343
Broad-beta lipoproteinemia, diagnosis and diet therapy, *1970*: Nov., 1396
Bronchial asthma. See *Asthma, bronchial.*
Bronchiectasis, tetracyclines for, *1970*: Sept., 1180
Bronchitis, acute, ampicillin for, *1970*: Sept., 1149
chronic, airway obstruction in, *1971*: March, 445
tetracyclines for, *1970*: Sept., 1180
Bronchogenic carcinoma, detection of, *1970*: May, **549–553**
Bronchopulmonary lavage, *1970*: May, **755–771**
Bronchoscopy, lung biopsy via, *1970*: July, **951–959**
Bronchospasm, corticosteroids for, *1971*: March, 450
management, *1971*: March, 447
Brucellosis, choice of therapy for, *1970*: Sept., 1163, 1164
tetracyclines for, *1970*: Sept., 1179
Bruton type agammaglobulinemia, *1970*: March, 285
Bullous pemphigoid, autoimmunity and, *1970*: Jan., 100–104
Burkitt's lymphoma, chemotherapy for, *1971*: May, 685
immunologic aspects, *1971*: May, 763–771; *1972*: March, 366, 504
Burns, Curling's ulcer and, intensive care for, *1971*: Sept., 1277–1279
disseminated intravascular coagulation and, *1972*: Jan., 181
sepsis, gentamicin for, *1970*: Sept., 1314
Bursa of Fabricius, *1972*: March, 306, 320
Busulfan, in cancer therapy, *1971*: May, 684–693
thrombocytopenia induced by, *1972*: Jan., 66
Butazolidin. See *Phenylbutazone.*

CACHEXIA, cardiac, complicating heart failure, *1970*: March, 319
Cadmium, nutritional significance of, *1970*: Nov., 1527
Cajal-Retzius cells, *1970*: Nov., 1419
Calcitonin, for postmenopausal and senile osteoporosis, *1972*: July, 993
Calcium, balance, in thyrotoxicosis, *1970*: Nov., 1482
gastrointestinal absorption, abnormal, *1972*: July, 962–964
altering, *1972*: July, 953–954, 958
metabolism, disorders of, in uremia, *1970*: March, 421–425; *1971*: Nov., 1387–1390
oral, for postmenopausal and senile osteoporosis, *1972*: July, 992
insufficiency, in chronic renal failure, *1971*: March, 348
radioactive, in tests for metabolic bone disease, *1970*: July, 1061–1063
renal excretion, increasing, *1972*: July, 954
serum, hyperparathyroidism and, *1970*: Jan., 132
screening, hyperparathyroidism and, *1970*: March, 516–517
urine, parathyroid hormone and, *1972*: July, 945
hyperparathyroidism and, *1970*: Jan., 135
California virus encephalitis, *1972*: Nov., 1395
Caloric balance, positive. See *Obesity.*
Caloric intake, in acute renal tubular insufficiency, *1971*: March, 338
Caloric requirements, activity and, *1970*: Nov., 1578
Caloric stores, variability of, *1970*: Nov., 1368
Candida albicans, vaginal infection, *1972*: Sept., 1110
Candidiasis, diabetes mellitus and, *1971*: July, 935
mucocutaneous, chronic, immunologic aspects, *1972*: March, 474
nystatin for, *1970*: Sept., 1329–1337
Capillaria philippinensis infestation, jejunal biopsy and, *1970*: July, 860
Capillary basement membrane, in diabetes mellitus, *1971*: July, **847–860**, 894
Capillary fragility test, *1970*: July, 890
Carbenicillin, for urinary tract infection, *1971*: Nov., 1451
Carbenoxolone, for peptic ulcer disease, *1971*: March, 312
Carbohydrate(s), disorders, nutritional management, *1970*: Nov., 1438–1441
glucose tolerance and, *1971*: July, 881
intolerance, capillary basement membrane thickening and, *1971*: July, 853–857
causes, *1971*: March, 296
metabolism, anesthetic drugs and, *1971*: July, 940
disturbances, in celiac disease, *1970*: May, 651
in uremia, *1971*: Nov., 1391–1393
estrogens and, *1971*: July, 950
in liver disease, *1970*: Nov., 1457
in pregnancy, *1971*: July, 947–951
oral contraception and, *1970*: Jan., 166

Carbohydrate(s) *(Continued)*
metabolism, pheochromocytoma and, *1970*: Nov., 1489
pregnancy and, *1971*: July, 947–951
requirements, for diabetics, *1970*: Nov., 1579
Carbon dioxide, for acute cerebrovascular disease, *1970*: March, 357
Carbuncle, renal, and prolonged fever, *1970*: March, 386
Carbutamide, thrombocytopenia induced by, *1972*: Jan., 66
Carcinoembryonic antigen, *1971*: May, 771
Carcinoid, malignant, 5-HIAA excretion in, *1971*: May, 616
Carcinoma, adrenocortical, treatment with o,p′-DDD, *1972*: July, **999–1012**
antigens, cell-mediated immune reactions to, *1971*: May, 772–777
antiviral activity and, *1971*: May, 721–728
bacterial infection with, *1971*: May, 733–738
causes, in vitro study, *1971*: May, **653–665**
cerebral metastases, *1971*: May, 625–631
chemically induced, *1971*: May, 659
chemotherapy. See under *Chemotherapy*.
circulating humoral antibodies in, *1972*: March, **481–499**
colorectal, investigation and treatment, *1972*: May, **665–675**
complicating celiac disease, *1970*: May, 655
complications, infectious, *1971*: May, **729–745**
neurologic, *1971*: May, **625–646**
nonmetastatic, *1971*: May, 639–645
cystathionine excretion in, *1971*: May, 615
dementia with, *1972*: Nov., 1415
diagnosis, biochemical procedures, *1971*: May, **613–624**
enzyme assays, *1971*: May, 619
nuclear materials in, *1971*: May, **545–560**
skin tests in, *1971*: May, 775
fever with, *1971*: May, 732
fungus infection with, *1971*: May, 739–742
ganglioradiculitis in, *1971*: May, 644
hepatocellular, alpha-fetoprotein in, *1970*: May, 798–802
hypercalcemia and, *1972*: July, 943–944
immunity, failure of, *1972*: March, 493
tests for, *1972*: March, 484–492
immunologic aspects, *1971*: May, 731, **761–785**
future of, *1972*: May, **801–836**
immunologic deficiency states and, *1972*: March, **501–514**
immunotherapy for, *1971*: May, 778–782; *1972*: March, 475–476
increased susceptibility to infection in, *1972*: March, 362
interferon induction in, *1971*: May, **721–728**
Carcinoma *(Continued)*
ionizing radiation as cause, *1971*: May, 661
localization of tumor, radionuclides in, *1971*: May, 557
medical aspects (symposium), *1971*: May, **525–785**
meningeal infiltration, diagnosis and treatment, *1971*: May, 636–639
metastatic, delayed, *1972*: March, 482
neurologic effects, remote, *1971*: May, 643
of breast, combination chemotherapy, *1971*: May, 696
screening patients for second tumor, *1971*: May, **527–544**
metastatic, *1972*: May, **651–664**
thermography in, *1970*: May, 606–611
of gastrointestinal tract, cell proliferation and differentiation, *1971*: May, **601–612**
chemotherapy, *1971*: May, 606
of kidney, and prolonged fever, *1970*: March, 387
of lung, detection of, *1970*: May, **549–553**
of pancreas, diabetes mellitus and, *1971*: July, 1039
glucose intolerance and, *1971*: July, 1062
of prostate, serum acid phosphatase level in, *1971*: May, 619
palliation, chemotherapy in, *1971*: May, 686
peripheral nerve metastases, diagnosis and treatment, *1971*: May, 635
polyneuritis and, *1972*: Nov., 1316
predisposition to, *1971*: May, 563
roentgen therapy, *1971*: May, **747–760**
serum alkaline phosphatase levels in, *1971*: May, 620
spinal cord metastases, *1971*: May, 631–635
spontaneous regression, *1972*: March, 483
training of internists in, *1971*: May, **647–652**
treatment, evaluation of, biochemical procedures, *1971*: May, **613–624**
virus as cause of, *1971*: May, 656; *1972*: March, 354, 365–367
virus infection with, *1971*: May, 742
Carcinomatosis, disseminated intravascular coagulation and, *1972*: Jan., 181
Cardiac. See also *Heart*.
Cardiac arrest, etiology, *1971*: Sept., 1158
in children, management, *1971*: Sept., 1273
Cardiac arrhythmia. See *Arrhythmia(s)*.
Cardiac cachexia, complicating heart failure, *1970*: March, 319
Cardiac conduction, electrophysiology of, *1971*: March, 435–438
Cardiac death, sudden, prevention and treatment, *1972*: May, **625–631**
Cardiac output, measuring, *1971*: Sept., 1189
monitoring for intensive care, *1971*: Sept., 1147–1149

Cardiogenic shock, causes, *1971*: Sept., 1185
intensive care after, *1971*: Sept., **1183–1191**
Cardiopulmonary resuscitation. See under *Resuscitation.*
Cardiopulmonary system, uremic manifestations in, *1971*: March, 351
Cardiospasm. See *Esophagus, achalasia.*
Cardiovascular system, diseases, nutrition and, *1970*: Nov., **1449–1454**
disorders, in uremia, *1970*: March, 415–419
with hemophilia, management of, *1972*: Jan., 114
Cardioversion, for atrial fibrillation, *1972*: May, 614
Carditis, gonococcal, *1972*: Sept., 1119–1120
Caries, dental, diet and, *1970*: Nov., 1560
Carotenemia, diabetes mellitus and, *1971*: July, 1024
Carotid artery, insufficiency, *1972*: Nov., 1264
cerebrovascular disease and, *1970*: March, 353
internal, aneurysm of, recurring headache and, *1972*: Nov., 1263
Carotid sinus stimulation, for angina pectoris, *1971*: March, 429; *1972*: May, 604
Cataracts, in diabetes mellitus, *1971*: July, 895
Catecholamines, in Parkinson's syndrome, *1972*: May, 696–698
tumors secreting, hypertension and, *1971*: Jan., 27–31
urinary, in neuroblastoma, *1971*: May, 614
Catheterization, cardiac, indications for, *1970*: July, **973–978**
subclavian vein, in intravenous hyperalimentation, *1970*: May, 578
CEA. See *Carcinoembryonic antigen.*
Celiac disease. See *Sprue, nontropical.*
Cells. See also specific types.
adipose tissue, size and number, *1970*: Nov., 1536–1537
Cajal-Retzius, *1970*: Nov., 1419
cancer, loss of contact inhibition, *1971*: May, 653
proliferation, experimental studies in leukemia, *1971*: May, 567–576
cultured, *1970*: May, **701–712**
function, potassium and, *1971*: March, 503
leukemic, cytokinetics of, *1971*: May, 576–586
Cellulitis, penicillins for, *1970*: Sept., 1087
Central nervous system. See *Nervous system, central.*
Cephalexin, *1970*: Sept., **1229–1244**
clinical pharmacology, *1970*: Sept., 1236
for urinary tract infection, *1971*: Nov., 1452
spectrum of activity, *1970*: Sept., 1232
toxic reactions, *1970*: Sept., 1240–1242
Cephaloglycin, *1970*: Sept., 1217, 1223
for urinary tract infection, *1971*: Nov., 1450
Cephaloridine, *1970*: Sept., 1217, 1220–1223
for syphilis in pregnancy, *1972*: Sept., 1157
nephrotoxicity, *1970*: Sept., 1222
Cephalosporins, *1970*: Sept., **1217–1228**
allergic reactions to, incidence of, *1970*: Jan., 62
Cephalothin (Keflin), *1970*: Sept., 1217, 1218–1220
for urinary tract infection, *1971*: Nov., 1451
spectrum of activity, *1970*: Sept., 1129
Cerebellum, degeneration due to cancer, *1971*: May, 644
Cerebral arteriosclerosis, dementia with, *1972*: Nov., 1411
pathogenesis, *1970*: March, 352
Cerebral atherogenesis, *1970*: March, 352
Cerebral edema, diabetic ketoacidosis and, *1971*: July, 908, 917
Cerebral ischemia, pathogenesis of, *1970*: March, 352–355
Cerebral palsy, *1972*: Nov., **1273–1279**
athetosis of, *1972*: Nov., 1328
Cerebrospinal fluid, gamma globulin, in multiple sclerosis, *1972*: Nov., 1344–1346
Cerebrovascular accident, athetosis after, *1972*: Nov., 1327
Cerebrovascular disease, anticoagulation and, *1972*: Jan., 243
current concepts, *1970*: March, **349–360**
occlusive, *1972*: Nov., **1281–1297**
Cervix, carcinoma of, herpes genitalis and, *1972*: Sept., 1190
viruses and, *1972*: March, 366
gonococcal infection of, complications, *1972*: Sept., **1115–1125**
Cesarean section, in pregnant diabetics, *1971*: July, 971
Chancroid, vs. herpes genitalis, *1972*: Sept., 1184, 1187
Charcoal, T_4 saturation and adsorption on, *1972*: July, 852–854
Chediak-Higashi syndrome, infections in, *1970*: May, 720
Chemical mediators of acute inflammatory and hypersensitivity reactions, *1972*: March, **541–556**
Chemicals, cancer due to, *1971*: May, 659
Chemotaxis, leukocyte, disorder of, serum inhibitor and, *1970*: May, 719
Chemotherapy. See also names of specific agents, as *Chlorambucil.*
of carcinoma, altered host resistance due to, *1971*: May, 731
experimental, *1971*: May, **667–682**
multiple drug, *1971*: May, 609, 696
neurologic complications, *1971*: May, 641
present status, *1971*: May, **683–701**
of gastrointestinal carcinoma, *1971*: May, 606
of Hodgkin's disease, *1971*: May, 696
immunologic deficiency and, *1970*: March, 298
of leukemia, cell kinetics and, *1971*: May, 583

Chemotherapy *(Continued)*
of leukemia, cell proliferation studies and, *1971*: May, 572–576
recent advances, *1971*: May, 564–566
Chest, flail, intensive care management, *1971*: Sept., 1306–1308
pain, coronary arteriography in, *1970*: July, 982
reflux esophagitis and, *1972*: May, **771–780**
trauma, intensive care management, *1971*: Sept., **1301–1313**
Childhood, early malnutrition in, *1970*: Nov., 1419
Children, diabetes mellitus in, *1971*: July, 802, **975–987**
diarrheal disease in, *1970*: March, **443–453**
hypothyroidism in, *1972*: July, **871–884**
intensive care of, *1971*: Sept., **1263–1275**
meningitis in, ampicillin for, *1970*: Sept., 1149
otitis media in, ampicillin for, *1970*: Sept., 1148
penicillins for, *1970*: Sept., 1087
streptomycin dosage in, *1970*: Sept., 1166
urinary screening tests in, *1971*: Nov., **1457–1471**
Chloasma, *1972*: July, 1043
Chloral hydrate, anticoagulants and, *1972*: Jan., 259
Chlorambucil, in cancer therapy, *1971*: May, 684–693
thrombocytopenia induced by, *1972*: Jan., 66
Chloramphenicol, *1970*: Sept., **1187–1197**
allergic reactions to, incidence, *1970*: Jan., 63
anticoagulants and, *1972*: Jan., 257
as alternate to penicillins, *1970*: Sept., 1193
blood dyscrasias from, *1970*: Sept., 1189, 1190
blood glucose level and, *1971*: July, 927
clinical indications, *1970*: Sept., 1191–1194
for urinary tract infection, *1971*: Nov., 1450
spectrum of activity, *1970*: Sept., 1189, 1193
thrombocytopenia induced by, *1972*: Jan., 66
Chlordiazepoxide, thrombocytopenia induced by, *1972*: Jan., 66
Chlorobutanol, anticoagulants and, *1972*: Jan., 259
Chloromycetin. See *Chloramphenicol.*
Chlorothiazide, thrombocytopenia induced by, *1972*: Jan., 66
Chlorpromazine, thrombocytopenia induced by, *1972*: Jan., 66
Chlorpropamide (Diabinese), hypoglycemia and, *1970*: March, 536
skin reactions, *1971*: July, 1026
thrombocytopenia induced by, *1972*: Jan., 66
Chlortetracycline, *1970*: Sept., 1174, 1175
Cholangiography, percutaneous transhepatic, *1970*: July, **875–879**
Cholecystitis, diabetes mellitus and, *1971*: July, 1040
diet and, *1970*: Nov., 1362
Cholecystomegaly, diabetes mellitus and, *1971*: July, 1040
Cholera, tetracyclines for, *1970*: Sept., 1179
Cholera-like syndrome and pancreatic islet cell tumors, *1970*: May, **567–575**
Cholestasis, chronic, pruritus of, *1972*: May, 762–765
Cholesterol, concentration, tests for, *1970*: July, **1029–1035**
plasma, atherosclerotic cardiovascular disease and, *1970*: Nov., 1450
transport, physiology of, *1970*: Nov., 1384–1386
Cholestyramine, anticoagulants and, *1972*: Jan., 256
for pruritus of biliary cirrhosis, *1971*: March, 374
Choloxin. See *Dextrothyroxine.*
Chordae tendineae, rupture of, complicating heart failure, *1970*: March, 320
Chorea, *1972*: Nov., 1323–1327
Huntington's, dementia in, *1972*: Nov., 1407, 1410
Christmas factor (IX), coagulation and, *1972*: Jan., 100
Chromaffin tissue, glucagon and, *1970*: Jan., 186
Chromium, nutritional importance, *1970*: Nov., 1520–1523
Chromosomes, analysis, in clinical medicine, *1970*: July, **1009–1027**
Chylomicronemias, eruptive xanthomas with, *1970*: Nov., 1387
treatment, *1970*: Nov., 1604
Chylomicrons, plasma transport, *1970*: Nov., 1384
Cinchopen, anticoagulants and, *1972*: Jan., 258
Circulation, extracorporeal, disseminated intravascular coagulation and, *1972*: Jan., 181
hemorrhage during and after, *1972*: Jan., 210
Cirrhosis, ascites and, vs. intractable heart disease, *1970*: March, 314
biliary, pruritus and, treatment, *1971*: March, 373
steatorrhea in, *1970*: Nov., 1458
malnutrition and, *1970*: March, 469
of liver, diabetes mellitus and, *1971*: July, 1040
intensive care for, *1971*: Sept., 1293
mineral metabolism in, *1970*: Nov., 1461
renal tubular acidosis with, *1971*: March, 369
Citrullinemia, fibroblast cultures in, *1970*: May, 704
Claudication, diabetes mellitus and, *1971*: July, 1046
Climacteric, management of, *1972*: May, **789–800**
Clindamycin and clinimycin, *1970*: Sept., 1300

Clinical medicine, drug interactions in, *1972*: May, **585–597**
hypnotherapy in, *1972*: May, **687–692**
Clofibrate (Atromid S, CPIB), anticoagulants and, *1972*: Jan., 257
for hyperlipoproteinemia, *1970*: Nov., 1605–1612
side-effects, *1970*: Nov., 1611
Clonal selection therapy of immunity, *1972*: March, 455
Clostridia infections, erythromycin for, *1970*: Sept., 1208
tetracyclines for, *1970*: Sept., 1180
Clot retraction test, *1972*: Jan., 36
for fibrinolytic disorders, 167
Clotting, blood. See *Coagulation.*
Cloxacillin, *1970*: Sept., **1127–1143**
clinical indications, *1970*: Sept., 1133
preparations and dosage, *1970*: Sept., 1136, 1137
serum protein-binding, *1970*: Sept., 1117
spectrum of activity, *1970*: Sept., 1129
toxic reactions, *1970*: Sept., 1135
Clubbing, cyanosis and, due to right-to-left shunts, *1970*: May, 625
Cluster headache, *1972*: Nov., 1262
CMI. See *Immune response, cell-mediated.*
CNS. See *Nervous system, central.*
Coagulation, fibrinolysis and, intravascular, syndrome of, *1970*: July, 898
"cascade" or "waterfall" theory, *1972*: Jan., 96
current, research problems, *1972*: Jan., 4
defects, after liver surgery, *1972*: Jan., 217
after massive transfusion, *1972*: Jan., 214
uremia and, *1972*: Jan., 222–223
disseminated intravascular, *1972*: Jan., **177–191**
diagnosis and treatment of, *1970*: May, **555–565;** *1971*: Sept., 1213
heparin for, *1972*: Jan., **193–200**
platelet transfusion for, *1972*: Jan., 88
vs. idiopathic thrombocytopenic purpura, *1972*: Jan., 49
early history of, *1972*: Jan., 10
extrinsic pathway, *1972*: Jan., 98
factors, concentrates, for hemophilia, *1972*: Jan., 106–110
deficiencies, *1972*: Jan., **119–125, 127–132**
terminology, *1972*: Jan., 96
intrinsic pathway, *1972*: Jan., 99
mechanism of, *1972*: Jan., **95–104**
oral contraception and, *1970*: Jan., 167
tests of, *1970*: July, 893–897
prior to surgery, *1972*: Jan., 208
time, in diagnosis of hemorrhage, *1972*: Jan., 19
Coagulopathy, consumption. See *Coagulation, disseminated intravascular.*
Coarctation of aorta. See under *Aorta.*
Cogentin. See *Benzatropine methanesulfonate.*
Colchicine, for gout, *1970*: March, 439
Colchicine *(Continued)*
thrombocytopenia induced by, *1972*: Jan., 66
Colistin (Coly-Mycin), *1970*: Sept., **1267–1276.** See also *Polymyxin E.*
clinical indications, *1970*: Sept., 1273
clinical pharmacology, *1970*: Sept., 1268
spectrum of activity, *1970*: Sept., 1270
Colitis, granulomatous. See *Granulomatous colitis.*
ulcerative, diet in, *1970*: Nov., 1361
intravenous hyperalimentation for, *1970*: May, 585
Collagen formation, nutrition and, *1970*: Nov., 1498
Colon, Crohn's disease of. See *Granulomatous colitis.*
diverticula of, low-residue diet for, *1970*: Nov., 1360
Colonization, in microbial suprainfection, *1971*: March, 473
Colony inhibition test. *1971*: May, 775; *1972*: March, 487
Colorectal cancer, investigation and treatment, *1972*: May, **665–675**
Coly-Mycin. See *Colistin.*
Coma, diabetic, *1972*: July, 1034
hyperosmolar hyperglycemic nonketotic, *1970*: May, **683–699**
intensive care for, *1971*: Sept., 1319–1322
hepatic, dietary control of, *1970*: Nov., 1464–1468
intensive care for, *1971*: Sept., 1296
treatment, *1971*: March, 373
lactic acidosis, diabetes and, *1971*: July, 914
metabolic, in cancer, *1971*: May, 639
myxedema, intensive care for, *1971*: Sept., 1327
nonketotic, diabetes mellitus and, *1971*: July, **913–918**
Community health, newer approaches to, *1970*: May, **671–682**
Complement fixation test, in drug-induced thrombocytopenia, *1972*: Jan., 73
Complement receptor lymphocytes (CRL), *1972*: March, 299
Complement system, in acute inflammatory reactions, *1972*: March, 548
Computers in medicine, analysis of scanning results, *1971*: May, 550
history taking, *1970*: July, **825–833**
Regional Medical Programs and, *1970*: Jan., 25
Congestive heart failure. See under *Heart, failure.*
Conjunctivitis, inclusion, tetracyclines for, *1970*: Sept., 1179
mild, therapy for, *1969*: Sept., 1151
Conn's syndrome. See *Aldosteronism, primary.*
Connective tissue disorders, jejunal biopsy in, *1970*: July, 855
viruses and, *1972*: March, 367–368
Consciousness, state of, evaluation of, *1971*: Sept., 1237

Constipation, diabetes mellitus and, *1971*: July, 1037
Constrictive pericarditis, vs. intractable heart disease, *1970*: March, 315
Consumption coagulopathy. See *Coagulation, disseminated intravascular.*
Contact inhibition, loss of carcinoma, *1971*: May, 653
Contraception, oral current status of, *1970*: Jan., **163–171**
Contraceptives, oral, diabetes mellitus and, *1971*: July, 956
  hyperlipemia and, *1971*: March, 407
  in hemophilia, *1972*: Jan., 110
  incidence of venereal disease and, *1972*: Sept., 1065
  lipid disturbances with, *1972*: July, 1018
  liver function and, *1970*: Jan., 166
Convulsive disorders, treatment, *1972*: Nov., **1225–1231.** See also *Seizures.*
Copper, deficiency, *1970*: Nov., 1512
  metabolism, *1970*: Nov., 1511
  nutritional significance, *1970*: Nov., 1510–1514
Cor pulmonale, chronic bronchitis and, *1971*: March, 451
Coronary arteriography, indications for, *1970*: July, **979–995**
Coronary artery disease, hyperlipidemic states and, *1970*: Nov., 1599
Coronary atherosclerosis, angina of, treatment, *1972*: May, **599–609**
  menopause and, *1972*: May, 793
Coronary care units, intermediate, *1971*: March, 290
  nurses and physicians for, Regional Medical Programs and, *1970*: Jan., 23–24
Coronary surgery, for angina pectoris, *1972*: May, 605
Corticosteroids, after kidney transplants, *1970*: Jan., 87
  for allergy to antibiotics, *1970*: Jan., 71
  for anaphylactoid purpura, *1972*: Jan., 204
  for anemia of renal failure, *1971*: Jan., 7
  for brain metastases, *1971*: May, 629
  for bronchospasm, *1971*: March, 450
  for hemophilia, *1972*: Jan., 110
  for idiopathic thrombocytopenic purpura, *1972*: Jan., 60
  for lupus nephritis, *1971*: Jan., 80
  for metastatic breast cancer, *1972*: May, 658
  for multiple sclerosis, *1972*: May, 712; Nov., 1358
  for ophthalmologic complications of exophthalmic goiter, *1970*: Jan., 126
  for osteoarthritis, *1971*: March, 465
  for status asthmaticus, *1970*: March, 499
  for viral hepatitis, *1970*: March, 460
  in cancer therapy, *1971*: May, 684–693
  sensitivity of lymphocytes to, *1972*: March, 308
Corticotropin, for gout, *1970*: March, 439
Cortisone. See *Corticosteroids.*
Corynebacterium diphtheriae infection, penicillin for, *1970*: Sept., 1087
Coumarins, overdosage, hemorrhage and, *1972*: Jan., **263–273**
  physiology and mode of action, *1972*: Jan., 255–256
Coxsackie virus, renal disease and, *1971*: Jan., 91
CPIB. See *Clofibrate.*
Craniopharyngioma, microneurosurgery for, *1972*: July, **915–930**
Craniotomy, transfrontal, for pituitary tumors, *1972*: July, 915
Creatinine, serum, glomerular filtration rate and, *1971*: March, 343
Creutzfeldt-Jakob disease, *1972*: Nov., 1407, 1409
CRL. See *Complement receptor lymphocytes.*
Crohn's disease, of colon. See *Granulomatous colitis.*
Crush syndrome, myoglobinuria in, *1972*: Nov., 1240–1242
Cryoglobulins, *1970*: July, 924
Crystalline zinc insulin (CZI), clinical pharmacology, *1971*: July, 862, 866
Curling's ulcer, intensive care for, *1971*: Sept., 1277–1279
Cushing's syndrome, glucose intolerance and, *1971*: July, 1059
  hypertension and, *1971*: Jan., 32
  metabolic and nutritional aspects, *1970*: Nov., 1483–1486
  tests for, *1970*: July, 1062
CVA. See *Cerebrovascular disease.*
Cyanocobalamin. See *Vitamin* B_{12}.
Cyanosis, clubbing and, due to right-to-left shunts, *1970*: May, 625
  in adults with congenital heart disease, cardiac catheterization in, *1970*: July, 976
Cyclophosphamide (Cytoxan), in bone marrow transplantation, *1972*: March, 435–436
  in cancer therapy, *1971*: May, 684–693, 713–716
  thrombocytopenia induced by, *1972*: Jan., 66
Cycloserine, for urinary tract infection, *1971*: Nov., 1451
Cycrimine (Pagitane), in parkinsonism, *1972*: Nov., 1390
Cyproneptadine hydrochloride (Periactin), for migraine, *1972*: Nov., 1268
Cystathionine synthetase deficiency, *1970*: Nov., 1437
Cystathioninuria, carcinoma and, *1971*: May, 615
  dietary control of, *1970*: Nov., 1438
Cystic fibrosis, bronchopulmonary lavage for, *1970*: May, 768
  fibroblast cultures in, *1970*: May, 703
Cystinuria, nephrolithiasis of, *1972*: July, 978–980
Cytokinetics, in leukemia, *1971*: May, 576
Cytosine arabinoside, in cancer therapy, *1971*: May, 684–693

Cytosine arabinoside *(Continued)*
thrombocytopenia induced by, *1972*: Jan., 66
Cytotoxic drugs, *1971*: May, 572
Cytotoxicity tests, in malignant disease, *1972*: March, 484–487
Cytoxan. See *Cyclophosphamide*.

DACTINOMYCIN, in cancer therapy, *1971*: May, 685–693
Daunorubicin, in cancer therapy, *1971*: May, 684–693
DBI. See *Phenformin*.
Deafness, due to dihydrostreptomycin, *1970*: Sept., 1161
due to kanamycin, *1970*: Sept., 1249
Defibrillation, electrical, in intensive care unit, *1971*: Sept., 1165
Defibrination syndrome. See *Coagulation, disseminated intravascular*.
Dehydration, hypertonic, in diabetic coma, *1970*: May, 691
Delalutin. See *Hydroxyprogesterone caproate*.
Dementia(s), *1972*: Nov., **1405–1418**
Demethylchlortetracycline, *1970*: Sept., 1174, 1175
Dental health, nutrition and, *1970*: Nov., **1555–1565**
Depression, anxiety and, drug therapy in medical practice, *1971*: March, **485–494**
home hemodialysis and, *1971*: Nov., 1486
Dermatitis, gonococcal, *1972*: Sept., 1117–1118
Dermatology, chemotherapy in, present status of, *1972*: May, **725–737**
Dermatomyositis, esophageal involvement, motility studies in, *1970*: July, 869
Dermatosis, diabetes mellitus and, *1971*: July, **1019–1029**
Desensitization for allergy to antibiotics, *1970*: Jan., 70
Desoxyephedrine (Desoxyn), for parkinsonism, *1972*: Nov., 1388
Development, growth and, retardation, hypothyroidism and, *1972*: July, 876
mental, nutrition and, *1970*: Nov., **1413–1429**
Dextran, for acute cerebral infarction, *1970*: March, 358
Dextroamphetamine sulfate (Dexedrine), for parkinsonism, *1972*: Nov., 1388
Dextrothyroxine (Choloxin), for hyperlipoproteinemias, *1970*: Nov., 1610
Diabetes insipidus, nephrogenic, dietary control, *1970*: Nov., 1441
due to demethylchlortetracycline, *1970*: Sept., 1182
Diabetes mellitus, acromegaly and, *1970*: Nov., 1477
aging and, *1971*: July, **835–846**
asymptomatic, treatment, *1971*: July, 1073
carotenemia and, *1971*: July, 1024
Diabetes mellitus *(Continued)*
cataracts in, *1971*: July, 895
cholecystitis and, *1971*: July, 1040
chromium and, *1970*: Nov., 1520–1523
claudication and, *1971*: July, 1046
coma of, intensive care for, *1971*: Sept., 1319–1322
nonketotic, *1971*: July, **913–918**
hyperosmolar hyperglycemic, *1970*: May, **683–699**
complicating urinary tract infection, *1970*: March, 401
constipation with, *1971*: July, 1037
course, *1971*: July, 801–804, 871
cutaneous manifestations, *1971*: July, **1019–1029**
definition, diagnosis, course, *1971*: July, **793–805**
diet therapy in, *1970*: Nov., **1577–1587**; *1971*: July, **877–887**, 1073
emotional and psychosocial aspects, *1971*: July, **1007–1018**
gastrointestinal manifestations, *1971*: July, **1031–1044**
genetic transmission, *1971*: July, 810
hyperlipemia and, *1971*: March, 414; July, 1024
hypertension and, *1971*: Jan., 26
hypoglycemia in, *1970*: March, 541; *1971*: July, **919–930**, 983
in childhood and adolescence, *1971*: July, 802, **975–987**
in pregnancy, medical aspects, *1971*: July, **947–959**
obstetrical management, *1971*: July, **961–974**
infections and, *1971*: July, **931–938**
inheritance, *1971*: July, **807–819**
insulin-dependent, natural history, *1971*: July, 871
insulin-independent, complications, *1971*: March, 302
diagnosis and treatment, *1971*: March, **295–304**
insulin secretion in, *1971*: Kuly, 828–831
insulin therapy, *1971*: July, **861–876**. See also *Insulin*.
jaundice in, *1971*: July, 1040
ketoacidosis in, *1971*: July, **899–911**. See also *Ketoacidosis*.
lipid disturbances in, *1971*: July, 1024, 1045; *1972*: July, 1013–1014
metabolic alterations, *1971*: July, 831
muscle disorders in, *1971*: July, 1005, 1046
nervous system disorders in, *1971*: July, 895, **1001–1006**
neurologic complications, *1972*: July, 1034
obesity and, *1970*: Nov., 1533
oral contraceptives and, *1971*: July, 956
oral hypoglycemic agents in, *1971*: July, 1065–1075. See also *Oral hypoglycemic agents*.
pathophysiology, *1971*: July, **821–834**
polyneuritis of, *1972*: Nov., 1306

Diabetes mellitus *(Continued)*
retinopathy of, pituitary ablation for, *1972*: July, 924–927
treatment, *1971*: July, **989–999**
stages of, *1971*: July, 794
symposium on, *1971*: July, **793–1075**
tolbutamide for, evaluation and precautions, *1971*: July, 1073–1074
treatment, evaluation of, *1971*: July, 890
in surgical patient, *1971*: July, **939–945**
vascular complications, *1971*: July, **889–897.** See also *Vascular disease in diabetics.*
Diabinase. See *Chlorpropamide.*
Diagnostic procedures, radiopharmaceuticals in, *1971*: May, **545–560**
sophisticated, symposium on, *1970*: July, **823–1070**
Dialysis, *1971*: Jan., **155–175.** See also *Hemodialysis.*
chronic intermittent, in end-stage renal disease, *1971*: March, 353
for acute renal failure, *1971*: Jan., 132–133
for acute tubular necrosis, *1971*: Sept., 1252
for drug intoxication, *1971*: Sept., 1258
for hypercalcemia, *1972*: July, 954–956, 967–970
in acute renal tubular insufficiency, *1971*: March, 340
maintenance, *1971*: Jan., 168–172
psychiatric observations, *1971*: Jan., **177–191**
peritoneal, *1971*: Jan., 155–160
platelets and, *1972*: Jan., 224
Dialysis disequilibrium syndrome, in uremia, *1970*: March, 414
Diarrhea, diabetic, *1971*: July, 1035
islet cell tumors and, *1970*: May, 567
of travelers, *1970*: March, 448, 450
weanling, *1970*: Nov., 1501–1503
Diarrheal disease, acute, *1970*: March, **443–453**
Diazepam (Valium), for status epilepticus, *1972*: Nov., 1229
DIC. See *Coagulation, disseminated intravascular.*
Dicloxacillin, *1970*: Sept., **1127–1143**
preparations and dosage, *1970*: Sept., 1137, 1138
serum protein-binding, *1970*: Sept., 1117
spectrum of activity, *1970*: Sept., 1129
Dicumarol, blood glucose level and, *1971*: July, 927
Diet, dental health and, *1970*: Nov., **1555–1565**
drugs and, *1972*: May, 585–587
elemental, in surgical nutrition, *1970*: Nov., 1376
Giordano-Giovannetti, *1971*: March, 516
hypertonic intravenous, administration of, *1970*: Nov., 1377–1381
in acid peptic disease, *1970*: Nov., 1357–1359
in blood lipid disorders, *1970*: Nov., **1383–1398**
Diet *(Continued)*
in coronary artery disease, *1970*: Nov., 1600
in diabetes mellitus, *1970*: Nov., **1577–1587**
as initial treatment, *1971*: July, 1073
vascular disease and, *1971*: July, **877–887**
in dysbetalipoproteinemia, *1970*: Nov., 1396
in edema, *1971*: March, 366
in experimental cancer therapy, *1971*: May, 670
in gastrointestinal disorders, *1970*: Nov., **1357–1366**
in gout, *1970*: March, 441
in hereditary disorders, *1970*: Nov., **1431–1448**
in hyperbetalipoproteinemia, *1970*: Nov., 1391
in hypercholesterolemia, *1971*: July, 883
in hyperlipidemia, *1970*: May, 663–665
in hyperlipoproteinemia, *1970*: Nov., 1396, 1604, 1609
in hypertriglyceridemia, *1970*: Nov., 1394
in kidney disorders, *1971*: March, **513–520**
in liver disease, *1970*: March, 473–475
clinical aspects, *1970*: Nov., 1461–1468
in nontropical sprue, *1970*: May, 654
in obesity, *1971*: March, 396
in pancreatitis, chronic, *1970*: March, 487
in peptic ulcer disease, *1971*: March, 309
in renal failure, acute, *1971*: Jan., 125
chronic, *1971*: Jan., 141–142
in uremia, *1970*: March, 425–428; *1971*: March, 516; Nov., 1386
iron requirements, *1970*: Nov., 1404
ketogenic, for convulsive disorders, *1972*: Nov., 1227
low-carbohydrate, in hyperlipoproteinemia, *1970*: Nov., 1608
low-protein, for patients on chronic hemodialysis, *1971*: Nov., 1486
for uremic symptoms, *1971*: March, 352
low-residue, uses, *1970*: Nov., 1359–1362
low-sodium, in congestive heart failure, *1970*: Nov., 1452
in liver disease, *1970*: Nov., 1466
sources of iron in, *1970*: Nov., 1403
Diethylstilbestrol, in cancer therapy, *1971*: May, 684–693
Difficult medical problems, symposium on, *1970*: March, **279–542**
DiGeorge syndrome, *1970*: March, 286
immunologic aspects, *1972*: March, 296, 326
treatment by transfer of immunity, *1972*: March, 471
Digitalis, administration of, in patients with renal failure, *1971*: Jan., 131
arrhythmias from, *1971*: Sept., 1199
cellular action of, *1970*: Jan., **221–234**
for cardiac arrhythmia, *1971*: March, 286
for cardiogenic shock, *1970*: Jan., 241

Digitalis (*Continued*)
in chronic heart failure, *1970*: March, 324
in paroxysmal atrial fibrillation, *1972*: May, 612
DiGuglielmo syndrome, vs. thrombocytopenic purpura, *1972*: Jan., 48, 49
Dihydrostreptomycin, deafness from, *1970*: Sept., 1161
Dilantin. See *Diphenylhydantoin.*
3,4-Dinitrochlorobenzene (DNCB) reactivity in human cancer, *1971*: May, 780
Diphenhydramine (Benadryl), for parkinsonism, *1972*: Nov., 1390
Diphenylhydantoin (Dilantin), anticoagulants and, *1972*: Jan., 257
for cardiac arrhythmias, *1971*: March, 440
for grand mal seizures, *1972*: Nov., 1226
intention tremor due to, *1972*: Nov., 1371
2,3-Diphosphoglycerate, red cell, alterations in, clinical conditions with, *1970*: May, 736
hypoxemia and, *1970*: May, 733
Diphtheria, erythromycin for, *1970*: Sept., 1207
Diplococcus pneumoniae infections, tetracyclines for, *1970*: Sept., 1179
Disaccharides, intolerance, dietary control, *1970*: Nov., 1440
in celiac disease, *1970*: May, 652
Disipal. See *Orphenadrine.*
Disks, intervertebral, herniated, thermography in, *1970*: May, 613
Disseminated intravascular coagulation. See under *Coagulation.*
Diuresis, effects of, *1971*: March, 361
Diuretics, clinical use, *1971*: March, 365–371
contraindications, *1971*: Jan., 15
for chronic hypertension, *1971*: March, 320
for edema, *1971*: March, **359–371**
in chronic heart failure, *1970*: March, 325–328
in congestive heart failure, *1971*: Sept., 1194–1196
in pregnant diabetics, *1971*: July, 964
oral, for essential hypertension, *1971*: Jan., 14
outpatient use, *1971*: March, 371
thiazide, gout and, *1970*: March, 432
hypercalcemia and, *1972*: July, 947
Donor selection. See under *Transplantation.*
Dopamine, deficiency, in parkinsonism, *1972*: Nov., 1377–1389
for shock in myocardial infarction, *1970*: Jan., 241
Down's syndrome, Australia antigen in, *1970*: May, 810
chromosomal abnormality in, *1970*: July, 1015
mosaic, fibroblast cultures in, *1970*: May, 707
Doxycycline hyclate, *1970*: Sept., 1174, 1175
Drugs. See also specific names and types of drugs, as *Antibiotics; Antiarrhythmic drugs.*
addiction, malnutrition and, *1970*: Nov., **1567–1575**
dosage, renal failure and, *1971*: March, 341
dyskinesias due to, *1972*: Nov., 1333–1335
effect on blood glucose level, *1971*: July, 927
for organ preservation, *1971*: Jan., 208
immunosuppressive, *1972*: March, 457, 467. See also *Immunosuppressive therapy.*
in cardiopulmonary resuscitation, *1971*: Sept., 1162–1164
interactions, in clinical medicine, *1972*: May, **585–597**
in multiple drug therapy, *1971*: March, **495–502**
intoxication, dementia with, *1972*: Nov., 1415
intensive care for, *1971*: Sept., **1258–1262**
metabolism, *1970*: Nov., 1567; *1972*: May, 591–594
muscle necrosis and, *1972*: Nov., 1242
polyneuropathies due to, *1972*: Nov., 1315
reactions, serum sickness-like, *1970*: Sept., 1094
thrombocytopenia due to, *1972*: Jan., **65–79**
Ductus arteriosus, patent, cardiac catheterization in, *1970*: July, 975–976
Dwarfism, hypopituitary, idiopathic, radioimmunoassay of gonadal hormones in, *1970*: July, 1055
Dyes, in experimental cancer therapy, *1971*: May, 672
Dying patient, physician's responsibility to, *1972*: May, **677–680**
Dysbetalipoproteinemia, diagnosis and diet therapy, *1970*: Nov., 1396
Dysgammaglobulinemias, *1972*: May, 752–753
Dyskinesias, clinical diagnosis of, *1972*: Nov., **1321–1341**
levodopa-induced, in parkinsonism, *1972*: Nov., 1384
Dyslipoproteinemias, diagnosis of, *1970*: Jan., **153–159**
Dyspepsia, diet and, *1970*: Nov., 1362
Dysphagia, diabetes mellitus and, *1971*: July, 1032
Dystonia, torsion, *1972*: Nov., 1328–1333
Dystonia musculorum deformans, *1972*: Nov., 1330–1332

EACA. See *Epsilon aminocaproic acid.*
Ear, middle, infections. See *Otitis media.*
toxic reactions. See *Ototoxic reactions.*
Eastern equine encephalitis, *1972*: Nov., 1394

EBV. See *Epstein-Barr virus.*
Ecchymosis and petechiae, in diagnosis of hemorrhage, *1972*: Jan., 18
ECHO virus, renal disease and, *1971*: Jan., 91
Ecology, nutritional, *1970*: Nov., 1505–1508
Eczema, diabetes mellitus and, *1971*: July, 1019
Edecrin. See *Ethacrynic acid.*
Edema, cerebral, diabetic ketoacidosis and, *1971*: July, 908, 917
  diuretic drug therapy for, *1971*: March, **359–371**
  in liver disease, dietary control, *1970*: Nov., 1466
  in pregnancy, *1971*: Jan., 50–60
  insulin, *1971*: July, 874
  pulmonary, acute, management, *1971*: March, 370
  refractory, treatment, *1971*: March, 367
EDTA, for hypercalcemia, *1972*: July, 955
Education, medical, continuing, current concepts and future needs, *1970*: Jan., **5–18**
  venereal disease control and, *1972*: Sept., **1101–1104**
Edwards' syndrome, chromosomal abnormality in, *1970*: July, 1018
Elavil. See *Amitriptyline.*
Elderly. See *Aged persons.*
Electrocardiogram, in pulmonary embolism, *1970*: March, 364
  monitoring, equipment for, *1971*: Sept., 1118
    in cardiopulmonary resuscitation, *1971*: Sept., 1164
Electrocardiography, abnormalities in, coronary arteriography in, *1970*: July, 984
Electrolytes. See also *Fluids and electrolytes.*
  imbalance, cardiac arrhythmias and, *1971*: Sept., 1197
Electromyography, in polyneuritis, *1972*: Nov., 1304
Electrophoresis. See also *Immunoelectrophoresis.*
  in classification of hyperlipoproteinemias, *1970*: Nov., 1601, 1602
  in diagnosis of hyperlipidemia, *1970*: July, 1031, 1033
  in diagnosis of syndromes associated with hyperglobulinemia, *1970*: July, 922–936
  in measurement of thyroxine-binding proteins, *1972*: July, 851–852
  in study of plasma lipoproteins, *1970*: Jan., 153
Elemental diets, in surgical nutrition, *1970*: Nov., 1376
Elements, trace, caries-inhibiting, *1970*: Nov., 1558
Embolectomy, pulmonary, *1970*: March, 372–374
Embolism, amniotic fluid, disseminated intravascular coagulation and, *1972*: Jan., 181
  fat, disseminated intravascular coagulation and, *1972*: Jan., 181
Embolism (*Continued*)
  pulmonary, complicating heart failure, *1970*: March, 317
    disseminated intravascular coagulation and, *1972*: Jan., 181
    management, *1970*: March, **361–377**
    surgical, *1970*: March, 372–374
    prevention, *1970*: March, 366–368
    prophylactic anticoagulation and, *1972*: Jan., 239
    vs. intractable heart failure, *1970*: March, 312
  systemic, anticoagulants and, *1972*: Jan., 248
Emotional disturbances, diabetes mellitus and, *1971*: July, **1007–1018**
  long-term dialysis and, *1971*: Jan., **177–191**
Emphysema, airway obstruction in, *1971*: March, 445
  pulmonary, vs. intractable heart failure, *1970*: March, 314
Empty sella syndrome, *1972*: July, **897–907**
Empyema, intensive care management, *1971*: Sept., 1312
Encephalitis, viral, acute, *1972*: Nov., **1393–1404**
Encephalomyelitis, allergic, experimental, immunologic mechanisms in, *1972*: March, 516–518
  disseminated, acute, immunologic mechanisms, *1972*: March, 519
Encephalopathy, Binswanger's, *1972*: Nov., 1411
  hepatic, dietary control, *1970*: Nov., 1464–1468
    intensive care for, *1971*: Sept., 1296
    treatment, *1971*: March, 373
  hypertensive, *1971*: March, 329
  metabolic, due to carcinoma, *1971*: May, 639
Endocarditis, bacterial, causing chronic renal failure, *1971*: Jan., 140
    oxacillin and cloxacillin for, *1970*: Sept., 1133
    penicillins for, *1970*: Sept., 1089
    prophylaxis for, *1970*: Sept., 1106
    streptomycin for, *1970*: Sept., 1164, 1165
  enterococcal, treatment of, *1970*: Sept., 1150
  prolonged fever and, *1970*: March, 382–384
  staphylococcal, antibacterials for, comparative effectiveness, *1970*: Sept., 1280
Endocrine glands. See also under names of glands.
  disorders, emergencies, intensive care for, *1971*: Sept., **1315–1329**
    glucose intolerance with, *1971*: July, **1057–1064**
    hypertension and, management, *1971*: Jan., **23–45**
    lipid disturbances in, *1972*: July, **1013–1020**
    neurologic problems in, *1972*: July, **1029–1039**

Endocrine glands (*Continued*)
disorders, nutrition and, *1970*: Nov., **1473–1494**
skin pigmentation in, *1972*: July, 1041–1049
symposium on, *1972*: July, **841–1049**
functions, malnutrition and, *1970*: Nov., 1490
secretions, osteoporosis and, *1970*: Jan., 147–149
Endotracheal intubation, evaluation of, *1971*: Sept., 1220
Energy expenditure, increased, in disease and injury, *1970*: Nov., 1374
nitrogen loss and, *1970*: Nov., 1371
Enhancement, immunologic, *1972*: March, 462
Enteritis, candidal, nystatin for, *1970*: Sept., 1335
regional. See *Regional enteritis*.
Enterobacter infections, choice of therapy for, *1970*: Sept., 1162
Enterococcus infections, choice of therapy for, *1970*: Sept., 1162
Enteropathy, diabetic, *1971*: July, 1004
Enzymes, defects, nutritional problems and, *1970*: Nov., 1431–1433
in diagnosis of cancer, *1971*: May, 619
in experimental therapy of cancer, *1971*: May, 673
serum, in chronic pancreatitis, *1970*: March, 481
in pulmonary embolism, *1970*: March, 365
urinary, disorders, *1972*: July, 982
quantitation of, *1971*: Nov., 1493–1508
Epileptic seizures, treatment, *1972*: Nov., 1229
Epinephrine, for bronchospasm, *1971*: March, 447
for status asthmaticus, *1970*: March, 498, 500
tremor due to, *1972*: Nov., 1367
Epipodophyllotoxin thenylidine glycoside, *1971*: May, 698
Epitheliomas, recurrent, chemosurgery in, *1972*: May, **739–745**
Epsilon aminocaproic acid, for disseminated intravascular coagulation, *1972*: Jan., 187
for fibrinolysis, *1972*: Jan., 171
for hemophilia, *1972*: Jan., 111
Epstein-Barr virus (EBV), *1970*: March, 366
in Burkitt's lymphoma, *1971*: May, 763–771
Ergotamine tartrate, for migraine, *1972*: Nov., 1267
Erysipelas, penicillins for, *1970*: Sept., 1087
Erythema multiforme, vs. herpes genitalis, *1972*: Sept., 1184, 1186
Erythrocytes, indices, iron deficiency and, *1970*: July, 907
oxygen transport by, heredity and environment and, *1970*: May, **731–743**
substitutes for, *1970*: May, **787–795**
urinary enzymes and, *1971*: Nov., 1496
Erythromycin, *1970*: Sept., **1199–1215**
allergic reactions to, incidence of, *1970*: Jan., 63
as alternate to penicillin, *1970*: Sept., 1205
clinical indications, *1970*: Sept., 1204–1207
for syphilis in pregnancy, *1972*: Sept., 1156
for urinary tract infection, *1971*: Nov., 1450
preparations, and dosage, *1970*: Sept., 1209
spectrum of activity, *1970*: Sept., 1200
toxic reactions, *1970*: Sept., 1204
Erythropoiesis, kidney and, *1971*: Jan., 5
kinetics of, *1971*: May, 576
Erythropoietin, current status of, *1970*: Jan., **173–181**
Escherichia coli infections, choice of therapy for, *1970*: Sept., 1162
Esophagitis, candidal, nystatin for, *1970*: Sept., 1335
reflux, *1972*: May, **771–780**
Esophagus, achalasia, intravenous hyperalimentation for, *1970*: May, 585
motility studies in, *1970*: July, 867
disorders, diabetes mellitus and, *1971*: July, 1032
motility studies, *1970*: July, **863–873**
neuromuscular abnormalities of, *1970*: July, 867–871
varices, bleeding, intensive care for, *1971*: Sept., 1293
Essential hypertension, management, *1971*: Jan., **11–22**. See also *Hypertension*.
Estrogen(s), carbohydrate metabolism and, *1971*: July, 950
in cancer therapy, *1971*: May, 684–693
in metastatic breast cancer, *1972*: May, 658
in postmenopausal and senile osteoporosis, *1972*: July, 991
in postmenopausal women, *1972*: May, 795–797
Ethacrynic acid (Edecrin), for renal insufficiency, *1971*: Jan., **107–119**
toxic effects, *1971*: March, 366
Ethambutol (Myambutol), *1970*: Sept., **1317–1325**
Ethanol metabolism, *1970*: Nov., 1568
Ether as enema, for status asthmaticus, *1970*: March, 500
Ethinyl estradiol, in cancer therapy, *1971*: May, 684–693
Ethopropazine (Parsidol), for parkinsonism, *1972*: Nov., 1390
Ethosuximide (Zarontin), for convulsive seizures, *1972*: Nov., 1227
Ethylchlorvynol, anticoagulants and, *1972*: Jan., 259
Euglobulin lysis time test, for fibrinolytic disorders, *1972*: Jan., 168
Excoriations, genital, vs. herpes genitalis, *1972*: Sept., 1183, 1184
Exercise, myoglobinuria and, *1972*: Nov., 1236, 1240

Extracellular fluid, overload syndromes, symptomatic treatment, *1971*: March, **359–371**
volume maintenance, in chronic renal failure, *1971*: March, 346
Extracorporeal circulation, disseminated intravascular coagulation and, *1972*: Jan., 181
hemorrhage during and after, *1972*: Jan., 210
Eyes, infections, chloramphenicol for, *1970*: Sept., 1192
tetracyclines for, *1970*: Sept., 1179
movements and oculovestibular responses, brain lesions and, *1971*: Sept., 1239
toxic reactions, to ethambutol, *1970*: Sept., 1319

FABRICIUS, bursa of, *1972*: March, 306, 320
Fabry's disease, fibroblast cultures in, *1970*: May, 703
Factors, coagulation. See under *Coagulation* and names of factors.
Fanconi syndrome, due to tetracyclines, *1970*: Sept., 1182
Fasciotomy, in vascular disease, indications, *1971*: Sept., 1211
Fasting, metabolic response to, *1970*: Nov., 1367–1373
Fat(s), absorption, medium chain triglycerides and, *1970*: Nov., 1376
body requirements, for diabetics, *1970*: Nov., 1579
body stores, measuring, *1970*: Nov., 1368
malabsorption, in liver disease, *1970*: Nov., 1457
with cirrhosis, treatment, *1971*: March, 374
metabolism, in liver disease, *1970*: Nov., 1458
Fat embolism, disseminated intravascular coagulation and, *1972*: Jan., 181
Fatigue, tremor due to, *1972*: Nov., 1367
Fatty acids, free, thyrotoxicosis and, *1970*: Nov., 1481
Ferrous sulfate, for iron deficiency, *1970*: Nov., 1407
Fetal antigens, *1971*: May, 771
Fetus, brain growth, critical periods in, *1970*: Nov., 1419
evaluation in diabetic mother, *1971*: July, 968
Fever, as reaction to antibiotics, *1970*: Jan., 61
complicating heart failure, *1970*: March, 319
hemorrhagic, acute, renal disease and, *1971*: Jan., 92
in neoplastic disease, *1971*: May, 732
Mediterranean, *1970*: March, 392
myoglobinuria and, *1972*: Nov., 1239
oxygen consumption and, *1970*: Nov., 1374

Fever (*Continued*)
penicillin toxicity and, *1970*: Sept., 1093
prolonged and perplexing, *1970*: March, **379–396**
psychogenic, *1970*: March, 392
relapsing, tetracyclines for, *1970*: Sept., 1179
Fibrillation, atrial, chronic, *1970*: March, 325
paroxysmal, *1972*: May, **611–614**
Fibrin stabilizing factor (XIII), coagulation and, *1972*: Jan., 97
deficiency, *1972*: Jan., **133–143**
Fibrinogen, coagulation and, *1972*: Jan., 97
deficiencies and disorders, *1972*: Jan., **133–143**
variants, *1972*: Jan., 134, 135
Fibrinolysins, for pulmonary embolism, *1970*: March, 369
Fibrinolysis, disorders of, *1972*: Jan., **163–176**
disseminated intravascular coagulation and, *1972*: Jan., 180
early history of, *1972*: Jan., 13
inhibitors of, *1972*: Jan., 157–158
physiology of, *1972*: Jan., **153–162**
primary, vs. disseminated intravascular coagulation, *1970*: May, 557; *1972*: Jan., 185
tests for, *1970*: July, 896
Fibrinolytic system, in acute inflammatory reactions, *1972*: March, 547
Fibroblast cultures, in genetic disorders, *1971*: May, **701–712**
Flail chest, intensive care management, *1971*: Sept., 1306–1308
Flora, gastrointestinal, immune mechanisms and, *1972*: March, 397
Fluids, and electrolytes, abnormalities, in chronic renal failure, *1971*: March, 345
in acute renal tubular insufficiency, *1971*: March, 338
in central nervous system disease, *1971*: Sept., 1246
in diabetic ketoacidosis, *1971*: July, 906
in status asthmaticus, *1970*: March, 499, 500
urinary concentration, diuretics and, *1971*: March, 363
balance, in acute renal failure, *1971*: Jan., 125
body, normal relationships, *1970*: May, 688–693
extracellular, hyperosmolarity of, coma of, *1971*: July, 915
overload syndromes, symptomatic treatment, *1971*: March, **359–371**
volume maintenance, in chronic renal failure, *1971*: March, 346
therapy, for diabetic coma, *1970*: May, 693
Fluoride, bone disease in renal patients and, *1972*: July, 964
bone metabolism and, *1970*: Nov., 1559
for postmenopausal and senile osteoporosis, *1972*: July, 993
metabolism, osteoporosis and, *1970*: Jan., 146–147

Fluoride (*Continued*)
tooth development and, *1970*: Nov., 1557
Fluorochemicals, as erythrocyte substitute, *1970*: May, 789–794
5-Fluorouracil, in cancer therapy, *1971*: May, 684–693
in gastrointestinal carcinoma, *1971*: May, 607
thrombocytopenia induced by, *1972*: Jan., 66
Fluoxymesterone, in cancer therapy, *1971*: May, 684–693
Folate, assay, in megaloblastic-macroovalocytic anemias, *1970*: May, 635
deficiency, *1970*: May, 639
etiology and pathogenesis, *1970*: May, 641
Follicle-stimulating hormone, radioimmunoassay for, *1970*: July, **1049–1059**
Food intolerance, in infancy, dietary management, *1970*: Nov., 1440
iron content, *1970*: Nov., 1403
tolerances, in liver disease, *1970*: Nov., 1468
Free fatty acids, thyrotoxicosis and, *1970*: Nov., 1481
Freezing, for organ preservation, *1971*: Jan., 207
Freund's adjuvant, in experimental allergic encephalomyelitis, *1972*: March, 516
Fructose, diabetes and, *1971*: July, 882
Fructosemia, dietary control, *1970*: Nov., 1439
Funduscopy, in miliary tuberculosis, *1970*: March, 380
Fungus infections, diabetes and, *1971*: July, 935
griseofulvin for, *1970*: Sept., **1339–1345**
in carcinoma, *1971*: May, 739–742
nystatin for, *1970*: Sept., **1329–1337**
Furadantin, for urinary tract infection, *1971*: Nov., 1450, 1451
Furosemide (Lasix), for renal insufficiency, *1971*: Jan., **107–119**
toxic effects, *1971*: March, 366

GALACTOSE-kinase insufficiency, in galactosemia, *1970*: Nov., 1439
Galactose-1-phosphate uridyl transferase deficiency, dietary control, *1970*: Nov., 1438
Galactosemia, dietary control, *1970*: Nov., 1438
Gallbladder disorders, diabetes mellitus and, *1971*: July, 1040
inflammation, diet and, *1970*: Nov., 1362
Gamma-fetoprotein antigen, *1971*: May, 772
Gamma globulin, cerebrospinal fluid, in multiple sclerosis, *1972*: Nov., 1344–1346
for prophylaxis of infectious hepatitis, *1970*: March, 463
Gammopathy, monoclonal, benign, *1970*: July, 923
Ganglioradiculitis, in cancer, *1971*: May, 644
Gangrene, diabetic vascular disease and, *1971*: July, 1051
Gantrisin. See *Sulfisoxazole*.
Gases, blood. See under *Blood*.
Gastrectomy, hypoglycemia after, diabetes and, *1971*: July, 922
Gastric. See also *Stomach*.
Gastric acid secretion, peptic ulcer and, *1971*: March, 305
Gastric analysis, in megaloblastic-macroovalocytic anemias, *1970*: May, 633
Gastritis, diabetes mellitus and, *1971*: July, 1034
Gastrointestinal tract, abnormalities, in uremic syndrome, *1971*: March, 351
calcium absorption, abnormal, *1972*: July, 962–964
altering, *1972*: July, 953–954
carcinoma, cell proliferation and differentiation, *1971*: May, **601–612**
chemotherapy for, *1971*: May, 606
disorders, complicating severe illness, *1971*: Sept., **1277–1284**
diabetes mellitus and, *1971*: July, 1031–1044
diet in, *1970*: Nov., **1357–1366**
due to lincomycin, *1970*: Sept., 1299
food intolerances and, *1970*: Nov., 1440–1441
motility, diabetes mellitus and, *1971*: July, 1004
with hemophilia, management of, *1972*: Jan., 114
flora, immune mechanisms and, *1972*: March, 397
mucosa, immunologic defense mechanisms, *1972*: March, **391–402**
Gastroparesis diabeticorum, *1971*: July, 1032
Gastroscopy, in peptic ulcer disease, *1971*: March, 308
Genetic disorders, fibroblast cultures in, *1970*: May, **701–712**
glucose intolerance in, *1971*: July, 815
nutritional management, *1970*: Nov., **1431–1448**
of kidney, urinary findings in, *1971*: Nov., 1466
Genetics, in regulation of immunoglobulin allotypes, *1972*: March, **557–575**
Genitalia, excoriations, vs. herpes genitalis, *1972*: Sept., 1183, 1184
Genitourinary tract, disorders, diabetes mellitus and, *1971*: July, 1004
with hemophilia, management of, *1972*: Jan., 114
flora of, *1972*: Sept., 1109
lower, nonspecific infection of, *1972*: Sept., 1193–1202
trichomonas infection of, *1972*: Sept., **1203–1209**
Gentamicin, *1970*: Sept., **1305–1315**
allergic reactions to, incidence of, *1970*: Jan., 63
clinical indications, *1970*: Sept., 1312

Gentamicin (*Continued*)
for urinary tract infection, *1971*: Nov., 1450
in mixture, synergistic effects, *1970*: Sept., 1309
ototoxicity, *1970*: Sept., 1312
spectrum of activity, *1970*: Sept., 1306, 1309
Giant hemangioma, disseminated intravascular coagulation and, *1972*: Jan., 181
Giardiasis, jejunal biopsy and, *1970*: July, 859
Gilles de la Tourette syndrome, *1972*: Nov., 1325
Giordano-Giovannetti diet, *1971*: March, 516
Glaucoma, pain of, *1972*: Nov., 1264
Globulin, antilymphocyte (ALG). See *Antilymphocyte globulin.*
immune, for prophylaxis of infectious hepatitis, *1970*: March, 463
Glomerular basement membrane, antibody reactive to, ALG therapy and, *1972*: March, 422
diabetes and, *1971*: July, 895
Glomerular filtration rate, blood urea nitrogen and, *1971*: March, 343
sodium excretion and, *1971*: Nov., 1509–1514
Glomerulonephritis, acute, post-streptococcal, *1971*: Nov., 1406
dietary management, *1971*: March, 514
rapidly progressive, syndrome of, *1971*: Nov., **1397–1415**
Glucagon, in chronic heart failure, *1970*: March, 324
physiologic role and therapeutic use, *1970*: Jan., **183–190**
Glucocorticoids, disorders, metabolic and nutritional aspects, *1970*: Nov., 1483–1490
increased production of, hypertension and, *1971*: Jan., 32–36
osteoporosis and, *1970*: Jan., 147–148
Glucose, blood, capillary vs. venous, *1971*: July, 795
drugs lowering, *1971*: July, 927
in diabetes mellitus, control of, *1971*: March, 298
insulin response to, *1971*: July, 822
intolerance, Cushing's syndrome and, *1971*: July, 1059
endocrinopathies and, *1971*: July, **1057–1064**
genetic syndromes and, *1971*: July, 815
in intravenous hyperalimentation, *1970*: May, 583
in uremia, *1971*: Nov., 1391
thyroid disorders and, *1971*: July, 1062
maternal-fetal relationships, *1971*: July, 948
metabolism, clinical evaluation, *1970*: Nov., 1540
disorders, obesity and, *1970*: Nov., 1533
nitrogen-sparing effect, *1970*: Nov., 1373
tolerance, carbohydrate intake and, *1971*: July, 881
Glucose (*Continued*)
tolerance, tests of, abnormal, chromium and, *1970*: Nov., 1520–1523
age and, *1971*: July, **835–846**
in diabetes mellitus, *1971*: March, 295
in pregnancy, *1971*: July, 951, 961
interpretation, *1971*: July, 796–801
need for standardization, *1970*: Nov., 1540
Glucose-galactose malabsorption, dietary control, *1970*: Nov., 1440
Glutamic pyruvic transamine, serum in Down's syndrome, *1970*: May, 811
Glutethimide, anticoagulants and, *1972*: Jan., 259
N-Glycine, in measurement of protein synthesis, *1970*: Nov., 1481
Glycogen metabolism, disorders of, myoglobinuria and, *1972*: Nov., 1236
Glycogenosis, fibroblast cultures in, *1970*: May, 706
Glycosides, cellular action of, *1970*: Jan., **221–234**
Glycosuria, in diabetic coma, *1970*: May, 690
Goiter, exophthalmic. See also *Hyperthyroidism.*
autoimmunity and, *1970*: Jan., 120–123
choice of treatment for, *1970*: Jan., 123–126
ophthalmologic complications, *1970*: Jan., 126–127
thyroid function tests in, *1970*: July, 1043
Gold salts, thrombocytopenia induced by, *1972*: Jan., 66
Gonadal dysfunction, lipid disturbances in, *1972*: July, 1018
Gonadotropin, human chorionic, urinary, in diagnosis of carcinoma, *1971*: May, 618
Gonococcus, sensitivity to penicillin, *1972*: Sept., 1063
Gonorrhea. See also *Venereal disease.*
asymptomatic, *1972*: Sept., **1127–1132**
complications of, *1972*: Sept., **1115–1125**
control of, problems in, *1972*: Sept., 1084–1086
diagnosis and treatment, *1972*: Sept., **1105–1113**
epidemiology of, *1972*: Sept., 1106
incidence, increase in, *1972*: Sept., 1059, 1061
in U.S., *1972*: Sept., 1073–1081
newer drugs for, *1970*: Sept., 1150
ophthalmic, *1972*: Sept., 1120–1121
penicillins for, *1970*: Sept., 1090
pharyngeal, *1972*: Sept., 1131
serum tests for, *1972*: Sept., 1068
tetracyclines for, *1970*: Sept., 1180
Goodpasture's syndrome, autoimmunity and, *1970*: Jan., 100
bronchopulmonary lavage for, *1970*: May, 768
rapidly progressive glomerulonephritis in, *1971*: Nov., 1399
viral infection and, *1971*: Jan., 93
Gout, *1970*: March, **431–441**

Gout (*Continued*)
uric acid lithiasis in, *1972*: July, 983–984
Graft vs. host assay, in tissue typing, *1970*: Jan., 46
Graft vs. host reaction, *1972*: March, 466
in bone marrow transplantation, *1972*: March, 436–438
Grafts, rejection, immunologic aspects, *1972*: March, 305–317, 453–455
management of, *1970*: Jan., 88
mechanism of, *1970*: Jan., 53–54
minimizing, *1972*: March, 456, 467. See also *Immunosuppressive therapy.*
Gram-negative infections, diabetes and, *1971*: July, 934
Granuloma annulare, *1971*: July, 1024
Granulomatosis, Wegener's, *1971*: Nov., 1407
Granulomatous colitis, prolonged fever and, *1970*: March, 391
Granulomatous disease, chronic, infection in, *1970*: May, 714–717
Graves' disease, *1972*: May, 717–720
Hashimoto's thyroiditis and, *1972*: July, 890–892
Gray baby syndrome, due to chloramphenicol, *1970*: Sept., 1190
Griseofulvin, *1970*: Sept., **1339–1345**
anticoagulants and, *1972*: Jan., 259
effect on porphyrin disturbances, *1970*: Sept., 1341
spectrum of activity, *1970*: Sept., 1339
Growth and development, retardation, hypothyroidism and, *1972*: July, 876
Growth hormone, deficiency, glucose intolerance and, *1971*: July, 1060
diabetogenic nature, *1970*: Nov., 1477
disorders, metabolic and nutritional aspects, *1970*: Nov., 1474–1480
excess of, long-term nutritional effects, *1970*: Nov., 1476
Guanethidine, for hypertension, *1971*: March, 323
essential, *1971*: Jan., 17
Guanidinosuccinic acid, platelet function and, in uremia, *1972*: Jan., 227
Guillain-Barré syndrome, immunologic mechanisms in, *1972*: March, 521

HAA. See *Hepatitis-associated antigen.*
Haemophilus influenzae infections, choice of therapy for, *1970*: Sept., 1162
erythromycin in, *1970*: Sept., 1207
Hageman factor (XII), coagulation and, *1972*: Jan., 99
in acute inflammatory reactions, *1972*: March, 546
HAI test. See *Hemagglutination-inhibition test.*
Hair disorders, hypothyroidism and, *1972*: July, 878
Haloperidol, blood glucose level and, *1971*: July, 927
Halothane, fulminant hepatic failure and, *1971*: March, 377
Hashimoto's thyroiditis, *1972*: July, **885–896**
autoimmunity and, *1970*: Jan., 121
HCG. See *Human chorionic gonadotropin.*
Headache, chronic recurring, *1972*: Nov., **1257–1271**
Heart, arrest, etiology, *1971*: Sept., 1158
in children, management, *1971*: Sept., 1273
arrhythmias. See *Arrhythmia(s).*
block, after myocardial infarction, treatment, *1971*: March, 278–285
catheterization, indications for, *1970*: July, **973–978**
defibrillation, electrical, *1971*: Sept., 1165
denervated, function of, *1970*: Jan., 109–110
disease, cyanotic, disseminated intravascular coagulation and, *1972*: Jan., 181
ill-defined, coronary arteriography in, *1970*: July, 986
disorders, complicating chronic renal failure, *1971*: Jan., 146–147
electrical slowing of, *1970*: Jan., **247–259**
electrophysiology of, *1971*: March, 435–438
failure, congestive, anticoagulation and, *1972*: Jan., 242–243
complicating acute renal failure, *1971*: Jan., 129
dietary control, *1970*: Nov., 1452
differential diagnosis, *1970*: March, 312–315
hypertrophy and, *1970*: Jan., 218
intensive care after, *1971*: Sept., **1191–1196**
in uremia, *1970*: March, 416
intractable, *1970*: March, **309–332**
acute, management of, *1970*: March, 321–323
chronic, management of, *1970*: March, 323–329
complications, *1970*: March, 316–320
glucagon and, *1970*: Jan., 186
gonococcal involvement, *1972*: Sept., 1119–1120
hypertrophy, cellular and subcellular basis of, *1970*: Jan., **211–220**
output, measuring, *1971*: Sept., 1189
monitoring for intensive care, *1971*: Sept., 1147–1149
pacemakers, paired ventricular stimulation by, *1970*: Jan., **247–259**
rate and rhythm, monitoring for intensive care, *1971*: Sept., 1118, 1164
surgery, hemorrhage after, *1972*: Jan., 216
tamponade, management, intensive care, *1971*: Sept., 1311
transplantation, antilymphocyte globulin therapy in, *1972*: March, 427
hemodynamic observations after, *1970*: Jan., **107–113**
manifestations of rejection after, *1970*: Jan., 110–111
valves, diseases of, coronary arteriography in, *1970*: July, 988

Heart (*Continued*)
valves, incompetence, *1970*: Jan., **261–274**
prosthetic, anticoagulants and, *1972*: Jan., 248
tricuspid, stenosis of, complicating heart failure, *1970*: March, 319
Heartburn, diabetes mellitus and, *1971*: July, 1032
Heat stroke, disseminated intravascular coagulation and, *1972*: Jan., 181
myopathy of, *1972*: Nov., 1245
Heavy chain diseases, *1970*: July, 923; *1972*: March, 384–385
Heavy metal intoxication, mental disturbances with, *1972*: Nov., 1414
polyneuropathy of, *1972*: Nov., 1315
Hemagglutination-inhibition (HAI) test, *1972*: March, 356
Hemangioma, giant, disseminated intravascular coagulation and, *1972*: Jan., 181
Hemarthroses, in hemophilia, *1972*: Jan., 111–112
Hematinics, inadequacy of, *1970*: Nov., 1407–1408
Hematologic disorders. See also names of specific disorders.
in uremia, *1970*: March, 419–421
Hematopoiesis, disturbed, as reaction to antibiotics, *1970*: Jan., 61
Hemichorea, *1972*: Nov., 1326
Hemiplegia, migraine and, *1972*: Nov., 1262
Hemochromatosis, *1972*: July, 1045
Hemodialysis, *1971*: Jan., 160–168. See also *Dialysis*.
at home, *1971*: Nov., **1473–1491**
hepatitis and, *1970*: March, 464; *1971*: Nov., 1481
in hypercalcemia of hyperparathyroidism, *1972*: July, 967–970
Hemoglobin, abnormalities of, oxygen dissociation curve in, *1970*: May, 737
fetal, red cell 2,3-diphosphoglycerate levels in, *1970*: May, 739
Hemoglobinuria, paroxysmal nocturnal, disseminated intravascular coagulation and, *1972*: Jan., 181
vs. thrombocytopenic purpura, *1972*: Jan., 48, 49
Hemolytic anemia, due to penicillins, *1970*: Sept., 1094
Hemolytic-uremic syndrome, disseminated intravascular coagulation and, *1972*: Jan., 181
viral infection and, *1971*: Jan., 93
Hemophilia, *1972*: Jan., **105–117**
vs. von Willebrand's disease, *1972*: Jan., 281
Hemophilus vaginitis, *1972*: Sept., 1110
Hemoptysis, intensive care management, *1971*: Sept., 1312
Hemorrhage, clinical manifestations of, *1972*: Jan., **17–24**
in disseminated intravascular coagulation, *1970*: May, 557
in vascular disease, intensive care for, *1971*: Sept., 1209
Hemorrhage (*Continued*)
intracranial, therapy for, *1970*: March, 356
overdose of anticoagulants and, *1972*: Jan., **263–273**
post-perfusion, platelet transfusion for, *1972*: Jan., 88
surgical, *1972*: Jan., **207–219**
symposium on, *1972*: Jan., **1–284**
uremia and, *1972*: Jan., **221–233**
Hemostasis, current research problems, *1972*: Jan., **3–8**
early history of, *1972*: Jan., **9–16**
mechanism of, evaluation of, *1970*: July, **889–902**
Hemothorax, intensive care management, *1971*: Sept., 1308–1310
Henderson equation, *1970*: Nov., 1544
Henoch-Schönlein purpura, *1972*: Jan., **201–206**
glomerulonephritis in, *1971*: Nov., 1409
Heparin, anticoagulants and, *1972*: Jan., 260
for disseminated intravascular coagulation, *1970*: May, 563, 564; *1972*: Jan., 186, **193–200**
for pulmonary embolism, *1970*: March, 368
Hepatic. See also *Liver*.
Hepatic coma, dietary control, *1970*: Nov., 1464–1468
intensive care for, *1971*: Sept., 1296
treatment, *1971*: March, 373
Hepatic failure, fulminant, treatment, *1971*: March, 377
Hepatitis, alcoholic, nutritional management, *1970*: Nov., 1464
treatment, *1971*: March, 386
chronic, treatment, *1971*: March, 380
complicating hemodialysis, *1970*: March, 464; *1971*: Nov., 1481
diet and, *1970*: Nov., 1363
malnutrition and, *1970*: March, 469
viral, *1970*: March, **455–466**
acute uncomplicated, treatment, *1971*: March, 374
Australia antigen and, *1970*: May, **805–817**
diabetes mellitus and, *1971*: July, 1039
dietary management, *1970*: Nov., 1462–1464
Hepatitis-associated antigen (HAA), chronic hepatitis and, *1971*: March, 383
Hepatocerebral degeneration, chronic, *1972*: Nov., 1372
Hepatoma, alpha-fetoprotein in, *1970*: May, 798–802
hypercholesterolemia and, *1971*: March, 404
malnutrition and, *1970*: March, 470
Hepatotoxic reactions, to erythromycin estolate, *1970*: Sept., 1204
to tetracyclines, *1970*: Sept., 1181
Herpes zoster infection, immunologic aspects, *1972*: March, 365
malignant disease and, *1972*: March, 362
Hereditary disorders. See also *Genetic disorders; Inheritance*.

Hereditary disorders (*Continued*)
nutritional management, *1970*: Nov., **1431–1448**
predisposition to carcinoma and, *1971*: May, 563
renal manifestations, dietary control, *1970*: Nov., 1441–1443
Heredopathia atactica polyneuritiformis, *1970*: Nov., 1442
Hernia, diaphragmatic, esophageal motility studies in, *1970*: July, 871
Heroin intoxication, myoglobinuria and, *1972*: Nov., 1244
Herpes genitalis, *1972*: Sept., 1110, **1175–1192**
clinical types, *1972*: Sept., 1182
treatment, *1972*: Sept., 1189
Herpes simplex virus, encephalitis due to, *1972*: Nov., **1398–1402**
Herpes virus, carcinoma and, *1971*: May, 763
Heterogeneity of diabetes mellitus, *1971*: July, 813
5-HIAA. See *5-Hydroxyindoleacetic acid.*
Hiatal hernia, esophageal motility studies in, *1970*: July, 871
Histocompatibility, HL-A system, *1972*: March, 403–408
ratio, net, *1972*: March, 409
testing, for kidney transplantation, *1971*: Jan., 196
mixed leukocyte culture in, *1972*: March, 341–343
serologic methods, *1972*: March, 342, 405
Histocompatibility antigens. See *Antigen(s), transplantation.*
History, medical, computer-aided, *1970*: July, **825–833**
HL-A antigens in clinical transplantation, *1972*: March, **403–417**
HL-A locus, *1970*: Jan., 52
Hodgkin's disease, chemotherapy for, *1971*: May, 696
herpes zoster infection and, *1972*: March, 362
immunologic aspects, *1970*: March, 298; *1972*: March, 327, 501–503
lymphography in, *1970*: July, 940
Home hemodialysis, *1971*: Nov., **1473–1491**
Homocystinuria, dietary control, *1970*: Nov., 1437
Hormone(s). See also under name of hormone.
antidiuretic, renal response, defect in, *1970*: Nov., 1441
gestational contra-insulin, *1971*: July, 949
growth. See *Growth hormone.*
in evaluation of cancer patient, *1971*: May, 616
in experimental therapy of cancer, *1971*: May, 672
sex. See *Androgen; Estrogen.*
therapy, in pregnant diabetics, *1971*: July, 968
Hospitals, legal aspects of intensive care units, *1971*: Sept., 1367
Host immaturity, viral infections and, *1972*: March, 360–363
Human cell cultures, *1970*: May, **701–712**
Human chorionic gonadotropin, urinary, in diagnosis of carcinoma, *1971*: May, 618
Humidification, in oxygen therapy, *1971*: Sept., 1223
Humoral agent, deficiency, defect of phagocytosis due to, *1970*: May, 717–719
Huntington's chorea, *1972*: Nov., 1325, 1407, 1410
Hurler's disease, fibroblast cultures in, *1970*: May, 703
Hyaline membrane disease, disseminated intravascular coagulation and, *1972*: Jan., 181
Hydralazine (Apresoline), for hypertension, *1971*: March, 322
essential, *1971*: Jan., 17
polyneuritis due to, *1972*: Nov., 1315
thrombocytopenia due to, *1972*: Jan., 66
Hydramnios, in pregnant diabetics, *1971*: July, 966
Hydrocephalus, normal pressure, dementia of, *1972*: Nov., 1415
Hydronephrosis, urinary obstruction and, *1971*: Nov., 1422–1424
5-Hydroxyindoleacetic acid, urinary excretion, in malignant carcinoid, *1971*: May, 616
Hydroxyprogesterone caproate (Delalutin), in cancer therapy, *1971*: May, 684–693
Hydroxyproline, urinary, in diagnosis of metabolic bone disease, *1970*: July, 1067
Hydroxyurea (Hydrea), in cancer therapy, *1971*: May, 684–693
in dermatologic disorders, *1972*: May, 732
Hyoscyamine, for parkinsonism, *1972*: Nov., 1390
Hyperalimentation, intravenous, *1970*: May, **577–589**
Hyperbaric oxygen, for organ preservation, *1971*: Jan., 207
Hyperbetalipoproteinemia, diagnosis and diet therapy, *1970*: Nov., 1390–1391
treatment, *1970*: Nov., 1393
Hypercalcemia, causes, *1970*: March, 519; *1972*: July, 941, 942
crisis, intensive care for, *1971*: Sept., 1326
hyperparathyroidism and, *1970*: Jan., 132
in kidney transplantation, *1972*: July, 970–973
nephrolithiasis of, *1972*: July, 982
nonparathyroid, hypertension and, *1971*: Jan., 24
progressive renal disease and, *1972*: July, **961–975**
prolonged, in hyperparathyroidism, *1970*: March, 513–514
syndromes, diagnostic considerations, *1972*: July, **941–950**
treatment, *1972*: July, **951–960**

Hypercholesterolemia, diagnosis and treatment, *1971*: March, 404
dietary treatment, *1971*: July, 883
familial, essential, treatment, *1970*: Nov., 1604
treatment, *1970*: Nov., 1393
Hyperchylomicronemia, diagnosis and diet therapy, *1970*: Nov., 1393, 1394
Hypercupremia, *1970*: Nov., 1511
Hyperglobulinemia, syndromes associated with, diagnosis of, *1970*: July, **917–938**
Hyperglycemia, control, diabetic vascular disease and, *1971*: July, **889–897**
prospective study, *1971*: July, **1065–1075**
in surgical patient, *1971*: July, **939–945**
oral agents for. See *Oral hypoglycemic agents.*
hyperlipemia and, *1971*: March, 414
in diabetes mellitus, management, *1971*: March, 298
in diabetic coma, *1970*: May, 687
infection and, *1971*: July, 932
Hyperhidrosis, diabetes mellitus and, *1971*: July, 1004
Hyperkalemia, diagnosis and management, *1971*: March, 506–510
in chronic renal failure, *1971*: March, 347
in oliguric patient, *1971*: March, 339
Hyperketonemia, insulin and, *1971*: July, 900
Hyperlipemia(s). See also *Hyperlipoproteinemia(s).*
causes, *1971*: March, 407
diabetes mellitus and, *1971*: March, 303; July, 1024
disseminated intravascular coagulation and, *1972*: Jan., 181
exogenous, diagnosis and diet therapy, *1970*: Nov., 1394
mixed, atherosclerotic cardiovascular disease and, *1970*: Nov., 1450
primary, *1971*: March, 408–414
Hyperlipidemia(s), carbohydrate-induced, *1971*: March, 296
clinical approach, *1971*: March, **403–419**
coronary artery disease and, *1970*: Nov., 1599
in atherosclerosis, dietary and drug treatment of, *1970*: May, **657–669**
in endocrine disorders, *1972*: July, **1013–1020**
plasma lactescence and, *1971*: March, 404
tests for, *1970*: July, **1029–1035**
treatment, *1970*: Nov., **1599–1613**
Hyperlipoproteinemias. See also *Hyperlipemia.*
characteristic alterations in, *1970*: Nov., 1392
chemotherapy, *1970*: Nov., 1605–1612
classification, *1970*: Nov., 1390–1397, 1601–1604
clinical, *1970*: May, 660
clinical features, *1970*: Nov., 1603
diagnosis, *1970*: Jan., 154–156
paper electrophoresis in, *1970*: Nov., 1601, 1602
Hyperlipidemia(s) (*Continued*)
diet therapy for, *1970*: Nov., 1604, 1609
familial, dietary control, *1970*: Nov., 1442
treatment, *1970*: Nov., 1393
low-carbohydrate diet in, *1970*: Nov., 1608
mixed, diagnosis and diet therapy, *1970*: Nov., 1395
physical findings, *1970*: Nov., 1387–1391
tests for, *1970*: Nov., 1386–1387
Hypermelanosis, circumscribed, *1972*: July, 1042
Hypernephroma, prolonged fever and, *1970*: March, 386
Hyperosmolar coma, diabetes and, *1971*: July, 915
Hyperosmolar hyperglycemic nonketotic diabetic coma, *1970*: May, **683–699**
intensive care for, *1971*: Sept., 1319–1322
Hyperoxaluria, primary, *1972*: July, 982
Hyperparathyroid crisis, intensive care for, *1971*: Sept., 1326
Hyperparathyroidism, ectopic, *1972*: July, 943
hypertension and, *1971*: Jan., 25
neurologic complications, *1972*: July, 1029
primary, *1970*: March, **511–529**
diagnosis, simplified approach to, *1970*: Jan., **131–139**
hypercalcemia with, *1972*: July, 944–947
secondary, in advanced renal failure, prevention and treatment, *1972*: July, **961–975**
in uremia, *1970*: March, 422; *1971*: Nov., 1387
tests for, *1970*: July, 1062
treatment, *1970*: Jan., 137–138
Hyperphenylalaninemia, dietary control of, *1970*: Nov., 1435
Hyperprebetalipoproteinemia, chemotherapy, *1970*: Nov., 1607
diagnosis and therapy, *1970*: Nov., 1391–1394
Hypersensitivity reactions, chemical mediators of, *1972*: March, **541–556**
to penicillin, *1970*: Sept., 1092–1097
Hypersplenism, vs. idiopathic thrombocytopenia, *1972*: Jan., 49
Hypertension, arterial, complicated, *1972*: May, **633–644**
cerebrovascular disease and, *1970*: March, 350
chronic, treatment, *1971*: March, **317–324**
complicating home hemodialysis, *1971*: Nov., 1480
Cushing's syndrome and, *1971*: Jan., 32
diabetes mellitus and, *1971*: Jan., 26
encephalopathy (crisis) in, *1971*: March, **325–332**
endocrine, management of, *1971*: Jan., **23–45**
essential, management of, *1971*: Jan., **11–22**
glucocorticoid production and, *1971*: Jan., 32–36

Hypertension (*Continued*)
headache and, *1972*: Nov., 1265
hydralazine for, *1971*: Jan., 17; March, 322
hyperparathyroidism and, *1971*: Jan., 25
in pregnancy, nontoxemic, *1971*: Jan., 62–64
in uremia, *1970*: March, 418
in vascular disease, intensive care for, *1971*: Sept., 1211
malignant, *1971*: March, 325–329
renal failure with, *1971*: Nov., 1411
portal, intensive care for, *1971*: Sept., 1293
pulmonary, cardiac catheterization in, *1970*: July, 976
renal disease and, in pregnancy, *1971*: Jan., **47–69**
renal failure and, acute, *1971*: Jan., 129
chronic, *1971*: Jan., 140, 147–148; March, 349
renovascular, diagnosis of, *1971*: Nov., **1429–1438**
thyroid disorders and, *1971*: Jan., 25
urinary obstruction and, *1971*: Nov., 1422–1424
Hypertensive crisis, *1972*: May, 640–642
Hyperthermia, malignant, myoglobinuria and, *1972*: Nov., 1239
Hyperthyroidism, *1972*: May, **717–724**
factitious, *1972*: July, 846
glucose intolerance and, *1971*: July, 1062
hypertension and, *1971*: Jan., 25
hypocholesterolemia in, *1970*: Nov., 1481
laboratory diagnosis, *1970*: July, **1037–1047**
metabolic and nutritional aspects, *1970*: Nov., 1480–1482
neurologic complications, *1972*: July, 1030–1031
red cell 2,3-diphosphoglycerate and, *1970*: May, 736
Hypertriglyceridemias, diabetes mellitus and, *1971*: March, 303; July, 1024
dietary treatment, *1971*: July, 884
endogenous, diagnosis and diet therapy, *1970*: Nov., 1391–1394
treatment, *1970*: Nov., 1604
Hyperventilation, vs. intractable heart failure, *1970*: March, 313
Hypnotherapy in clinical medicine, *1972*: May, **687–692**
Hypnotic drugs, anticoagulants and, *1972*: Jan., 259
Hypoaldosteronism, familial, dietary control, *1970*: Nov., 1442
Hypocalcemia, in chronic renal failure, *1971*: March, 348
Hypocalcemic agents, dosages, *1972*: July, 958
Hypocholesterolemia, in hyperthyroidism, *1970*: Nov., 1481
Hypogammaglobulinemia, *1972*: May, 753–754
acquired (late-onset), *1970*: March, 294
pernicious anemia and, *1970*: May, 640
Hypoglycemia, clinical approaches, *1970*: March, **531–542**
coma of, *1972*: July, 1034
complicating insulin therapy, *1971*: July, 872
dementia with, *1972*: Nov., 1412
in diabetes mellitus, *1970*: March, 541; *1971*: July, 919–930
juvenile, *1971*: July, 983
leucine-sensitive, dietary control of, *1970*: Nov., 1436
post gastrectomy, *1970*: March, 540
reactive, in diabetes, coma and, *1971*: July, 913
Hypoglycemic agents, oral. See *Oral hypoglycemic agents.*
thrombocytopenia induced by, *1972*: Jan., 66
Hypogonadism, radioimmunoassay of gonadal hormones in, *1970*: July, 1056
zinc deficiency and, *1970*: Nov., 1517
Hypokalemia, diagnosis and management, *1971*: March, 510–512
in liver disease, *1970*: Nov., 1466
myoglobinuria and, *1972*: Nov., 1245
Hypolipoproteinemias, diagnosis of, *1970*: Jan., 156–157
Hyponatremia, *1972*: May, **645–649**
diuretic therapy and, *1971*: March, 364
Hypoparathyroidism, neurologic complications, *1972*: July, 1030
Hypophosphatemia, hyperparathyroidism and, *1970*: Jan., 134
Hypophysectomy, for metastatic breast cancer, *1972*: May, 659
microneurosurgical techniques, *1972*: July, **915–930**
Hypophysis. See *Pituitary gland.*
Hypopituitarism, glucose intolerance and, *1971*: July, 1060
metabolic and nutritional aspects, *1970*: Nov., 1478
Hypoprothrombinemia, congenital, *1972*: Jan., **127–132**
Hypotension, in vascular disease, intensive care for, *1971*: Sept., 1209
Hypothalamus, disorders, neurologic complications, *1972*: July, 1036
pigmentary disturbances and, *1972*: July, 1046
thyroid disease and, *1972*: July, 844
Hypothermia, for organ preservation, *1971*: Jan., 206
Hypothyroidism. See also *Myxedema.*
dementia with *1972*: Nov., 1412
hypertension and, *1971*: Jan., 26
hypothalamic, *1972*: July, 844
in childhood, *1972*: July, **871–884**
laboratory diagnosis, *1970*: July, **1037–1047**
metabolic and nutritional aspects, *1970*: Nov., 1482
neurologic complications, *1972*: July, 1031–1033
thyroid function tests in, *1970*: July, 1043
Hypoventilation, hypoxia due to, *1970*: May, 617

Hypoxemia, in acute respiratory failure and obstructive airway disease, management, *1971*: March, 446
red cell 2,3-diphosphoglycerate and, *1970*: May, 733
Hypoxia, cardiac arrhythmias and, *1971*: Sept., 1199
cerebral, dementia and, *1972*: Nov., 1412
pathophysiology of, *1970*: May, 617–624

ICF syndrome, diagnosis of, *1970*: July, 898
Icterus. See *Jaundice*.
I.F. See *Intrinsic factor*.
Ileitis, regional (terminal, distal). See *Regional enteritis*.
Imipramine (Tofranil), in parkinsonism, *1972*: Nov., 1388
Immune complex disease, rheumatoid arthritis as, *1972*: March, **529–539**
Immune defects, in carcinoma, *1971*: May, 731
Immune response, afferent limb of, concept of, *1970*: May, 714
disorders of, *1970*: May, 714–720
cell-mediated, *1972*: March, 310–314, 322
in virus infection, *1972*: March, 357–358
migration inhibitory factor and, *1972*: March, 298
T lymphocyte in, *1972*: March, 293
cellular basis of, *1972*: March, 322
disorders of. See *Immunological deficiency diseases*.
failure in carcinoma, *1972*: March, 493
humoral, *1972*: March, 310–314, 321–322
in cancer, *1972*: March, **481–499**
virus infection and, *1972*: March, 355–357
lymphoid cells and, *1970*: March, 282
mechanisms of, *1972*: March, 453–455
mucosal, *1972*: March, **391–402**
thymus and, *1970*: March, 281
to viruses, *1972*: March, 355–360
transfer of, *1972*: March, **465–480**
Immune system, deficiency, role of lymphocytes in, *1972*: March, **305–317**. See also *Immunologic deficiency disorders*.
development and nature of, *1972*: March, 310–315, 319–323
function. See *Immune response*.
M components, diseases associated with, *1972*: March, **371–389**
Immunity. See also *Autoimmunity; Immune response*.
"adoptive," *1972*: March, 465
clonal selection theory of, *1972*: March, 455
"local," *1972*: March, 394
role of lymphocyte in, *1972*: March, **293–303, 305–317**
tissue, biological significance of, *1970*: Jan., 55
tissue typing and, *1970*: Jan., **43–58**
Immunity (*Continued*)
transfer of, *1972*: March, **465–480**
viral infection and, *1972*: March, **353–370**
Immunocompetent cells, detection by mixed leukocyte culture, *1972*: March, 343
origin of, *1972*: March, 455–456
selective depletion in transplantation, *1972*: March, 461
Immunocytes, migration pathways, *1972*: March, 312
Immunodeficiency, combined, treatment, *1972*: March, 471. See also *Immunologic deficiency disorders*.
Immunoelectrophoresis, in diagnosis of syndromes associated with hyperglobulinemia, *1970*, July, 927–936
Immunofluorescence tests, for cancer, *1972*: March, 487
indirect, in Burkitt's lymphoma, *1971*: May, 764
Immunoglobulin(s), abnormalities, diagnosis of, *1970*: July, **917–938**
allotypes, genetic regulation of, *1972*: March, **557–575**
deficiencies, *1972*: March, 327. See also *Immunologic deficiency disorders*.
in celiac disease, *1970*: May, 651
in multiple myeloma, *1971*: May, 705
monoclonal, diseases associated with, *1972*: March, **371–389**
selective transport of, *1972*: March, 399
Immunoglobulin A, deficiency of, isolated, *1970*: March, 291
Immunologic deficiency disorders, *1970*: March, **281–307**; *1972*: May, **747–757**
autoimmunity and, *1972*: March, 328
bone marrow transplantation in, *1972*: March, 342, 443
cell-mediated, *1970*: March, 284, 286–288
classification, *1972*: March, 324–328
combined type, *1970*: March, 288–290
congenital, treatment by transfer of immunity, *1972*: March, 470–473
detection of, in vitro lymphocyte responses in, *1972*: March, **293–303**
mixed leukocyte culture in, *1972*: March, 343
gastrointestinal and respiratory manifestations, *1972*: March, 398
humoral, *1970*: March, 284–286
malignant disease and, *1972*: March, **501–514**
partial, *1970*: March, 291–296
secondary, *1970*: March, 296–298
susceptibility to viral infection in, *1972*: March, 360
Immunologic reactions, idiopathic thrombocytopenic purpura and, *1972*: Jan., 48
to drugs, thrombocytopenia and, *1972*: Jan., 70
Immunologic tolerance, *1970*: Jan., 54–55; *1972*: March, 343, 459
Immunology, human tumor, *1971*: May, **761–785**; *1972*: May, **801–836**

Immunosuppression. See also *Immunosuppressive drugs.*
after kidney transplantation, *1970*: Jan., 85–86
in transplantation, *1971*: Jan., 200–201
malignant disease and, *1970*: March, 299–300
Immunosuppressive drugs, after kidney transplants, *1970*: Jan., 84
for idiopathic thrombocytopenic purpura, *1972*: Jan., 60
for lupus nephritis, *1971*: Jan., 82
sensitivity of lymphocytes to, *1972*: March, 308
Immunosuppressive therapy, *1972*: March, 456–457, 467
antilymphocyte globulin in, clinical application, *1972*: March, **419–432**
immunodeficiency due to, *1972*: March, 327
infection and, *1972*: March, 361, 423
mixed leukocyte culture in evaluation of, *1972*: March, 343
Immunotherapy, of human cancer, *1971*: May, 778–782
of leukemia, *1971*: May, 563
Imuran. See *Azathioprine.*
Inborn errors of metabolism, nutritional management of, *1970*: Nov., **1431–1448**
INCAP (Institute of Nutrition of Central America), studies on nutrition, *1970*: Nov., 1424
Inderal. See *Propranolol hydrochloride.*
Indomethacine, anticoagulants and, *1972*: Jan., 257
for gout, *1970*: March, 439
thrombocytopenia induced by, *1972*: Jan., 66
Infant(s), hypothyroidism in, *1972*: July, 872–875
intensive care of, *1971*: Sept., **1263–1275**
iron deficiency in, *1970*: Nov., 1402
kanamycin dosage for, *1970*: Sept., 1249
low birth weight, cerebral palsy and, *1972*: Nov., 1273
newborn, gonococcal ophthalmia in, *1972*: Sept., 1120–1121
herpes genitalis and, *1972*: Sept., 1190
intravenous hyperalimentation in, *1970*: May, 580
syphilis in, *1972*: Sept., **1151–1160**
pernicious anemia in, dietary management, *1970*: Nov., 1445. See also *Anemia, pernicious.*
total parenteral nutrition for, methods, *1970*: Nov., 1377–1381
urinary screening tests in, *1971*: Nov., **1457–1471**
Infarction, myocardial. See under *Myocardium.*
Infection, antibiotics and suprainfection, *1971*: March, **471–483**
bacterial, diarrhea and, *1970*: March, 445–446
penicillins, for *1970*: Sept., 1086–1091
chronic renal failure and, *1971*: Jan., 139
complicating acute renal failure, *1971*: Jan., 130
Infection (*Continued*)
complicating carcinoma, *1971*: May, 729–745
complicating kidney transplantation, *1970*: Jan. 89
dementia with, *1972*: Nov., 1416
diarrheal, *1970*: March, **443–453**
enhanced susceptibility to, *1970*: May, **713–722**
in diabetics, *1971*: July, **931–938**
in hemophilia, management of, *1972*: Jan., 113
in malnourished subjects, *1970*: Nov., **1495–1508**
in multiple myeloma, *1971*: May, 709
intra-abdominal, and prolonged fever, *1970*: March, 384–386
nosocomial, in surgical intensive care unit, *1971*: Sept., **1331–1352**
resistance factors, nutrition and, *1970*: Nov., 1499
surgical, for, *1970*: Sept., 1153
vascular disease and, intensive care for, *1971*: Sept., 1214
viral. See *Viral infections.*
Infectious disease, treatment by transfer of immunity, *1972*: March, 473
Infectious mononucleosis, ampicillin in, rash with, *1970*: Sept., 1154
human tumor antigens and, *1971*: May, 763–771
Infectious polyneuritis, immunologic mechanism, *1972*: March, 521
Inflammatory reaction, vascular, chemical mediators of, *1972*: March, **541–556**
INH. See *Isoniazid.*
Inheritance, in diabetes mellitus, *1971*: July, **807–819**
Injury, nutrition after, *1970*: Nov., 1373–1375
Inorganic salts, in experimental chemotherapy of cancer, *1971*: May, 668
Institute of Nutrition of Central America (INCAP), studies on nutrition, *1970*: Nov., 1424
Insulin, allergy to, *1971*: July, 874
biosynthesis of, *1970*: Jan., 191–192; *1971*: July, 821
crystalline zinc, clinical pharmacology, *1971*: July, 862, 866
edema due to, *1971*: July, 874
excess, hypoglycemia and, *1970*: March, 535
for chronic pancreatitis, *1970*: March, 487
lente, clinical pharmacology, *1971*: July, 865
maternal-fetal relationships, *1971*: July, 948
metabolic effects, *1971*: July, 824–828
neutral protamine Hagedorn (NPH), *1971*: July, 863, 867
osteoporosis and, *1970*: Jan., 148
protamine zinc (PZI), clinical pharmacology, *1971*: July, 862
protein synthesis and, *1970*: Jan., **201–207**
resistance, *1971*: July, 873
obesity and, *1970*: Nov., 1534

Insulin (*Continued*)
secretion, diabetes and, *1971*: July, 828–831
physiologic regulation, *1971*: July, 821–824
skin reactions, *1971*: July, 1026
therapy, *1971*: July, **861–876**
advances, *1971*: July, 875
complications, *1971*: July, 872–874
hypoglycemia due to, *1971*: July, 923–926
in children and adolescents, *1971*: July, 979
in diabetic ketoacidosis, *1971*: July, 905
in pregnancy, *1971*: July, 952, 965
in surgical patient, *1971*: July, 871, **939–945**
liver function, and, *1971*: July, 824, 901
vs. oral hypoglycemia agents, *1971*: July, 1073
Insulinoma, hypoglycemia and, *1970*: March, 537
Intact nephron hypothesis, *1971*: March, 343
Intensive care unit(s), cardiac problems in, management, *1971*: Sept., **1183–1205**
cardiopulmonary resuscitation in, *1971*: Sept., **1157–1170**
central nervous system disease in, *1971*: Sept., **1233–1248**
chest problems in, management, *1971*: Sept., **1301–1313**
coronary, intermediate, *1971*: March, 290
nurses and physicians for, Regional Medical Programs and, *1970*: Jan., 23–24
electrical systems and safety, *1971*: Sept., **1095–1105**
endocrine emergencies in, *1971*: Sept., **1315–1329**
for respiratory disease, *1971*: Sept., **1217–1231**
gastrointestinal problems in, *1971*: Sept., **1277–1284**
hepatic disease in, *1971*: Sept., **1285–1299**
legal aspects, *1971*: Sept., **1365–1374**
monitoring systems for, *1971*: Sept., **1107–1126**
pediatric, *1971*: Sept., **1263–1275**
physiological measurements in, *1971*: Sept., **1141–1155**
planning, *1971*: Sept., **1083–1093**
psychiatric problems in, *1971*: Sept., **1353–1363**
renal failure and drug intoxication in, *1971*: Sept., **1249–1262**
staffing and nurses training, *1971*: Sept., **1127–1140**
surgical, sepsis in, *1971*: Sept., **1331–1352**
symposium on, *1971*: Sept., **1083–1374**
trauma patient in, *1971*: Sept., **1171–1181**
vascular disease in, *1971*: Sept., **1207–1215**
Intention tremor, *1972*: Nov., 1371
Interferon, in response to virus infection, *1972*: March, 358–360
nutritional deficiency and, *1970*: Nov., 1499
Interferon induction in cancer, *1971*: May, **721–728**
Internists, training in cancer, *1971*: May, **647–652**
Intestinal tract, diseases, nephrolithiasis with, *1972*: July, 984
Intestines. See also *Bowel*.
disorders of. See also names of disorders.
diabetes mellitus and, *1971*: July, 1035–1038
inflammatory, prolonged fever and, *1970*: March, 391
fistulas, medium chain triglycerides in, *1970*: Nov., 1375
malabsorption in. See *Malabsorption*.
parasites, jejunal biopsy and, *1970*: July, 859
small, biopsy of, *1970*: July, **851–862**
Intoxication, drug intensive care for, *1971*: Sept., **1258–1262**
vasopressin, hypertension and, *1971*: Jan., 24
Intracranial pressure, increased, emergency management, *1971*: Sept., 1244
Intravenous alimentation, *1970*: Nov., 1377–1381
Intravenous hyperalimentation, *1970*: May, **577–589**
Intrinsic factor, assay of, in megaloblastic-macroovalocytic anemias, *1970*: May, 637
Iodide, excessive circulating, thyroid function tests and, *1972*: July, 844
intravenous, for status asthmaticus, *1970*: March, 499
Iodine, protein-bound, thyroid function and, factors in interpretation, *1970*: Jan., 117
radioactive, for exophthalmic goiter, *1970*: Jan., 125
uptake, factors in interpretation, *1970*: Jan., 118
in thyroid disorders, *1972*: July, 842
Iron, absorption, *1970*: Nov., 1402
body, distribution, *1970*: Nov., 1401
measurement, *1970*: July, 909, 912
requirements, *1970*: Nov., 1404
deficiency, diagnosis and therapy, *1970*: July, **903–915**; Nov., 1405–1410
evaluation, marrow biopsy in, *1970*: Nov., 1405
prevention, *1970*: Nov., 1410
metabolism, *1970*: Nov., **1400–1406**
oral dosage, *1970*: Nov., 1408
parenteral, *1970*: Nov., 1409
therapeutic, as diagnostic test, *1970*: July, 912–913
Irradiation. See *Radiation; Roentgen*.
Ischemia, cerebral, pathogenesis of, *1970*: March, 352–355
muscle necrosis and, *1972*: Nov., 1242
transient attacks, anticoagulation and, *1972*: Jan., 243

Ischemia (*Continued*)
transient attacks, cerebrovascular disease and, *1970*: March, 351
therapy for, *1970*: March, 356
Ischemic mononeuropathy multiplex, *1971*: July, 1003
ISD. See *Isosorbide dinitrate.*
Islet cells of pancreas. See under *Pancreas.*
Isocarboxazid (Marplan), for parkinsonism, *1972*: Nov., 1387
Isoenzyme studies, in alcoholic muscle disease, *1970*: May, 726
Isolation of patients in surgical intensive care unit, *1971*: Sept., 1332–1334
Isoniazid (INH), blood glucose level and, *1971*: July, 927
polyneuritis due to, *1972*: Nov., 1315
thrombocytopenia induced by, *1972*: Jan., 66
Isoproterenol (Isuprel), for shock in myocardial infarction, *1970*: Jan., 240
for status asthmaticus, *1970*: March, 500
Isosorbide dinitrate, for intractable angina, *1970*: March, 335–336, 338–342
Isoxazolyl penicillins, *1970*: Sept., **1127–1143**
Isuprel. See *Isoproterenol.*
ITP syndrome. See *Purpura, idiopathic thrombocytopenic.*

JAPANESE encephalitis, *1972*: Nov.,
Jarisch-Herxheimer reaction, *1972*: Sept., 1172
Jaundice, chronic obstructive, *1972*: May, **759–770**
diabetes mellitus and, *1971*: July, 1040
intrahepatic cholestatic, due to erythromycin estolate, *1970*: Sept., 1204
Jejunum, biopsy of, *1970*: July, **851–862**
Joint(s), aspiration of, in hemophilia, *1972*: Jan., 111–112
disease, degenerative, diabetes mellitus and, *1971*: July, 1004

Kanamycin, *1970*: Sept., **1245–1256**
administration and dosage, *1970*: Sept., 1246, 1248, 1253
allergic reactions to, incidence of, *1970*: Jan., 63
bacteria resistant to, *1970*: Sept., 1250
clinical indications, *1970*: Sept., 1251
for urinary tract infection, *1971*: Nov., 1450
in infants, *1970*: Sept., 1249
Kaposi's sarcoma, immunologic aspects, *1972*: March, 504
Karyotyping, *1970*: July, 1011–1013
Kasabach-Merritt syndrome, disseminated intravascular coagulation and, *1972*: Jan., 181
Kayser-Fleischer ring, *1972*: Nov., 1335
Keflin. See *Cephalothin.*
Kemadrin. See *Procyclidine.*
Ketoacidosis, *1971*: July, **899–911**
acute abdomen in, *1971*: July, 1041
in pregnancy, *1971*: July, 954
infection and, *1971*: July, 932
insulin therapy in, *1971*: July, 870–905
intensive care for, *1971*: Sept., 1316–1319
Ketogenic diet, for convulsive disorders, *1972*: Nov., 1227
Ketonuria, branched-chain. See *Maple syrup urine disease.*
Kidney. See also *Renal.*
carbuncle, and prolonged fever, *1970*: March, 386
carcinoma of, prolonged fever and, *1970*: March, 387
colic, hyperparathyroidism and, *1970*: March, 514–515
disease, ampicillin in patients with, *1970*: Sept., 1146, 1154
animal models of, *1971*: Jan., 98–99
diabetes and, hypoglycemia in, *1971*: July, 924
due to methicillin, *1970*: Sept., 1122
ECHO virus and, *1971*: Jan., 91
enzymuria in, *1971*: Nov., 1502
fever, *1971*: Jan., 92
genetic, urinary findings in, *1971*: Nov., 1466
hypertension and, in pregnancy, *1971*: Jan., **47–69**
modern concepts in, symposium, *1971*: Nov., **1379–1574**
multiple myeloma and, *1971*: May, 709
nutritional management, *1971*: March, **513–520**
obstructive, clinical aspects, *1971*: Nov., **1417–1427**
symposium on, *1971*: Jan., **1–266**
syphilitic, *1972*: Sept., 1165
enzyme activity in, *1971*: Nov., 1498
erythropoiesis and, *1971*: Jan., 5
failure. See *Renal failure.*
function, clinical testing of, *1971*: Jan., **231–241**
in renovascular hypertension, *1971*: Nov., 1433
in liver disease, dietary control, *1970*: Nov., 1467
insufficiency, furosemide and ethacrynic acid for, *1971*: Jan., **107–119**
sodium colistimethate dosage in patients with, *1970*: Sept., 1272
involvement in urinary tract infection, tests for, *1971*: Nov., 1442–1444
regulation of sodium excretion, *1971*: Nov., **1509–1514**
scanning, *1971*: May, 554
stones, diagnosis and treatment, *1972*: July, **977–988**
idiopathic, *1972*: July, 984–986
systemic lupus erythematosus and, *1970*: Jan., 96
toxic reactions. See *Nephrotoxic reactions.*

Kidney (*Continued*)
transplantation of, antilymphocyte globulin therapy in, *1972*: March, 424–427
complications, *1970*: Jan., 88
dialysis and, *1970*: Jan., 75–77
donor selection in, *1970*: Jan., 79–83
HL-A antigen and, *1972*: March, 408–411
hypercalcemia and, *1972*: July, 961, 970–973
immunologic considerations, *1971*: Jan., **193–204**
medical criteria for, *1970*: Jan., 78
patient selection and management in, *1970*: Jan., **75–94**
of postoperative care, *1970*: Jan., 84
preparation for, *1970*: Jan., 83
tubular necrosis of, acute, after transplantation, *1970*: Jan., 89
tumors, prolonged fever and, *1970*: March, 386
vascular disease, dietary control, *1970*: Nov., 1453
viruses and, *1971*: Jan., **89–106**
Kinin system, in acute inflammatory reactions, *1972*: March, 546
Klebsiella infections, choice of therapy for, *1970*: Sept., 1162
Klinefelter's syndrome, chromosomal abnormality in, *1970*: July, 1018
radioimmunoassay of gonadal hormones in, *1970*: July, 1056

LABOR and delivery, management in diabetics, *1971*: July, 970–973
Lactic acidosis, coma of, diabetes and, *1971*: July, 914
intensive care for, *1971*: Sept., 1321
Lactic dehydrogenase (LDH), serum, in carcinoma, *1971*: May, 621
urinary, *1971*: Nov., 1493
Lactulose, for hepatic coma, *1971*: March, 373
Lacunar state, *1972*: Nov., 1411
Laennec's cirrhosis. See *Cirrhosis*.
Landry-Guillain-Barré syndrome, *1972*: Nov., 1307–1312
LAP. See *Leucine aminopeptidase*.
Lasix. See *Furosemide*.
Lavage, bronchopulmonary, *1970*: May, **755–771**
LDH. See *Lactic dehydrogenase*.
LDL. See *Lipoproteins, low-density*.
Lead intoxication, mental disturbance with, *1972*: Nov., 1414
Lee-White clotting time, anticoagulant therapy and, *1972*: Jan., 237
Legal aspects of intensive care units, *1971*: Sept., **1365–1374**
Lente insulins, clinical pharmacology, *1971*: July, 865
Leprosy, treatment by transfer of immunity, *1972*: March, 474
Leucine aminopeptidase (LAP), determination in urine, *1971*: Nov., 1493
Leucine-sensitive hypoglycemia, dietary control of, *1970*: Nov., 1436
Leukemia, acute, immunologic aspects, *1972*: March, 506
pathogenesis, *1971*: May, 566
treatment, changing concepts, *1971*: May, **561–600**
bone marrow transplantation in, *1972*: March, 441–442
cell kinetics and chemotherapy, *1971*: May, 576–586
cell proliferation, experimental studies, *1971*: May, 567–576
chemotherapy, cell proliferation studies and, *1971*: May, 572–576
multiple drugs, *1971*: May, 757
recent advances, *1971*: May, 564–566
chromosomal abnormality in, *1970*: July, 1021–1023
etiology, *1971*: May, 563
excessive fibrinolytic activity and, *1972*: Jan., 165
increased susceptibility to infection in, *1972*: March, 362
lymphatic, chronic, immunological, deficiency and, *1970*: March, 299
lymphocytic, chronic, immunologic aspects, *1972*: March, 504–505
myeloid, chronic, immunologic aspects, *1972*: March, 507
plasma cell, immunologic aspects, *1972*: March, 382
platelet transfusion for, *1972*: Jan., 86
Leukocyte(s), allogeneic, lymphocyte response in vitro, *1972*: March, 294–295
chemotaxis, disorder of, serum inhibitor and, *1970*: May, 719
urinary enzymes and, *1971*: Nov., 1496
Leukoencephalitis, hemorrhagic, acute, immunologic mechanisms in, *1972*: March, 519
Leukorrhea, causes of, *1972*: Sept., 1109
Levodopa, for Parkinson's syndrome, *1970*: May, 775–784; *1972*: May, 696–698; Nov., 1380–1387
Levophed. See *Norepinephrine*.
Levothyroxine, for hyperlipoproteinemias, *1970*: Nov., 1610
Lichen myxedematosus, immunologic aspects, *1972*: March, 386
Linconmycin, *1970*: Sept., **1295–1303**
Lipemia(s), treatment, *1970*: Nov., 1393
Lipid(s), abnormalities, diabetes mellitus and, *1971*: July, 1024, 1045
alterations, in atherosclerotic cardiovascular disease, *1970*: Nov., 1450,
disorders, diagnosis and dietary treatment, *1970*: Nov., **1383–1398**
genetic, dietary control, *1970*: Nov., 1442–1443
metabolism, disturbances in endocrine disorders, *1972*: July, **1013–1020**
plasma, in hyperlipoproteinemia, *1970*: Nov., 1386–1387
vs. lipoproteins, *1970*: May, 657
plasma transport, physiology of, *1970*: Nov., 1384–1386

Lipid(s) (*Continued*)
response to insulin, *1971*: July, 826
Lipoatrophy, insulin and, *1971*: July, 1027
Lipodystrophy, in juvenile diabetics, *1971*: July, 985
insulin and, *1971*: July, 874
Lipohypertrophy, insulin and, *1971*: July, 1027
Liproproteinemia(s). See also specific types.
broad-beta, diagnosis and diet therapy, *1970*: Nov., 1396
Liproproteins. See also *Hyperlipemias; Lipemias.*
beta, plasma transport, *1970*: Nov., 1385
electrophoretic properties, *1970*: Nov., 1602
low density (LDL), plasma transport, *1970*: Nov., 1385
plasma, abnormal, diagnosis of, *1970*: Jan., **153–159**
physicochemical properties, *1970*: Nov., 1384
prebeta, plasma transport, *1970*: Nov., 1385
transport, disorders, diagnosis and dietary treatment, *1970*: Nov., **1383–1398**
very low density (VLDL), *1970*: Nov., 1385
Lipschütz ulcer, vs. herpes genitalis, *1972*: Sept., 1184, 1186
Listeria monocytogenes infections, choice of therapy for, *1970*: Sept., 1163
tetracyclines for, *1970*: Sept., 1180
Lithiasis, uric acid, *1972*: July, 983–984
Lithium, tremor due to, *1972*: Nov., 1370
Lithium carbonate, in manic and depressive episodes, *1972*: May, **681–686**
Liver. See also *Hepatic.*
abscess, prolonged fever and, *1970*: March, 384
as source of lipoproteins, *1970*: Nov., 1384
cirrhosis of. See *Cirrhosis.*
disease. See also *Hepatitis.*
acute, dietary control, *1970*: Nov., 1462–1464
androgenic steroids in, *1970*: Nov., 1456
carbohydrate metabolism in, *1970*: Nov., 1457
chronic, dietary control, *1970*: Nov., 1464–1468
coma with. See *Hepatic coma.*
dementia with, *1972*: Nov., 1412
diabetes mellitus and, *1971*: July, 1039
diet and, *1970*: Nov., 1363
dietary control in, clinical aspects, *1970*: Nov., 1461–1468
disseminated intravascular coagulation and, *1972*: Jan., 180
heparin therapy, *1972*: Jan., 197
excessive fibrinolytic activity and, *1972*: Jan., 164
fat malabsorption in, *1970*: Nov., 1457
food tolerances in, *1970*: Nov., 1468
hypoglycemia and, *1970*: March, 533
intensive care for, *1971*: Sept., **1285–1299**
Liver (*Continued*)
disease, metabolic defects in, *1970*: Nov., 1455
nitrogen balance in, *1970*: Nov., 1456
nutrition and, *1970*: Nov., **1455–1472**
nutritional deficiencies in, *1970*: March, **467–477**
obstructive, hypercholesterolemia and, *1971*: March, 404
potassium deficiency in, *1970*: Nov., 1466
protein metabolism in, *1970*: Nov., 1456
renal function in, dietary control, *1970*: Nov., 1467
steatorrhea in, *1960*: Nov., 1458
therapeutic considerations, *1971*: March, **373–390**
vitamin deficiency in, *1970*: Nov., 1459–1461
failure, fulminant, halothane and, *1971*: March, 377
function, insulin and, *1971*: July, 824, 901
oral contraception and, *1970*: Jan., 166
tests, in Hashimoto's thyroiditis, *1972*: July, 892
gonorrhea and, *1972*: Sept., 1121
inflammation. See *Hepatitis.*
metastases, from colorectal cancer, *1972*: May, 670–673
scanning, *1971*: May, 545
surgery, coagulation defect after, *1972*: Jan., 217
toxic reactions to drugs. See *Hepatotoxic reactions.*
tumors, malnutrition and, *1970*: March, 470
prolonged fever and, *1970*: March, 389
Local immunity, *1972*: March, 394
Lofenalac, in phenylketonuria, *1970*: Nov., 1433
Low-residue diet, uses, *1970*: Nov., 1359–1362
Lung(s). See also *Pulmonary.*
abscess, penicillins in, *1970*: Sept., 1088
carcinoma of, detection of, *1970*: May, **549–553**
diseases, diffuse, transbronchoscopic lung biopsy in, *1970*: July, **951–959**
infections, antimicrobials for, *1970*: Sept., 1192
gram-negative, gentamicin for, *1970*: Sept., 1313
lesions, discrete, transthoracic needle aspiration of, *1970*: July, **961–971**
scanning, *1971*: May, 553
in pulmonary embolism, *1970*: March, 365
tuberculosis, without radiologic evidence, *1970*: March, 381
Lupus erythematosus, systemic, autoimmunity and, *1970*: Jan., 95–100
circulating anticoagulants and, *1972*: Jan., 148–150
esophageal involvement, motility studies in, *1970*: July, 869

Lupus erythematosus (*Continued*)
systemic, nephritis of, *1971*: Nov., 1407
reactions to antibiotics resembling, *1970*: Jan., 61
Lupus nephritis, *1971*: Nov., 1407
diagnosis and treatment, *1971*: Jan., **71–87**
Luteinizing hormone, radioimmunoassay for, *1970*: July, **1049–1059**
Lymphangiectasia, intestinal, *1970*:March, 296
jejunal biopsy in, *1970*: July, 858
Lymphangitis, penicillins for, *1970*: Sept., 1087
Lymphoblast cell lines, *1970*: May, 709
Lymphocyte(s), abnormalities, in vitro tests for, *1972*: March, **293–303**
bone-marrow dependent, *1972*: March, 307, 319–321
complement receptor (CRL), *1972*: March, 299
cytotoxicity test, *1970*: Jan., 47–50; *1971*: May, 775
differentiation of, physicochemical, *1972*: March, 307–310
function in mixed leukocyte culture, *1972*: March, 337
heterogeneity of, *1972*: March, **305–317**
immune response in vitro, significance of, *1972*: March, **293–303**, 309
immunocompetent, *1972*: March, 343, 455–456, 461
in resistance to virus infection, *1972*: March, 358
life span of, *1972*: March, 308
migration pathways in vivo, *1972*: March, 307, 312–315
response to phytohemagglutinin in malignant disease, *1972*: March, 502–509
thymus-dependent, *1972*: March, 294–295, 307
migration inhibitory factor and, *1972*: March, 298
thymus-independent, *1972*: March, 295
transfer test, in tissue typing, *1970*: Jan., 46
tumor antigens and, *1971*: May, 774–776
Lymphography, in lymphoma, *1970*: July, **939–949**
Lymphoid cells, immune response and, *1970*: March, 282
transfer of, problems associated with, *1972*: March, 466
Lymphoid system, nature of, *1972*: March, 306
Lymphoma, Burkitt's, *1972*: March, 366
chemotherapy for, *1971*: May, 685
immunologic aspects, *1971*: May, 763–771; *1972*: March, 503–504
lymphography in, *1970*: July, **939–949**
prolonged fever and, *1970*: March, 387
small bowel involvement, jejunal biopsy in, *1970*: July, 856, 857
Lymphopenia, in infants, immunologic deficiency and, *1970*: March, 288
Lymphoproliferative disorders, *1971*: May, 704
Lymphoreticular disorders, malignant, immunodeficiency in, *1972*: March, 327
susceptibility to infection in, *1972*: March, 362
Lymphosarcoma, immunologic aspects, *1972*: March, 503–504

M COMPONENTS. diseases associated with, *1972*: March, **371–389**
Macroglobulinemia, immunologic aspects, *1972*: March, 382–384, 506
Waldenström's, electrophoresis in diagnosis, *1970*: July, 923
Macrolide antibiotics, allergic reactions to, incidence of, *1970*: Jan., 63
Magnesium, intoxication, in chronic renal failure, *1971*: Jan., 144
Malabsorption, fat, cirrhosis and, treatment, *1971*: March, 374
in liver disease, *1970*: Nov., 1457
glucose-galactose, dietary control, *1970*: Nov., 1440
in celiac disease, *1970*: May, 650
Malaria, Burkitt's lymphoma and, *1971*: May, 767
disseminated intravascular coagulation and, *1972*: Jan., 181
Malignant disease. See *Carcinoma;* and *Tumors, malignant.*
Malignant hyperthermia, myoglobinuria and, *1972*: Nov., 1239
Malignant melanoma, cytoxicity tests in, *1972*: March, 485
immunologic aspects, *1971*: May, 768–770
Malignant myeloma, hypercalcemia with, *1972*: July, 944
Malleomyces pseudomallei infections, choice of therapy for, *1970*: Sept., 1163
Malnutrition, alcoholism and, *1970*: Nov., **1567–1575**
brain growth and, *1970*: Nov., 1414–1419
brain weight and, *1970*: Nov., 1419
cyclic nature of problem, *1970*: Nov., 1426
drug addiction and, *1970*: Nov., **1567–1575**
endocrine function and, *1970*: Nov., 1490–1491
infectious disease and, *1970*: Nov., **1495–1508**
liver disease and, *1970*: March, **467–477**
mental development and, *1970*: Nov., **1413–1429**
peripheral neuropathy and, *1970*: March, 473
Manganese, nutritional significance of, *1970*: Nov., 1525–1527
poisoning, mental disturbance with, *1972*: Nov., 1414

Manic-depressive reactions, lithium carbonate in, *1972*: May, **681-686**
Maple syrup urine disease, dietary control of, *1970*: Nov., 1435
genetic variants, *1970*: Nov., 1436
Marchiafava-Bignami's disease, dementia with, *1972*: Nov., 1414
Marfan's syndrome, fibroblast cultures in, *1970*: May, 703
Marplan. See *Isocarboxazid.*
Matulane. See *Procarbazine hydrochloride.*
Matylane. See *Procarbazine.*
May-Hegglin anomaly, *1972*: Jan., 43
MBC. See *Minimum bactericidal concentration.*
MDM. See *Minor determinant mixture.*
Measles, German. See *Rubella.*
in malnourished children, *1970*: Nov., 1503-1505
Measles virus. See *Rubella virus.*
Mechlorethamine hydrochloride, in cancer therapy, *1971*: May, 684-693
thrombocytopenia induced by, *1972*: Jan., 66
Mediastinitis, intensive care management, *1971*: Sept., 1312
Medical disorders, common treatment of, symposium on, *1971*: March, **273-520**
Medical education, evaluation of, *1970*: May, **591-602**
venereal disease control and, *1972*: Sept., **1101-1104**
Medicine, modern challenges in, symposium on, *1970*: Jan., **1-274**
new developments in, symposium on, *1970*: May, **547-817**
Medium chain triglycerides, in surgical nutrition, *1970*: Nov., 1375
Medroxyprogesterone acetate (Provera), in cancer therapy, *1971*: May, 684-693
Megakaryocytes, status of, in diagnosis of hemorrhage, *1972*: Jan., 19
Megaloblastic-macroovalocyte anemias, tests in, *1970*: May, 632-640
Melanin pigmentation, process of, *1972*: July, 1041-1042
Melanoma, malignant, cytotoxicity tests in, *1972*: March, 485
immunologic aspects, *1971*: May, 768-770
Melasma, *1972*: July, 1043
Melioidosis, chloramphenicol for, *1970*, Sept., 1192
Melphalan, in cancer therapy, *1971*: May, 684-693, 713-716
Meniere's disease, streptomycin for, *1970*: Sept., 1164
Meninges, metastases, diagnosis and treatment, *1971*: May, 636-639
Meningitis, bacterial, in children, ampicillin for, *1970*: Sept., 1149
penicillins for, *1970*: Sept., 1088
gonococcal, *1972*: Sept., 1121
kanamycin for, *1970*: Sept., 1254
Menopause, management, *1972*: May, **789-800**
Menopause (*Continued*)
osteoporosis after, *1972*: July, **989-997**
Menstruation, disorders of, investigation and classification, *1972*: July, **931-936**
oral contraception and, *1970*: Jan., 167
Mental development, nutrition and, *1970*: Nov., **1413-1429**
Mental retardation, hypothyroidism and, *1972*: July, 878
Meprobamate, anticoagulants and, *1972*: Jan., 259
thrombocytopenia induced by, *1972*: Jan., 66
6-Mercaptopurine, in cancer therapy, *1971*: May, 684-693
thrombocytopenia induced by, *1972*: Jan., 66
Mercury poisoning, mental disturbance with, *1972*: Nov., 1414
Metabolic acidosis. See *Acidosis, metabolic.*
Metabolic alkalosis. See *Alkalosis, metabolic.*
Metabolic coma in cancer, *1971*: May, 639
Metabolic disorders, dementia with, *1972*: Nov., 1412
Metabolic stone disease, diagnosis and treatment, *1972*: July, **977-988**
Metabolism, alcohol, *1970*: Nov., 1568
amino acids. See *Amino acids, metabolism.*
bone. See *Bone, metabolism.*
calcium, disorders of, in uremia, *1970*: March, 421-425; *1971*: Nov., 1387-1390
carbohydrate. See *Carbohydrates, metabolism.*
cerebral, in cerebral ischemia, *1970*: March, 354-355
changes in, uremia and, *1971*: Nov., **1381-1396**
chromium, *1970*: Nov., 1521
copper, *1970*: Nov., 1511
disorders of, in liver disease, *1970*: Nov., 1455
obesity and, *1970*: Nov., 1533-1542; *1972*: July, 1023
urinary findings in, *1971*: Nov., 1468
drug, *1970*: Nov., 1567
growth hormone and, *1970*: Nov., 1474
in disease and injury, *1970*: Nov., 1371, 1373-1375
inborn errors of, nutritional management, *1970*: Nov., **1431-1448**
iron, *1970*: Nov., **1400-1406**
protein. See *Protein(s), metabolism.*
starvation and, *1970*: Nov., **1367-1373**
trace elements and, current concepts, *1970*: Nov., **1509-1542**
zinc, *1970*: Nov., 1514
Metachromasia, cellular, fibroblast cultures in, *1970*: May, 703
Metalloenzymes, zinc, *1970*: Nov., 1514
Metastatic disease, delayed, immunologic aspects, *1972*: March, 482
Methacycline, *1970*: Sept., 1174, 1175

Methenamine mandelate, for urinary tract infection, *1971*: Nov., 1451
Methicillin, *1970*: Sept., **1113–1125**
in patients with renal failure, *1970*: Sept., 1118
nephritis due to, *1970*: Sept., 1122
spectrum of activity, *1970*: Sept., 1114, 1129
Methimazole, for exophthalmic goiter, *1970*: Jan., 124
Methotrexate (Amethopterin), in bone marrow transplantation, *1972*: March, 436
in cancer therapy, *1971*: May, 685–693
in dermatologic disorders, *1972*: May, 731–732
Methsuximide, thrombocytopenia induced by, *1972*: Jan., 66
Methyldopa (Aldomet), for hypertension, *1971*: March, 322
Methylhydantoin, thrombocytopenia induced by, *1972*: Jan., 66
Methylmalonic acidemia, dietary control, *1970*: Nov., 1444
fibroblast cultures in, *1970*: May, 705
Methylphenidate (Ritalin), for parkinsonism, *1972*: Nov., 1388
Methysergide maleate (Sansert), for migraine, *1972*: Nov., 1268
Metronidazole, for trichomonas vaginalis, *1972*: Sept., 1207–1208
MIC. See *Minimum inhibitory concentration.*
Microbial suprainfection, recognition and management, *1971*: March, **471–483**
Microcytotoxicity test, *1972*: March, 406
Microneurosurgery of pituitary gland, *1972*: July, **915–930**
Microradiography, in diagnosis of metabolic bone disease, *1970*: July, 1063
Microvascular disease in diabetes mellitus, *1971*: July, **847–860**
MIF. See *Migration inhibitory factor.*
Migraine, *1972*: Nov., 1257–1263
Migration inhibitory factory (MIF), *1971*: May, 777; *1972*: March, 298
Migration pathways, immunocyte, *1972*: March, 312
Military, venereal disease in, *1972*: Sept., **1087–1100**
Milkmaid's grasp, *1972*: Nov., 1324
Mineral(s), metabolism, in liver disease, *1970*: Nov., 1461
trace, current concepts, *1970*: Nov., **1509–1542**
Mineralocorticoids, increased production of, hypertension and, *1971*: Jan., 36–40
Minimum bactericidal concentration (MBC), *1970*: Sept., 1113
Minimum inhibitory concentration (MIC), *1970*: Sept., 1113
Minnesota Multiphasic Personality Inventory (MMPI), automated, *1970*: July, **835–849**
Minocycline, *1970*: Sept., 1174, 1175
Minor determinant mixture (MDM), in skin tests for penicillin allergy, *1970*: Sept., 1094, 1097
Mithramycin, in cancer therapy, *1971*: May, 684–693
Mitogen, lymphocyte response to, *1972*: March, 293–294, 309
Mitral valve, disease, cardiac catheterization in, *1970*: July, 974–975
incompetence, *1970*: Jan., **261–274**
Mixed leukocyte culture, *1972*: March, **337–351**
Mixed lymphocyte culture, in tissue typing, *1970*: Jan., 50–52
MMPI. See *Minnesota Multiphasic Personality Inventory.*
Mohs' technique, for recurrent epitheliomas, *1972*: May, **738–745**
Molybdenum, nutritional significance of, *1970*: Nov., 1527
Monamine oxidase cells, *1970*: Nov., 1419
Monamine oxidase inhibitors, anticoagulants and, *1972*: Jan., 258
Mongolism. See *Down's syndrome.*
Moniliasis, *1972*: Sept., 1110
Monitoring. See also under name of part or function.
equipment, for intensive care units, *1971*: Sept., **1107–1126**
Monoamine oxidase inhibition, in parkinsonism, *1972*: Nov., 1387
Mononeuritis multiplex, *1972*: Nov., 1300–1302
Mononeuropathy multiplex, ischemic, *1971*: July, 1003
Mononucleosis, infectious, ampicillin in, rash with, *1970*: Sept., 1154
human tumor antigens and, *1971*: May, 763–771
Morphine sulfate, blood glucose level and, *1971*: July, 927
to relieve anxiety in heart failure, *1970*: March, 321
Motor responses, brain lesions and, *1971*: Sept., 1241
Movement, involuntary, See *Dyskinesias* and specific disorders, as *Chorea.*
Mucinosis, papular, immunologic aspects, *1972*: March, 386
Mucolytic agents, for status asthmaticus, *1970*: March, 500
Mucous membranes, immunologic defense mechanisms of, *1972*: March, **391–402**
Multiple myeloma. See *Myeloma, multiple.*
Multiple sclerosis, *1972*: May, **711–716**
antilymphocyte globulin therapy in, *1972*: March, 429
immunologic mechanisms, *1972*: March, 519–521
recent advances in, *1972*: Nov., **1343–1362**
Mumps virus, renal disease and, *1971*: Jan., 91
Murphy-Pattee test for thyroxine, *1970*: July, 1044
Muscle(s), biopsy, in diagnosis of diabetes mellitus, *1971*: March, 297
diseases, alcoholic, *1970*: May, **723–730**
progressive, myoglobinuria and, *1972*: Nov., 1246

Muscle(s) (*Continued*)
disorders, diabetes mellitus and, *1971*: July, 1005, 1046
hypothyroidism and, *1972*: July, 877
myoglobinuria and, *1972*: Nov., **1233–1256**
insulin and, *1971*: July, 827
necrosis, myoglobinuria and, *1972*: Nov., 1242
skeletal, motor responses, brain lesions and, *1971*: Sept., 1241
Musculoskeletal system, disorders of, with hemophilia, management of, *1972*: Jan., 115
Myambutol. See *Ethambutol.*
Myasthenia gravis, immunologic mechanisms in, *1972*: March, 521–523
Myasthenic syndrome, as remote effect of cancer, *1971*: May, 644
Mycobacterial infections, nontuberculous, ethambutol for, *1970*: Sept., 1324
Mycoplasma pneumoniae infections, tetracyclines for, *1970*: Sept., 1179
Myelin, encephalitogenic component, *1972*: March, 516
Myelination, malnutrition and, *1970*: Nov., 1417
Myeloma, malignant, hypercalcemia with, *1972*: July, 944
multiple, amyloidosis and, *1971*: May, 708
chemotherapy for, *1971*: May, 710–716
clinical features and complications, *1971*: May, 709
diagnosis and management, *1971*: May, **703–719**
electrophoresis in diagnosis, *1970*: July, 922
immunologic aspects, *1972*: March, 377–382, 506
immunological deficiency and, *1970*: March, 299
immunoglobulins in, *1971*: May, 705
M components in, *1972*: March, 376
Myeloproliferative disorders, chromosomal abnormalities in, *1970*: July, 1023
uric acid lithiasis in, *1972*: July, 983
Myocardium, contraction, cellular events of, *1970*: Jan., 224–225
excitation, cellular events of, *1970*: Jan., 222–224
infarction, anticoagulants and, *1972*: Jan., 244
arrhythmias after, treatment, *1971*: March, **273–293**
early treatment, *1972*: May, 627–630
heart block after, *1971*: March, 278–285
hemodynamic effects and results of therapy, *1970*: Jan., **235–246**
oxygen consumption, *1972*: May, 599–600
revascularization, coronary arteriography after, *1970*: July, 991–993
for intractable angina, *1970*: March, 343–346
Myoglobinuria, *1972*: Nov., **1233–1256**
Mysoline. See *Primidone.*
Myxedema. See also *Hypothyroidism.*
coma of, intensive care for, *1971*: Sept., 1327
Myxedema (*Continued*)
dementia with, *1972*: Nov., 1412
hypercholesterolemia in, *1971*: March, 404
lipid disturbances in, *1972*: July, 1014–1016
neurologic complications, *1972*: July, 1031–1033
vs. intractable heart disease, *1970*: March, 314

NAFCILLIN, serum protein-binding, *1970*: Sept, 1117
spectrum of activity, *1970*: Sept., 1129
Nalidixic acid (NegGram), in urinary tract infections, *1970*: Sept., **1347–1350**
Narctoic metabolism, *1970*: Nov., 1569
Nasopharyngeal carcinoma, human tumor antigens and, *1971*: May, 763–771
Natriuretic drugs, *1971*: March, 359
Necrobiosis lipoidica diabeticorum, *1971*: July, 1020–1022
NegGram. See *Nalidixic acid.*
Neisseria gonorrhoeae, *1972*: Sept., 1107
antibiotic resistance in, *1972*: Sept., **1133–1144**
Neomycin, allergic reactions to, incidence of, *1970*: Jan., 63
for diarrheal disease, *1970*: March, 449, 451
sprue-like syndrome from, *1970*: Nov., 1458
Neoplasms. See *Carcinoma; Tumor(s).*
Nephritis, interstitial, acute, *1971*: Nov., 1410
lupus, *1971*: Nov., 1407
diagnosis and treatment, *1971*: Jan., **71–87**
methicillin, *1970*: Sept., 1122
Nephrolithiasis, idiopathic, *1972*: July, 984–986
in gout, *1970*: March, 435–436
metabolic, diagnosis and treatment, *1972*: July, **977–988**
Nephropathy. See *Kidney, disease.*
Nephrotic syndrome, diet in, *1971*: March, 519
electrophoretic diagnosis, *1970*: July, 925
hyperlipemia and, *1971*: March, 407
vs. intractable heart disease, *1970*: March, 315
Nephrotoxic reactions, to cephaloridine, *1970*: Sept., 1222
to polymyxins, *1970*: Sept., 1263
to sodium colistimethate, *1970*: Sept., 1271
to tetracyclines, *1970*: Sept., 1182
to vancomycin, *1970*: Sept., 1281
Nerve(s), peripheral, disorders, in uremia, *1970*: March, 412
malnutrition and, *1970*: March, 473
metastases, diagnosis and treatment, *1971*: May, 635
regeneration, patterns of, *1972*: Nov., 1301
vascular, disorders in diabetes, *1971*: July, 1003

Nerve conduction velocities, in polyneuritis, *1972*: Nov., 1305
Nervous system, abnormalities, in uremia, *1971*: March, 351
central, disorders of, in uremia, *1970*: March, 413
intensive care for, *1971*: Sept., **1233-1248**
ventilation therapy in, *1971*: Sept., 1243
penicillin toxicity and, *1970*: Sept., 1093
viral infections, *1972*: Nov., **1393-1403**. See also *Encephalitis*.
complications in carcinoma, *1971*: May, **625-646**
disorders. See also *Neuropathy*.
complicating chronic renal failure, *1971*: Jan., 149-150
diabetes mellitus and, *1971*: July, **1001-1006**
hypoglycemia and, *1970*: March, 532
immunologic mechanisms in, *1972*: March, **515-527**
with hemophilia, management of, *1972*: Jan., 114
hypothyroidism in infancy and, *1972*: July, 872
peripheral, disorders of, *1972*: Nov., **1299-1319**
toxic reactions, to polymyxins, *1970*: Sept., 1263
Net histocompatibility ratio (NHR), *1972*: March, 409
Neural crest tumors, diagnosis, biochemical, *1971*: May, 613
Neuritis, allergic, experimental, immunologic mechanisms in, *1972*: March, 518
Neuroblastoma, biochemistry of, diagnosis, biochemical, *1971*: May, 613
chemotherapy, *1971*: May, 685
immunologic aspects, *1971*: May, 776
urinary catecholamines and, *1971*: May, 614
Neurologic complications of cancer, *1971*: May, **625-646**
Neurologic disease, immunologic mechanisms in, *1972*: March, **515-527**
Neurologic problems in endocrine disease, *1972*: July, **1029-1039**
Neurology, clinical, symposium on, *1972*: Nov., 1225
Neuropathy, diabetic, *1971*: July, 895, 1002
peripheral, in uremia, *1970*: March, 412
malnutrition and, *1970*: March, 473
visceral, in diabetes, *1971*: July, 1031, 1036
Neurotoxic reactions, to polymyxins, *1970*: Sept, 1263
Neutral protamine Hagedorn (NPH) insulin, *1971*: July, 863, 867
Neutral third party test, in tissue typing, *1970*: Jan., 46
Neutrophil function, disorder of, in chronic granulomatous disease, *1970*: May, 714-717
infection and, *1971*: July, 932
Newborn. See under *Infant(s)*.
NHR. See *Net histocompatibility ratio*.
Nitrites, for angina pectoris, *1971*: March, 426; *1972*: May, 601-602
Nitrogen, balance, in Addison's disease, *1970*: Nov., 1487
in Cushing's syndrome, *1970*: Nov., 1485
protein metabolism and, *1971*: March, 513
loss, energy expenditure and, *1970*: Nov., 1371-1373
extrarenal, in disease and injury, *1970*: Nov., 1374
glucose and, *1970*: Nov., 1373
metabolism, abnormal, in disease, *1970*: Nov., 1373-1375
in liver disease, *1970*: Nov., 1456
in uremia, *1971*: Nov., 1384-1385
Nitrogen mustard. See *Mechlorethamine hydrochloride*.
Nitroglycerin, for intractable angina, *1970*: March, 334-335
Nontropical sprue. See *Sprue, nontropical*.
Norepinephrine (Levophed), for shock in myocardial infarction, *1970*: Jan., 240
Nosocomial infections, in surgical intensive care unit, *1971*: Sept., **1331-1352**
Novobiocin, *1970*: Sept., **1282-1287**
Nuclear medicine, diagnostic, *1971*: May, **545-560**
5′-Nucleotidase, serum, in carcinoma, *1971*: May, 620
Nurses, in intensive care unit, psychological hazards, *1971*: Sept., 1360
training, *1971*: Sept., **1127-1140**
Nutramigen, for galactosemia, *1970*: Nov., 1439
Nutrition, acromegaly and, *1970*: Nov., 1475
body composition and fuel supplies, *1970*: Nov., 1367-1373
brain function and, *1970*: Nov., 1421-1428
chronic obstructive jaundice and, *1972*: May, 760-762
clinical, current concepts, symposium on, *1970*: Nov., **1357-1613**
deficiencies. See also *Malnutrition*.
in liver disease, *1970*: March, **467-477**
polyneuritis and, *1972*: Nov., 1305
dental health and, *1970*: Nov., **1555-1565**
disturbances, dementias with, *1972*: Nov., 1413
in endocrine disorders, *1970*: Nov., **1473-1494**
drugs and, *1972*: May, 585-587
endocrine disease and, *1970*: Nov., **1473-1494**
in aged persons, *1970*: Nov., **1589-1597**
in cardiovascular disease, *1970*: Nov., **1449-1454**
in hereditary disorders, *1970*: Nov., **1431-1448**
in intravenous hyperalimentation, *1970*: May, 581, 582
in liver disease, *1970*: Nov., **1445-1472**

Nutrition (*Continued*)
in liver disease, clinical aspects, *1970*: Nov., 1461–1468
mental development and, *1970*: Nov., **1413–1429**
osteoporosis and, *1970*: Jan., 144-147
parenteral, total, *1970*: Nov., 1377–1381
surgical, *1970*: **1367–1381**
methods of treatment, *1970*: Nov., 1375–1381
tooth development and, *1970*: Nov., 1556–1559
Nutritional anemias, recent advances in, *1970*: May, **631–645**
Nutritional ecology, *1970*: Nov., 1505–1508
Nystatin, *1970*: Sept., **1329–1337**

OBESITY. adipose tissue growth in, *1970*: Nov., 1536–1539
carbohydrate intolerance and, *1971*: March, 296
causes of, *1971*: March, 392
diabetes mellitus and, *1970*: Nov., 1533; *1971*: July, 881
edema and, vs. intractable heart failure, *1970*: March, 313
management, *1971*: March, **391–401**
metabolic studies, *1970*: Nov., **1533–1542**
newer concepts of, *1970*: May, **745–754**
risks, causes, and treatment, *1972*: July, **1021–1028**
therapeutic considerations, *1970*: Nov., 1540
types of, *1970*: Nov., 1537
Ocular toxicity, to ethambutol, *1970*: Sept., 1319
Oligomenorrhea, investigation and classification, *1972*: July, **931–936**
Oliguria, in acute renal tubular insufficiency, treatment, *1971*: March, 337
Oncogenesis, antilymphocyte serum and, *1972*: March, 424
Oncogens, in vitro study, *1971*: May, **653–665**
Oncology, clinical, training in, *1971*: May, **647–652**
Oncorna virus, *1971*: May, 770
Oncovin. See *Vincristine*.
Onycholysis, treatment of, *1970*: Sept., 1336
Oophorectomy, in metastatic breast cancer, *1972*: May, 657
Ophthalmia, gonococcal, *1972*: Sept., 1120–1121
Ophthalmoplegia, migraine and, *1972*: Nov., 1262
Oral cavity, disease, diet and, *1970*: Nov., 1559–1563
Oral contraceptives. See *Contraceptives, oral*.
Oral health, nutrition and, *1970*: Nov., **1555–1565**
Oral hypoglycemic agents, evaluation of use, *1971*: July, **1065–1075**
Oral hypoglycemic agents (*Continued*)
in surgical patient, *1971*: July, 945
skin reactions, *1971*: July, 1026
symptomatic hypoglycemia with, *1971*: July, 926
Orinase. See *Tolbutamide*.
Orotic aciduria, hereditary, dietary control, *1970*: Nov., 1443
Orphenadrine (Disipal), for parkinsonism, *1972*: Nov., 1390
Osteitis fibrosis, chronic renal failure and, *1971*: March, 350
Osteitis fibrosa cystica, hyperparathyroidism and, *1970*: March, 514
Osteoarthritis, comprehensive regimen for, *1971*: March, **457–469**
Osteodystrophy, renal, *1970*: March, 421–422
metabolic changes in, *1971*: Nov., 1387–1390
tests for, *1970*: July, 1062
treatment, *1971*: March, 349
Osteogenic sarcoma, thermography in, *1970*: May, 612
Osteomalacia, tests for, *1970*: July, 1062
treatment, *1971*: March, 349
Osteomyelitis, kanamycin for, *1970*: Sept., 1254
lincomycin for, *1970*: Sept., 1298
oxacillin and cloxacillin for, *1970*: Sept., 1134
penicillins for, *1970*: Sept., 1090
Osteoporosis, bone metabolism and, *1970*: Jan., **141–152**
in postmenopausal women, *1972*: May, 792
postmenopausal and senile, *1972*: July, **989–997**
primary, tests for, *1970*: July, 1062
Otitis media, acute, in children, ampicillin for, *1970*: Sept., 1148
penicillins for, *1970*: Sept., 1087
Ototoxic reactions, to dihydrostreptomycin, *1970*: Sept., 1161
to gentamicin, *1970*: Sept., 1312
to kanamycin, *1970*: Sept., 1247, 1249
to vancomyin, *1970*: Sept., 1281
Ouabain, blood glucose level and, *1971*: July, 927
Ouchterlony test, *1971*: May, 765
Overeating, situational determinants of, *1970*: May, 747
Oxacillin, clinical indications, *1970*: Sept., 1133
preparations and dosage, *1970*: Sept., 1136, 1137
spectrum of activity, *1970*: Sept., 1129
toxic reactions, *1970*: Sept., 1135
Oxandrolone, for postmenopausal and senile osteoporosis, *1972*: July, 992
Oxolinic acid, for urinary tract infection, *1971*: Nov., 1452
Oxygen, arterial. See *Blood gases*.
consumption, fever and, *1970*: Nov., 1374
thyroxine and, *1970*: Nov., 1481
hyperbaric, for organ preservation, *1971*: Jan., 207

Oxygen (*Continued*)
therapy, for intensive care, *1971*: Sept., 1223–1226
for status asthmaticus, *1970*: March, 501
humidification with, *1971*: Sept., 1223
transport by erythrocytes, *1970*: May, 787
heredity and environment and, *1970*: May, **731–743**
Oxytetracycline, *1970*: Sept., 1174, 1175

PACEMAKER. cardiac, in heart block with acute myocardial infarction, *1971*: March, 281, 284
paired ventricular stimulation by, *1970*: Jan., **247–259**
Paget's disease, tests for, *1970*: July, 1062
Pagitane, See *Cycrimine*.
Pancreas, carcinoma, diabetes and, *1971*: July, 1039
glucose intolerance and, *1971*: July, 1062
cystic fibrosis of, fibroblast cultures in, *1970*: May, 703
disorders, neurologic complications, *1972*: July, 1034–1036
dysfunction, diabetes and, *1971*: July, 1036, 1038
function, preservation in diabetics, *1971*: July, 878
tests of, *1970*: March, 483
islet cell tumors. See also *Insulinoma*.
cholera-like syndrome and, *1970*: May, **567–575**
hypoglycemia and, *1970*: March, 537
neurologic complications, *1972*: July, 1035
scanning, *1970*: March, 486; July, 881–888; *1971*: May, 556
Pancreatitis, acute, disseminated intravascular coagulation and, *1972*: Jan., 181
chronic, *1970*: March, **479–492**
Pancreatography, *1970*: March, 485
Panencephalitis, sclerosing, subacute, *1972*: March, 364, 515
Papular mucinosis, immunologic aspects, *1972*: March, 386
Para-aminosalicylic acid (PAS), blood glucose level and, *1971*: July, 927
Parahemophilia (factor V deficiency), *1972*: Jan., **119–125**
Paralysis, cerebral, *1972*: Nov., **1273–1279**
athetosis of, *1972*: Nov., 1328
Paramethadione, thrombocytopenia induced by, *1972*: Jan., 66
Parasite(s) intestinal, immunologic aspects, *1972*: March, 396
jejunal biopsy and, *1970*: July, 859
Parathormone. See *Parathyroid hormone*.
Parathyroid gland(s), crisis, intensive care for, *1971*: Sept., 1326
disorders, hypertension and, *1971*: Jan., 25
Parathyroid gland(s) (*Continued*)
disorders, neurologic problems, *1972*: July, 1029–1030
function, *1970*: March, 511–512
scanning, *1971*: May, 556
Parathyroid hormone, calcium and phosphorus levels and, *1972*: July, 945
osteoporosis and, *1970*: Jan., 149
phosphorus levels and, *1972*: July, 945
radioimmunoassay, *1972*: July, **937–940**
hyperparathyroidism and, *1970*: Jan., 136–137
Pargyline, for hypertension, *1971*: Jan., 17; *1971*: March, 323
Parkinson's disease, *1972*: May, **693–709**; Nov., 1339–1340, 1365–1366
amantidine for, *1970*: May, 784
levodopa for, *1970*: May, 775–784
newer medical treatments for, *1970*: May, **773–785**
treatment, current concepts, *1972*: Nov., **1377–1392**
Parnate. See *Trancylpromine*.
Paronychia, treatment, *1970*: Sept., 1336
Parsidol. See *Ethopropazine*.
Partial thromboplastin time test, *1970*: July, 894
PAS (Para-aminosalicylic acid), blood glucose level and, *1971*: July, 927
Pasteurella infections, choice of therapy for, *1970*: Sept., 1163
tetracyclines for, *1970*: Sept., 1179
Patau's syndrome, chromosomal abnormality in, *1970*: July, 1016
Patent ductus arteriosus, cardiac catheterization in, *1970*: July, 975–976
Patient Inventory Questionnaire, *1970*: July, 828
PBI. See *Iodine, protein-bound*.
Pellagra, mental disturbance with, *1972*: Nov., 1414
Pelvic inflammatory disease, gonococcal, *1972*: Sept., 1118–1119
treatment, *1972*: Sept., 1112
Pemphigus vulgaris, autoimmunity and, *1970*: Jan., 100–104
Penicillin, allergic reactions, *1970*: Sept., 1092–1097
contaminants and, *1970*: Jan., 64
incidence of, *1970*: Jan., 62
prevention of, *1970*: Jan., 66–68
skin tests in, *1970*: July, **997–1007**
benzathine, hypersensitivity reactions, *1970*: Sept., 1094
biosynthesis of, *1970*: Sept., 1082
chloramphenicol as alternate to, *1970*: Sept., 1193
clinical indications, *1970*: Sept., 1086–1091
for gonorrhea, *1972*: Sept., 1111
for syphilis, *1972*: Sept., 1171–1173
in pregnancy, *1972*: Sept., 1155
hypersensitivity reaction to, *1972*: Sept., 1172
isoxazolyl, *1970*: Sept., **1127–1143**
natural, *1970*: Sept., **1081–1099**

Penicillin (*Continued*)
penicillinase-resistant, *1970*: Sept., 1130
phenoxyalkyl, *1970*: Sept., 1101–1111
prophylactic use, *1970*: Sept., 1091, 1106
protein-binding activity in, *1970*: Sept., 1094, 1095, 1131
extent and significance, *1970*: Sept., 1117
renal excretion, *1970*: Sept., 1084, 1105
resistance of gonococcus to, *1972*: Sept., **1133–1144**
semisynthetic, for staphylococcal infections, *1970*: Sept., 1118–1121
sensitivity of gonococcus to, *1972*: Sept., 1063
serum concentrations, *1970*: Sept., 1083, 1084, 1104
structure, *1970*: Sept., 1082, 1101, 1102
Penicillin G, for urinary tract infection, *1971*: Nov., 1450
pharmacology, *1970*: Sept., 1083
spectrum of activity, *1970*: Sept., 1103, 1129
toxic reactions, *1970*: Sept., 1093
vs. methicillin, *1970*: Sept., 1114
Penicillin V, *1970*: Sept., 1101–1111
preparations and dosage, *1970*: Sept., 1105
spectrum of activity, *1970*: Sept., 1103
toxic reactions, *1970*: Sept., 1108
Penicilloylation, 1094, 1095, *1970*: Sept., 1094, 1095
Peptic ulcer, diabetes and, *1971*: July, 1035
diet and, *1970*: Nov., 1357–1359
gastroscopy in, *1971*: March, 308
uncomplicated, treatment, *1971*: March, **305–315**
Perfusion, for organ preservation, *1971*: Jan., 209, 211
Periactin. See *Cyproneptadine hydrochloride*.
Pericarditis, constrictive, vs. intractable heart disease, *1970*: March, 315
fibrinous, uremia and, *1971*: March, 351
tuberculous, *1970*: March, 381
uremic, *1970*: March, 415
Pericardium, diseases of, cardiac catheterization in, *1970*: July, 977
Peripheral nervous system. See under *Nervous system*.
Peritoneal dialysis, *1971*: Jan., 155–160. See also *Dialysis; Hemodialysis*.
Perlèche, nystatin for, *1970*: Sept., 1334
Pernicious anemia. See under *Anemia*.
Personality, assessment, automated, *1970*: July, **835–849**
Pertussis, erythromycin for, *1970*: Sept., 1207
Peyer's patches, *1972*: March, 308, 311, 314
pH, effect on antimicrobial drugs, *1971*: Nov., 1448
PHA. See *Phytohemagglutinin*.
Phagocytosis, defect of, due to humoral agent deficiency, *1970*: May, 717–719
nutrition and, *1970*: Nov., 1498
III-IV Pharyngeal pouch syndrome, *1970*: March, 286
Pharyngitis, bacterial, efficacy of penicillins for, *1970*: Sept., 1086
Pharyngitis (*Continued*)
gonococcal, *1972*: Sept., 1131
treatment, *1972*: Sept., 1112
streptococcal, oxacillin and cloxacillin in, *1970*: Sept., 1134
Phase contrast microscopy, of urinary sediment, *1971*: Jan., 244–254
Phenacemide, thrombocytopenia induced by, *1972*: Jan., 66
Phenethicillin, *1970*: Sept., 1101–1111
indications for, *1970*: Sept., 1106
spectrum of activity, *1970*: Sept., 1103
Phenformin, in diabetes mellitus, *1971*: March, 301
Phenindamine (Thephorin), for parkinsonism, *1972*: Nov., 1390
Phenobarbital, for grand mal seizures, *1972*: Nov., 1226
Phenol and phenolic acids, platelet function and, in uremia, *1972*: Jan., 228
Phenothiazines, anticoagulants and, *1972*: Jan., 256
dyskinesias due to, *1972*: Nov., 1333
Phenoxyalkyl penicillins, *1970*: Sept., 1101–1111
Phenoxyethylpenicillin. See *Phenethicillin*.
Phenoxymethylpenicillin. See *Penicillin V*.
Phenylalanine hydroxylase defect, *1970*: Nov., 1433
Phenylbutazone (Butazolidin), anticoagulants and, *1972*: Jan., 256
blood glucose level and, *1971*: July, 927
for gout, *1970*: March, 439
thrombocytopenia induced by, *1972*: Jan., 66
Phenylketonuria, nutritional management, *1970*: Nov. 1433–1435
Phenyramidol, anticoagulants and, *1972*: Jan., 258
blood glucose level and, *1971*: July, 927
Pheochromocytoma, diagnosis, biochemical, *1971*: May, 613
glucose intolerance and, *1971*: July, 1061
hypertension and, *1971*: Jan., 27
lipid disturbances in, *1972*: July, 1017
nutritional disturbances in, *1970*: Nov., 1488
Philadelphia Pulmonary Neoplasm Research Project, *1970*: May, **549–553**
PHLA. See *Post-heparin lipolytic activity*.
Phosphate(s), in prevention of dental caries, *1970*: Nov., 1561
oral, for hypercalcemia, *1972*: July, 957
tubular reabsorption of, hyperparathyroidism, and, *1970*: Jan., 135
Phosphohexose isomerase (PHI), serum, in carcinoma, *1971*: May, 621
Phospholipids, in plasma lipid transport, *1970*: Nov., 1384
Phosphorus, serum and urine, hypercalcemia and, *1972*: July, 965–966
parathyroid hormone and, *1972*: July, 946
tubular reabsorption, hyperparathyroidism and, *1970*: March, 524
Phosphorylase deficiency, myoglobinuria with, *1972*: Nov., 1236
Photocoagulation for diabetic retinopathy, *1971*: July, 996

Photoscan display system, evaluation, *1971*: May, 550
Photosensitivity reaction, to antibiotics, *1970*: Jan., 60
to tetracyclines, *1970*: Sept., 1182
Phycomycosis, diabetes and, *1971*: July, 935
Physicians, legal liability and intensive care units, *1971*: Sept., 1366, 1368
training in cancer, *1971*: May, **647–652**
Physiology, clinical, tests, in intensive care units, *1971*: Sept., **1141–1155**
Phytohemagglutinin (PHA), lymphocyte response, in vitro, *1972*: March, 294–295, 309
in malignant disease, *1972*: March, 502–509
Pick's disease, *1972*: Nov., 1407, 1409
Pigmenturia, *1972*: Nov., 1235
Pineal gland, pigmentary disturbances and, *1972*: July, 1045
Pituitary fossa, herniation of arachnoid through, *1972*: July, 897
Pituitary gland, ablation for diabetic retinopathy, *1971*: July, 993–996
disorders, hypertension and, *1971*: Jan., 24
lipid disturbances, *1972*: July, 1016–1017
neurologic complications, *1972*: July, 1036
pigmentary disturbances, *1972*: July, 1046
insufficiency, hypoglycemia and, *1970*: March, 534
microneurosurgery, *1972*: July, **915–930**
surgery, current trends, *1972*: July, **909–914**
for metastatic breast cancer, *1972*: May, 659
surgical approaches, *1972*: July, 915
tumors, surgical removal, *1972*: July, 927
Pituitary hormones, thyroid disease and, *1970*: July, 1038; *1972*: July, 841, 843
Plaque test, *1971*: May, 775
Plasma, appearance, in lipoprotein anomalies, *1970*: Nov., 1386
cholesterol, atherosclerotic cardiovascular disease and, *1970*: Nov., 1450
factors, assay of, *1970*: July, 896
deficiencies of, tests for, *1970*: July, 894–897
lactescence, hyperlipidemias and, *1971*: March, 404
lipids. See *Lipids; Lipoproteins.*
platelet-rich, for transfusion, *1972*: Jan., 82
renin, in renovascular hypertension, *1971*: Nov., 1433
triglycerides, atherosclerotic cardiovascular disease and, *1970*: Nov., 1450
in diagnosis of hyperlipidemias, *1971*: March, 403
volume, diuretics and, *1971*: March, 362
Plasma cell leukemia, *1972*: March, 382
Plasma cell neoplasms, management, *1971*: May, **703–719**
Plasma clot time test, *1970*: July, 894
Plasma thromboplastin antecedent (factor XI), coagulation and, *1972*: Jan., 99
Plasma transglutaminase precursor. See *Fibrin stabilizing factor (XIII).*
Plasminogen, activators in fibrinolysis, *1972*: Jan., 154–157
structure and function, *1972*: Jan., 154
Platelet(s), adhesiveness, tests of, *1972*: Jan., 36
aggregation, tests of, *1972*: Jan., 37
biochemistry of, *1972*: Jan., 26–29
coagulation and, *1972*: Jan., 101
concentrates, for transfusion, *1972*: Jan., 82
current research problems, *1972*: Jan., 5
defects, uremia and, *1972*: Jan., 223–231
early history of, *1972*: Jan., 12
frozen, for transfusion, *1972*: Jan., 84
function, *1972*: Jan., **25–33**
aspirin and, *1972*: Jan., 40
disorders, *1972*: Jan., **35–46**
uremia and, *1972*: Jan., 223
tests, *1970*: July, 891; *1972*: Jan., 35–38
von Willebrand's disease and, *1972*: Jan., 277–278
life span of, shortened, *1972*: Jan., **47–64.** See also *Purpura, idiopathic thrombocytopenic.*
number of, in diagnosis of hemorrhage, *1972*: Jan., 18
structure of, electron microscope study, *1972*: Jan., 25
survival and turnover, *1972*: Jan., 52
transfusions, *1972*: Jan., **81–94**
dosage, *1972*: Jan., 89–91
immunologic aspects, *1972*: Jan., 91–92
in idiopathic thrombocytopenic purpura, *1972*: Jan., 58
Platelet anti-aggregant therapy, in occlusive cerebrovascular disease, *1972*: Nov., 294
Pleural effusion, in uremia, *1970*: March, 416
Pleuritis, in uremia, *1970*: March, 416
Pneumonia, aspiration, penicillins for, *1970*: Sept., 1088
bacterial suprainfection and, *1971*: March, 476
mycoplasma, erythromycin for, *1970*: Sept., 1206
pneumococcal, erythromycin for, *1970*: Sept., 1205
penicillins for, *1970*: Sept., 1088, 1133
viral, vs. intractable heart failure, *1970*: March, 313
Pneumothorax, intensive care after, *1971*: Sept., 1308–1310
PNH. See *Hemoglobinuria, paroxysmal nocturnal.*
Poisoning, dialysis for, *1971*: Sept., 1259
heavy metal, polyneuropathy of, *1972*: Nov., 1315
tremor due to, *1972*: Nov., 1372
Pokeweed mitogen (PWM), lymphocyte response in vitro, immunologic significance, *1972*: March, 294, 297
Poly I:C anti-oncogenic and antitumor effects, *1971*: May, 723

Polyarteritis nodosa, glomerulonephritis in, *1971*: Nov., 1409
Polycythemia, erythropoietin and, *1970*: Jan., 177–178
Polymyositis, as remote effect of cancer, *1971*: May, 644
Polymyxin(s), *1970*: Sept., **1257–1265**
clinical indications, *1970*: Sept., 1263
for diarrheal disease, *1970*: March, 451
for urinary tract infection, *1971*: Nov., 1451
preparations and dosage, *1970*: Sept., 1260
reduction schedule to avoid renal injury, *1970*: Sept., 1261
spectrum of activity, *1970*: Sept., 1257
toxic reactions, *1970*: Sept., 1263
Polymyxin B sulfate, *1970*: Sept., 1259
Polymyxin E. See also *Colistin*.
Polymyxin E sulfomethyl derivative, *1970*: Sept., 1259, 1262
Polyneuritis, *1972*: Nov., **1299–1319**
infectious, immunologic mechanisms in, *1972*: March, 521
Pompe's disease, fibroblast cultures in, *1970*: May, 706
Porphyria, polyneuropathy of, *1972*: Nov., 1313
Porphyrin, disturbances, griseofulvin and, *1970*: Sept., 1341
Post-heparin lipolytic activity (PHLA), *1970*: Nov., 1385
Potassium body, in renal failure, acute, *1971*: Jan., 126
chronic, *1971*: Jan., 143
cell function and, *1971*: March, 503
deficiency, diagnosis and management, *1971*: March, 510–512
in liver disease, *1970*: Nov., 1466
myoglobinuria and, *1972*: Nov., 1245
excessive, diagnosis and management, *1971*: March, 506–510
in chronic renal failure, *1971*: March, 347
in oliguric patient, *1971*: March, 339
exchangeable body, in acromegaly, *1970*: Nov., 1475
measurement of, *1970*: Nov., 1368, 1370
in intravenous hyperalimentation, *1970*: May, 584
metabolism, disorders, diagnosis and treatment, *1971*: March, **503–512**
Potassium iodide, for thyrotoxicosis, *1970*: Jan., 127
Pre-beta-lipoproteins, plasma transport, *1970*: Nov., 1385
Prednisone, in cancer therapy, *1971*: May, 684–693
in leukemia, *1971*: May, 586, 590
Preeclampsia, prophylaxis and therapy, *1971*: Jan., 60–62
renal pathology in, *1971*: Jan., 49
Pregnancy, carbohydrate metabolism in, *1971*: July, 947–951
Pregnancy (*Continued*)
diabetes mellitus in, medical aspects, *1971*: July, **947–959**
obstetrical management, *1971*: July, **961–974**
edema in, *1971*: Jan., 50–60
glucose tolerance test in, *1971*: July, 951, 961
herpes genitalis in, *1972*: Sept., 1190
hypertension in, nontoxemic, *1971*: Jan., 62–64
with renal disease, *1971*: Jan., **47–69**
lipid disturbances in, *1972*: July, 1018
syphilis in, *1972*: Sept., **1151–1160**
Preleukemia, vs. thrombocytopenic purpura, *1972*: Jan., 48, 49
Primidone (Mysoline), for grand mal seizures, *1972*: Nov., 1226
Proaccelerin (factor V), coagulation and, *1972*: Jan., 98
deficiency, *1972*: Jan., **119–125**
Probenecid (Genemid), blood glucose level and, *1971*: July, 927
Procainamide, for cardiac arrhythmias, *1971*: March, 439
for paroxysmal ventricular tachycardia, *1972*: May, 622
Procaine penicillin G, for gonorrhea, *1972*: Sept., 1111
Procarbazine hydrochloride, (Matylane), in cancer therapy, *1971*: May, 684–693
in dermatologic disorders, *1972*: May, 735
Proctitis, gonococcal, treatment, *1972*: Sept., 1112
Procyclidine (Kemadrin), in parkinsonism, *1972*: Nov., 1390
Progesterone, carbohydrate metabolism and, *1971*: July, 950
Progestins, in cancer therapy, *1971*: May, 684–693
Proinsulin, *1970*: Jan., **191–199**
Properdin, nutritional deficiency and, *1970*: Nov., 1499
Promazine, thrombocytopenia induced by, *1972*: Jan., 66
Propranolol, (Inderal), for angina pectoris, *1971*: March, 428
intractable, *1970*: March, 337, 338–342
for cardiac arrhythmia, *1971*: March, 275, 287, 441
for hypertension, *1971*: March, 323
for paroxysmal atrial fibrillation, *1972*: May, 612
for thyrotoxicosis, *1970*: Jan., 128
Propylthiouracil, anticoagulants and, *1972*: Jan., 258
blood glucose level and, *1971*: July, 927
for exophthalmic goiter, *1970*: Jan., 124
Prostate gland, carcinoma, serum acid phosphatase level in, *1971*: May. 619
surgery of, hemorrhage and, *1972*: Jan., 212
Prostatitis, nonspecific urethritis and, *1972*: Sept., 1196–1197
Protamine zinc insulin (PZI), clinical pharmacology, *1971*: July, 862

Protein(s), calcium level and, *1972*: July, 941
clearance of, selective, clinical significance, *1971*: Jan., 219
deficiency, liver disease and, *1970*: March, 467–470
glomerular filtration and tubular reabsorption, mechanism of, *1971*: Jan., 214
metabolism, in liver disease, *1970*: Nov., 1456
in uremia, *1971*: Nov., 1381–1387
nitrogen balance and, *1971*: March, 513
nutritional status during infectious disorders, *1970*: Nov., 1500
requirements, for diabetics, *1970*: Nov., 1579
restriction, in uremia, *1970*: March, 425–428
synthesis of, cardiac hypertrophy and, *1970*: Jan., 214–216
insulin and, *1970*: Jan., **201–207**
measurement, *1970*: Nov., 1481
regulation, thyroxine in, *1970*: Nov., 1481
thyroxine-binding, anomalies, *1972*: July, 844–845
measurement, *1972*: July, **849–860**
total body, measurement, *1970*: Nov., 1368
Protein binding, in penicillins, *1970*: Sept., 1094, 1095, 1131
Protein-bound iodine, thyroid function and, factors in interpretation, *1970*: Jan., 117
Proteinosis, alveolar, bronchopulmonary lavage for, *1970*: May, 762
Proteinuria, *1971*: Jan., **213–230**
normal, *1971*: Jan., 223–225
Proteolytic agents, for status asthmaticus, *1970*: March, 500
Proteus infections, choice of therapy for, *1970*: Sept., 1162
Prothrombin, coagulation and, *1972*: Jan., 97
deficiency, *1972*: Jan., **127–132**
Prothrombin consumption test, *1970*: July, 896
Prothrombin time test, *1970*: July, 895
Protozoal infection, in carcinoma, *1971*: May, 743
Provera. See *Medroxyprogesterone acetate.*
Prower factor (X), coagulation and, *1972*: Jan., 98
Pruritus, diabetes and, *1971*: July, 1019
in chronic cholestasis, *1972*: May, 762–765
of biliary cirrhosis, treatment, *1971*: March, 373
Pruritus ani, candidal, nystatin for, *1970*: Sept., 1335
Pseudoaldosteronism, licorice-induced, hypertension and, *1971*: Jan., 39
Pseudohyperparathyroidism, *1972*: July, 943
Pseudomonas infections, choice of therapy for, *1970*: Sept., 1162
polymyxins for, *1970*: Sept., 1263
sodium colistimethate for, *1970*: Sept., 1270
Pseudomonas infections (*Continued*)
sodium colistimethate for, efficacy, *1970*: Sept., 1273
Psittacosis, tetracyclines for, *1970*: Sept., 1179
Psychiatric problems in intensive care units, *1971*: Sept., **1353–1363**
Psychological aspects of dying, *1972*: May, **677–680**
Psychological evaluation, automated, *1970*: July, **835–849**
Psychosocial factors in diabetes mellitus, *1971*: July, **1007–1018**
Puberty, early or late, radioimmunoassay of gonadal hormones in, *1970*: July, 1054, 1055
Pulmonary. See also *Lung(s).*
Pulmonary edema, acute, treatment, *1971*: March, 370
Pulmonary embolism. See *Embolism, pulmonary.*
Pulmonary emphysema, vs. intractable heart failure, *1970*: March, 314
Pulmonary tuberculosis. See *Tuberculosis.*
Pulse(s), loss, diabetes mellitus and, *1971*: July, 1046
peripheral, monitoring, equipment for, *1971*: Sept., 1114
Pump-oxygenator systems, for organ preservation, *1971*: Jan., 209
Pupillary disturbances, diabetes mellitus and, *1971*: July, 1005
Pupils, size and reaction, brain lesions and, *1971*: Sept., 1239
Purpura, anaphylactoid, *1972*: Jan., **201–206**
Henoch-Schönlein, glomerulonephritis in, *1971*: Nov., 1409
idiopathic thrombocytopenic, *1972*: Jan., **47–64**
acute, chronic, and recurrent, *1972*: Jan., 50–52
differential diagnosis, *1972*: Jan., 47–49
laboratory tests for, *1972*: Jan., 54–56
platelet transfusion for, *1972*: Jan., 87
pregnancy and, *1972*: Jan., 57
therapy, *1972*: Jan., 56–61
thrombotic thrombocytopenic, *1971*: Nov., 1412
PWM. See *Pokeweed mitogen.*
Pyloric obstruction, intravenous hyperalimentation for, *1970*: May, 584
Pyoderma gangrenosum, immunologic aspects, *1972*: March, 387
Pyrabenzamine. See *Tripelennamine.*
Pyridoxine, as antagonist to levodopa effect, *1970*: May, 783
for vitamin B_6-dependent convulsive disorders, *1970*: Nov., 1444
for xanthurenic aciduria, *1970*: Nov., 1445
Pyrimidine analogs, in experimental therapy of cancer, *1971*: May, 677
Pyroglobulins, *1970*: July, 924
Pyroscan, use of, *1970*: May, 605
Pyruvate kinase deficiency, red cell 2,3-diphosphoglycerate and, *1970*: May, 737

QUICK prothrombin time test, anticoagulant therapy and, *1972*: Jan., 237
Quinacrine, in cancer therapy, *1971*: May, 684–693
thrombocytopenia induced by, *1972*: Jan., 66
Quinidine, for cardiac arrhythmias, *1971*: March, 438
for paroxysmal ventricular tachycardia, *1972*: May, 622

RADIATION. See also *Roentgen*.
ionizing, cancer due to, *1971*: May, 661
Radioimmunoassay, for follicle-stimulating and luteinizing hormones, *1970*: July, **1049–1059**
Radioisotope scanning. See *Scanning*.
Radionuclides, distribution, quantitative imaging of, *1971*: May, 550
estimated radiation dose from, *1971*: May, 546
in diagnosis of carcinoma, *1971*: May, **545–560**
in localization of malignant tumors, *1971*: May, 557
Rauwolfia, for essential hypertension, *1971*: Jan., 16
Raynaud's syndrome, thermography in, *1970*: May, 612
Rectum, as site of asymptomatic gonococcal infection, *1972*: Sept., 1128–1130
Red cells. See *Erythrocytes*.
Refsum's disease, dietary control, *1970*: Nov., 1442
Reflux esophagitis, *1972*: May, **771–780**
Regional enteritis, diet in, *1970*: Nov., 1361
intravenous hyperalimentation for, *1970*: May, 585
prolonged fever and, *1970*: March, 391
Regional Medical Programs, rural, *1970*: Jan., **19–28**
urban, *1970*: Jan., **29–33**
Rejection reaction, graft vs. host, *1972*: March, 466
immunologic aspects, *1972*: March, 305–317, 453–455
in bone marrow transplantation, *1972*: March, 436–438
minimizing, *1972*: March, 456, 467. See also *Immunosuppressive therapy*.
pathophysiology of, *1971*: Jan., 194
Renal. See also *Kidney*.
Renal failure, acute, diagnosis and treatment, *1971*: March, **335–342**
dietary management, *1971*: March, 519
furosemide and ethacrynic acid in, *1971*: Jan., 114–115
heart failure with, *1971*: Jan., 129
intensive care for, *1971*: Sept., **1249–1262**
oliguric, conservative management, *1971*: Jan., **121–135**
anemia of, *1971*: Jan., **3–9**
Renal failure (*Continued*)
chronic, bacterial endocarditis and, *1971*: Jan., 140
conservative management, *1971*: Jan., **137–154**
diagnosis and treatment, *1971*: March, **342–357**
fluid and electrolyte abnormalities in, *1971*: March, 345
furosemide and ethacrynic acid in, *1971*: Jan., 110–114
heart disorders with, *1971*: Jan., 146–147
hypocalcemia in, *1971*: March, 348
magnesium intoxication in, *1971*: Jan., 144
metabolic consequences, *1971*: March, 344
drug dosages and, *1971*: March, 341
due to cephaloridine, *1970*: Sept., 1222
hyperparathyroidism in, prevention and treatment, *1972*: July, **961–975**
intravenous hyperalimentation for, *1970*: May, 586
methicillin in patients with, *1970*: Sept., 1118
urinary obstruction and, *1971*: Nov., 1421
Renal insufficiency, furosemide and ethacrynic acid for, *1971*: Jan., **107–119**
sodium colistimethate dosage in patients with, *1970*: Sept., 1272
Renal osteodystrophy, *1970*: March, 421–422
metabolic changes in, *1971*: Nov., 1387–1390
tests for, *1970*: July, 1062
treatment, *1971*: March, 349
Renal shutdown, in vascular disease, intensive care for, *1971*: Sept., 1211
Renal toxicity. See *Nephrotoxic reactions*.
Renal tubular acidosis, chronic renal failure and, *1971*: March, 347
cirrhosis and, *1971*: March, 369
dietary control, *1970*: Nov., 1442
nephrolithiasis in, *1972*: July, 978–980
treatment, *1971*: March, 339
Renal tubular insufficiency, acute, diagnosis and treatment, *1971*: March, 335
Renal tubular necrosis, acute, after transplantation, *1970*: Jan., 89
Renal vein thrombosis, management, acute, *1971*: Sept., 1256
Renin, plasma, in renovascular hypertension, *1971*: Nov., 1433
Renovascular disease, dietary control, *1970*: Nov., 1453
Renovascular hypertension, diagnosis, *1971*: Nov., 1429–1438
Reptilase, blood defibrination by, *1972*: Jan., 182
Reserpine (Sandril; Serpasil), for hypertension, *1971*: March, 321
Respiration, abnormalities, brain lesions and, *1971*: Sept., 1238

Respiration (*Continued*)
assisted, in central nervous system disease, *1971*: Sept., 1243
in obstructive airway disease, *1971*: March, 452–455
monitoring, equipment for, *1971*: Sept., 1115
for intensive care, *1971*: Sept., 1227–1230
Respiratory disease, gastrointestinal complications of, *1971*: Sept., 1279
Respiratory distress syndrome, disseminated intravascular coagulation and, *1972*: Jan., 181
Respiratory failure, acute, in obstructive airway disease, *1971*: March, 446
intensive care after, *1971*: Sept., **1217–1231**
Respiratory tract disorders, immunodeficiency and, *1972*: March, 398
Respiratory tract infections, in surgical intensive care units, *1971*: Sept., 1334
lower, oxacillin and cloxacillin for, *1970*: Sept., 1133
Respiratory syncytial virus infection, immunologic aspects, *1972*: March, 364
Resuscitation, cardiopulmonary, equipment for, *1971*: Sept., 1120–1122
in children, *1971*: Sept., 1273
in intensive care units, *1971*: Sept., **1157–1170**
technique, *1971*: Sept., 1159–1162
Reticular dysgenesis, immunologic aspects, *1972*: March, 324
Reticuloendothelial system, disseminated intravascular coagulation and, *1972*: Jan., 179
Reticulum cell disease, *1971*: May, 704
Reticulum cell sarcoma, immunologic aspects, *1972*: March, 503–504
lymphography in, *1970*: July, 940
Retinopathy, diabetic, pituitary ablation for, *1972*: July, 924–927
treatment, *1971*: July, **989–999**
Revascularization of myocardium, coronary arteriography after, *1970*: July, 991–993
for intractable angina, *1970*: March, 343–346
Rheumatic fever, Sydenham's chorea and, *1972*: Nov., 1324
Rheumatoid arthritis, Arthus reaction and, *1972*: March, 535
as immune complex disease, *1972*: March, **529–539**
neuropathies of, *1972*: Nov., 1317
virus and, *1972*: March, 367
Rheumatoid factor, *1972*: March, 533
Rickets, chronic renal failure and, *1971*: March, 349
vitamin D-dependent, dietary management, *1970*: Nov., 1445
Rickettsial infections, chloramphenicol for, *1970*: Sept., 1191
tetracyclines for, *1970*: Sept., 1179
Rifampin, for urinary tract infection, *1971*: Nov., 1452
Ristocetin, allergic reactions to, incidence of, *1970*: Jan., 64
platelet destruction by, *1972*: Jan., 49
Ritalin. See *Methylphenidate*.
RMP. See *Regional Medical Programs*.
RNA virus, oncogenic, *1971*: May, 770
Rocky Mountain spotted fever, disseminated intravascular coagulation and, *1972*: Jan., 181
Roentgen examination, in chronic pancreatitis, *1970*: March, 484
in hyperparathyroidism, *1970*: March, 521
in pulmonary embolism, *1970*: March, 364
in renal failure, acute, *1971*: Jan., 124
chronic, *1971*: Jan., 138
of bile ducts, percutaneous and transhepatic, *1970*: July, **875–879**
Roentgen treatment, enteritis due to, jejunal biopsy in, *1970*: July, 858
for carcinoma, *1971*: May, **747–760**
neurologic complications, *1971*: May, 642
for peptic ulcer disease, *1971*: March, 314
RSV. See *Respiratory syncytial virus*.
Rubella virus, immunization, complications, *1972*: March, 363–364
infection, antibody tests in, *1972*: March, 356, 357
Rubin tube, for jejunal biopsy, *1970*: July, 852

ST. LOUIS encephalitis, *1972*: Nov., 1395
Salicylates, anticoagulants and, *1972*: Jan., 257
blood glucose level and, *1971*: July, 927
for osteoarthritis, *1971*: March, 463
Salmonella infections, ampicillin for, *1970*: Sept., 1152
chloramphenicol for, *1970*: Sept., 1191
choice of therapy for, *1970*: Sept., 1162
Sandril. See *Reserpine*.
Sansert. See *Methysergide maleate*.
Sarcoidosis, hypercalcemia and, *1972*: July, 947
Sarcoma, immunologic aspects, *1971*: May, 770
osteogenic, thermography in, *1970*: May, 612
reticulum cell, lymphography in, *1970*: July, 940
viruses and, *1972*: March, 366
Scanning, *1971*: May, **545–560**
computer-analyzed, *1971*: May, 550
pancreas, *1970*: March, 486; July, **881–888**
pulmonary, *1971*: May, 553
in pulmonary embolism, *1970*: March, 365
thyroid gland, *1971*: May, 553
Schilling test, *1971*: May, 556
in megaloblastic-macroovalocytic anemias, *1970*: May, 637

Scleremyxedema, immunologic aspects, *1972*: March, 386
Scleroderma, esophageal involvement, motility studies in, *1970*: July, 868
glomerulonephritis in, *1971*: Nov., 1411
thermography in, *1970*: May, 612
Sclerosis, multiple. See *Multiple sclerosis.*
systemic, progressive, glomerulonephritis in, *1971*: Nov., 1411
Scopolamine hydrobromide, for parkinsonism, *1972*: Nov., 1390
Sedatives, anticoagulants and, *1972*: Jan., 259
for status asthmaticus, *1970*: March, 502
Seizures, convulsive, treatment of, *1972*: Nov., **1225–1231**
uremic, complicating acute renal failure, *1971*: Jan., 129
vitamin B_6-dependent, management, *1970*: Nov., 1444
myoglobinuria and, *1972*: Nov., 1240
Selenium, nutritional significance, *1970*: Nov., 1523–1525
Sella turcica, enlargement, syndrome of, *1972*: July, **897–907**
Senile dementia, *1972*: Nov., 1407, 1409
Senile osteoporosis, *1972*: July, **989–997**
Sepsis, diabetic vascular disease and, *1971*: July, 1051
in surgical intensive care units, *1971*: Sept., **1331–1352**
Septal defect(s), cardiac catheterization in, *1970*: July, 975–976
Septicemia, disseminated intravascular coagulation and, *1972*: Jan., 181
heparin therapy, *1972*: Jan., 196
in surgical intensive care units, *1971*: Sept., 1345–1347
platelet destruction in, vs. idiopathic thrombocytopenic purpura, *1972*: Jan., 49
Serial thrombin time, in disseminated intravascular coagulation, *1970*: May, 559
Serotonin, in mechanism of migraine, Nov., 1259
Serotyping, mixed leukocyte culture vs., *1972*: March, 342
Serpasil. See *Reserpine.*
Serratia infections, choice of therapy for, *1970*: Sept., 1162
Serum enzymes, in pulmonary embolism, *1970*: March, 365
Serum globulin, immune, for prophylaxis of infectious hepatitis, *1970*: March, 463
Serum glutamic pyruvic transaminase, in Down's syndrome, *1970*: May, 811
Serum inhibitor, leukocyte chemotaxis disorder and, *1970*: May, 719
Serum sickness-like reactions to drugs, *1970*: Sept., 1094
Sex, changes in attitudes and practices, venereal disease and, *1972*: Sept., 1065
Sex hormones. See *Androgen, Estrogen*
Sexual maturation, delayed and precocious, hypothyroidism and, *1972*: July, 880–883
Sheehan's syndrome, nutritional changes in, *1970*: Nov., 1478
Shigellosis, ampicillin for, *1970*: Sept., 1153
choice of therapy for, *1970*: Sept., 1163
Shock, cardiogenic, causes, *1971*: Sept., 1185
intensive care after, *1971*: Sept., **1183–1191**
disseminated intravascular coagulation and, *1972*: Jan., 181
myocardial infarction and, *1970*: Jan., 237–238
surgical, hemorrhage and, *1972*: Jan., 211
Shunt(s), portacaval, hemorrhage and, *1972*: Jan., 213
right-to-left, blood gas measurements in, *1970*: May, 624–626
hypoxia due to, *1970*: May, 620–624
Shwartzman reaction, generalized, pathogenesis of, *1970*: May, 562
Sight. See *Vision.*
Simmond's disease, nutritional changes in, *1970*: Nov., 1478
Sinusitis, acute bacterial, penicillins in, *1970*: Sept., 1087
Skeletal system. See *Bone(s).*
Skin, disorders, autoimmune factors in, *1970*: Jan., **95–105**
chemotherapy in, *1972*: May, **725–737**
impaired reactivity in malignant disease, *1972*: March, 507–508
osteoporosis and, *1970*: Jan., 143
pigmentation, altered, endocrine disorders and, *1972*: July, 1049
reactions, in diabetes mellitus, *1971*: **1019–1029**
to antibiotics, *1970*: Jan., 60
to chlorpropamide, *1971*: July, 1026
to penicillins, *1970*: Sept., 1094
to vancomycin, *1970*: Sept., 1281
tests, for antigen hypersensitivity, *1972*: March, 324
for cancer, *1971*: May, 775
for penicillin allergy, *1970*: July, **997–1007**
Skull, thermography of, *1970*: May, 613
SLE. See *Lupus erythematosus, systemic.*
Slow-reacting substances (SRS), in acute inflammatory reactions, *1972*: March, 548
Snake venom, disseminated intravascular coagulation and, *1972*: Jan., 181
Sodium, balance, in diabetic coma, *1970*: May, 689
body, in pregnancy, *1971*: Jan., 52
in renal failure, acute, *1971*: Jan., 126
chronic, *1971*: Jan., 143
deficiency, *1972*: May, **645–649**
diuretic therapy and, *1971*: March, 364
excretion, diuretics and, *1971*: March, 359–361
in chronic renal failure, *1971*: March, 345
renal regulation, *1971*: Nov., **1509–1514**
restriction, for chronic heart failure, *1970*: March, 324

Sodium (*Continued*)
restriction, for congestive heart failure, *1970*: Nov., 1452
in liver disease, *1970*: Nov., 1466
Sodium colistimethate, *1970*: Sept., **1267–1276**
Soft tissue infections, diabetes and, *1971*: July, 934
Somatomammotropin, human chorionic, carbohydrate metabolism and, *1971*: July, 949
Somatotropin. See *Growth hormone*.
Sophisticated diagnostic procedures, symposium on, *1970*: July, **823–1070**
Spasm, torsion, *1972*: Nov., 1328–1333
Spasmus nutans, *1972*: Nov., 1372
Spinal cord compression, due to metastases, *1971*: May, 631–635
Spine, osteoarthritis of, *1971*: March, 467
thermography of, *1970*: May, 613
Spirillum infections, choice of therapy for, *1970*: Sept., 1162
Spleen, congenital hypoplasia of, susceptibility to infections in, *1970*: May, 720
scanning, *1971*: May, 555
Splenectomy, for idiopathic thrombocytopenic purpura, *1972*: Jan., 58
Spondylitis, ankylosing, nonspecific urethritis and, *1972*: Sept., 1199
Sprue, nontropical, *1970*: **647–656**
diabetes mellitus and, *1971*: July, 1036
jejunal biopsy in, *1970*: July, 854
tropical, jejunal biopsy in, *1970*: July, 855, 858
SSPE (Subacute sclerosing panencephalitis), *1972*: March, 364, 515
Staphylococcal abscess, intravenous hyperalimentation for, *1970*: May, 585
Staphylococcal infections, erythromycin for, *1970*: Sept., 1202, 1206
methicillin for, *1970*: Sept., 1113–1125
methicillin-resistant, *1970*: Sept., 1121
novobiocin for, *1970*: Sept., 1284
penicillin G vs. methicillin for, *1970*: Sept., 1114
semisynthetic penicillins for, evaluation, *1970*: Sept., 1118–1121
soft-tissue, isoxazolyl penicillins for, *1970*: Sept., 1132
vancomycin for, *1970*: Sept., 1277–1281
Starvation, metabolic response to, *1970*: Nov., 1367–1373
Status asthmaticus, *1970*: March, **493–509**. See also *Asthma*.
Status epilepticus, treatment, *1972*: Nov., 1229
Steatorrhea, diabetic, *1971*: July, 1035
jejunal biopsy in, *1970*: July, 851
liver disease and, *1970*: Nov., 1458
Stem cells, lymphopoietic, *1972*: March, 320, 455
defects in, diseases resulting from, *1972*: March, 324–326
Stenosis. See name of organ or part.
Sterilization, in diabetics, *1971*: July, 972
Steroid(s), androgenic, in liver disease, *1970*: Nov., 1456
Steroid(s) (*Continued*)
therapy. See *Corticosteroids*.
Stomach, disorders, diabetes mellitus and, *1971*: July, 1032
neuropathy, diabetes mellitus and, *1971*: July, 1004
ulcer. See *Peptic ulcer*.
Stools, examination, in chronic pancreatitis, *1970*: March, 482
Stramonium, for parkinsonism, *1972*: Nov., 1390
Streptococcal infections, acute glomerulonephritis after, *1971*: Nov., 1406
choice of therapy for, *1970*: Sept., 1162
erythromycin for, *1970*: Sept., 1204
lincomycin for, *1970*: Sept., 1298
oxacillin and cloxacillin for, *1970*: Sept., 1134
penicillin G vs. methicillin for, *1970*: Sept., 1114
tetracyclines for, *1970*: Sept., 1179
Streptokinase, for pulmonary embolism, *1970*: March, 369
Streptomycin, allergic reactions to, incidence of, *1970*: Jan., 63
dosage, *1970*: Sept., 1164
pediatric, *1970*: Sept., 1166
for bacterial endocarditis, *1970*: Sept., 1089
present status of, *1970*: Sept., **1161–1172**
recommended use against various organisms, *1970*: Sept., 1162
thrombocytopenia induced by, *1972*: Jan., 66
toxic reactions, *1970*: Sept., 1164, 1166
Streptonigrin, *1972*: May, 734
Stress ulcer, in intensive care unit, *1971*: Sept., 1280, 1284
Stroke. See *Cerebrovascular disease*.
Stuart factor (X), coagulation and, *1972*: Jan., 98
Stypven time test, *1970*: July, 895
Subclavian vein catheterization, for intravenous hyperalimentation, *1970*: May, 578
Subphrenic abscess, and prolonged fever, *1970*: March, 385
Sudden cardiac death, prevention and treatment, *1972*: May, **625–631**
Sulfinpyrazone, in preventing transient ischemic episodes, *1972*: Nov., 1294
Sulfisoxasole (Gantrisin), anticoagulants and, *1972*: Jan., 257
blood glucose level and, *1971*: July, 927
for urinary tract infections, *1970*: Sept., 1079
Sulfonamides, for urinary tract infections, *1970*: Sept., **1077–1080**; *1971*: Nov., 1450, 1452
dosage, *1970*: Sept., 1079
long-term therapy in children, *1970*: Sept., 1080
resistance of gonococcus to, *1972*: Sept., 1134
thrombocytopenia induced by, *1972*: Jan., 66
toxic reactions, *1970*: Sept., 1078

Sulfonylureas, hypoglycemia from, *1970*: March, 536
in diabetes mellitus, *1971*: March, 300
evaluation, *1971*: July, 1073–1074
Sulfose. See *Trisulfapyrimidines*.
Sulzberger-Chase phenomenon, *1972*: March, 396
Superinfection, during antibiotic therapy, *1970*: Sept., 1170
microbial, *1971*: March, 473
with lincomycin, *1970*: Sept., 1299
with tetracyclines, *1970*: Sept., 1183
Suprainfection, microbial, recognition and management, *1971*: March, **471–483**
Surgery, excessive fibrinolytic activity and, *1972*: Jan., 164
for chronic pancreatitis, *1970*: March, 488–490
for hyperparathyroidism, *1970*: March, 525
for peptic ulcer disease, *1971*: March, 313
hemorrhage in, *1972*: Jan., **207–219**
infection with, ampicillin for, *1970*: Sept., 1153
intensive care after, *1971*: Sept., 1331–1352
nutritional support in, *1970*: Nov., **1367–1381**
methods, *1970*: Nov., 1375–1381
Surgical patient, diabetic, insulin therapy in, *1971*: July, 871
management, *1971*: July, **939–945**
Susceptibility factors. See *Antigen(s), transplantation*.
Sweating, diabetes mellitus and, *1971*: July, 1004
Swiss-type agammaglobulinemia, *1970*: March, 288
Sydenham's chorea, *1972*: Nov., 1324
Syme's amputation, *1971*: July, 1053
Symmetrel. See *Amantadine*.
Sympathectomy, in diabetic vascular disease, *1971*: July, 1049
Syndrome. See specific syndrome.
Syphilis. See also *Venereal disease*.
clinical manifestations, *1972*: Sept., 1161–1166
congenital, *1972*: Sept., **1151–1160**
serologic tests for, *1972*: Sept., 1157–1158
control of, problems in, *1972*: Sept., 1081–1084
diagnosis and treatment, *1972*: Sept., **1161–1174**
experimental vaccine for, *1972*: Sept., **1217–1220**
in pregnancy, *1972*: Sept., **1151–1160**
incidence, in U.S., *1972*: Sept., 1073–1081
worldwide, *1972*: Sept., 1057–1059, 1061
penicillins for, *1970*: Sept., 1091
serodiagnosis of, *1972*: Sept., **1145–1150**, 1168–1171
tests for, nontreponemal, *1972*: Sept., 1146–1147
in pregnancy, *1972*: Sept., 1154
Syphilis (*Continued*)
tests for, treponemal, *1972*: Sept., 1147–1149
in pregnancy, *1972*: Sept., 1154
tetracyclines for, *1970*: Sept., 1180
treatment of, *1972*: Sept., 1171–1173
vs. herpes genitalis, *1972*: Sept., 1184, 1187–1188
Systemic lupus erythematosus. See *Lupus erythematosus, systemic*.

T LYMPHOCYTE. See *Lymphocyte, thymus-dependent*.
T_3 resin uptake test, factors in interpretation, *1970*: Jan., 118
Tamponade, cardiac, intensive care management, *1971*: Sept., 1311
pericardial, in uremia, *1970*: March, 415
Tanned red cell agglutination test, for thyroid autoantibodies, *1970*: Jan., 120
Tardive dyskinesia, *1972*: Nov., 1334
Teeth, development, nutrition and, *1970*: Nov., 1556–1559
discolored, in children, due to tetracyclines, *1970*: Sept., 1183
Temperature, in central nervous system disease, *1971*: Sept., 1245
in hypothyroidism, *1972*: July, 874
monitoring, equipment for, *1971*: Sept., 1116
for intensive care, *1971*: Sept., 1152
Temporal arteritis, *1972*: Nov., 1264
Tendons, thickening, in hyperlipoproteinemia, *1970*: Nov., 1388, 1389
Terminal ileitis. See *Regional enteritis*.
Test(s), bleeding time, *1970*: July, 890; *1972*: Jan., 35
in von Willebrand's disease, *1972*: Jan., 276–277
blood, in Burkitt's lymphoma, *1971*: May, 764–765
nuclear medicine and, *1971*: May, 555
blood urea nitrogen, *1971*: Jan., 236
capillary fragility, *1970*: July, 890
clot retraction, *1972*: Jan., 36
for fibrinolytic disorders, *1972*: Jan., 167
clotting factor, deficiencies, *1970*: July, 896
coagulation, *1970*: July, 893–897
prior to surgery, *1972*: Jan., 208
colony inhibition, *1971*: May, 775; *1972*: March, 487
complement fixation, in drug-induced thrombocytopenia, *1972*: Jan., 73
cytotoxicity, in malignant disease, *1972*: March, 484–487
euglobulin lysis time, for fibrinolytic disorders, *1972*: Jan., 168
for acute renal failure, *1971*: Jan., 124
for antigen-reactive cell, *1972*: March, 297
for disseminated intravascular coagulation, *1972*: Jan., 184–186
for fibrinolytic disorders, *1970*: July, 896; *1972*: Jan., 167, 168

Test(s) (*Continued*)
for gonorrhea, *1972*: Sept., 1068
for hyperlipidemia, *1970*: July, **1029–1035**
for idiopathic thrombocytopenic purpura, *1972*: Jan., 54–56
for immunity to malignant disease, *1972*: March, 484–492
for syphilis, *1972*: Sept., **1145–1150**, 1168–1171
for urinary pigments, *1972*: Nov., 1235
glucose tolerance, in pregnancy, *1971*: July, 951, 961
interpretation, *1971*: July, 796–801
age and, *1971*: July, 835–846
hemagglutination-inhibition, *1972*: March, 356
histocompatibility, *1971*: Jan., 196; *1972*: March, 341–343, 403–408
immunofluorescence, indirect, *1971*: May, 764
in celiac disease, *1970*: May, 653
in Cushing's syndrome, *1970*: July, 1062
in evaluation of medical education, *1970*: May, 598
in hyperosmolar hyperglycemic nonketotic diabetic coma, *1970*: May, 685
in hyperparathyroidism, *1970*: March, 519; July, 1062
in megaloblastic-macroovalocytic anemias, *1970*: May, 632–640
in metabolic bone disease, *1970*: July, **1061–1070**
in osteodystrophy, renal, *1970*: July, 1062
in osteomalacia, *1970*: July, 1062
in osteoporosis, primary, *1070*: July, 1062
in Paget's disease, *1970*: July, 1062
in pancreatitis, chronic, *1970*: March, 482–484
in pulmonary embolism, *1970*: March, 365
in thyroid disorders, *1970*: July, 1043
iron tolerance, oral, *1970*: July, 911
isoenzyme, in alcoholic muscle disease, *1970*: May, 726
lymphocyte cytotoxicity, *1971*: May, 775
microcytotoxicity, *1972*: March, 406
Murphy-Pattee, for thyroxine, *1970*: July, 1044
Ouchterlony, *1971*: May, 765
partial thromboplastin time, *1970*: July, 894
phenolsulfonphthalein excretion, *1971*: Jan., 235
plaque, *1971*: May, 775
plasma clot time, *1970*: July, 894
platelet function, *1970*: July, 891; *1972*: Jan., 35–38
prothrombin consumption, *1970*: July, 896
prothrombin time, *1970*: July, 895
Quick, *1972*: Jan., 237
renal concentration, *1971*: Jan., 233
Schilling, *1971*: May, 556
serial thrombin time, in disseminated intravascular coagulation, *1970*: May, 559

Test(s) (*Continued*)
serum, creatinine, *1971*: Jan., 237
iron and iron-binding capacity, *1970*: July, 909
uric acid, *1971*: Jan., 238
skin, antigen hypersensitivity, *1972*: March, 324
for cancer, *1971*: May, 775
for penicillin allergy, *1970*: July, **997–1007**
Stypven time, *1970*: July, 895
tanned red cell agglutination, for thyroid autoantibodies, *1970*: Jan., 120
thromboplastin generation, *1970*: July, 896
thyroid function, *1970*: July, **1037–1047**
methods, advantages, and disadvantages, *1970*: July, 1044–1045
thyrotropin injection, *1972*: July, 892
tolbutamide response, age and, *1971*: July, 844
transplantation antigens, *1970*: Jan., 46–52
triiodothyronine suppression, *1972*: July, 842
triiodothyronine uptake, *1972*: July, 854–858
urea and creatinine clearance, *1971*: Jan., 238
urine, *1971*: Jan., **243–266**
screening, in infants and children, *1971*: Nov., **1457–1471**
Testes, failure of, radioimmunoassay of gonadal hormones in, *1970*: July, 1056
Testosterone propionate, *1971*: May, 684–693
Tetracyclines, *1970*: Sept., **1173–1186**
allergic reactions to, incidence of, *1970*: Jan., 63
fluorescence of, and tests for malignancy, *1970*: Sept., 1177
for syphilis, *1972*: Sept., 1171
in pregnancy, *1972*: Sept., 1156
for urinary tract infection, *1971*: Nov., 1450
inactivation of, *1970*: Sept., 1175
major analogues, *1970*: Sept., 1174
preparations and routes of administration, *1970*: Sept., 1183
spectrum of activity, *1970*: Sept., 1177–1180
superinfections, *1970*: Sept., 1183
toxic reactions, *1970*: Sept., 1181–1183
Thayer-Martin culture, in asymptomatic gonorrhea, *1972*: Sept., 1127
Thephorin. See *Phenindamine*.
Thiazide(s), for gout, *1970*: March, 432
hypercalcemia and, *1972*: July, 947
6-Thioguanine, *1971*: May, 684–693
Thiotepa, *1971*: May, 684–693
Thorax, surgery of, intensive care after, *1971*: Sept., **1301–1313**
Thrombasthenia, *1972*: Jan., 41–43. See also *Platelets, function, disorders*.
Thrombin, coagulation and, *1972*: Jan., 97
Thrombocytopathy, *1972*: Jan., 38–41. See also *Platelets, function, disorders*.

Thrombocytopenia, drug-induced, *1972*: Jan., **65–79**
platelet transfusion for, *1972*: Jan., 87
hereditary, *1972*: Jan., 43–44
idiopathic (immunologic) vs. other types, *1972*: Jan., 48, 49
platelet transfusion for, *1972*: Jan., 85, 87
thrombocytolytic vs. idiopathic (immunologic), *1972*: Jan., 49
thrombocytopathic, *1972*: Jan., 43
uremia and, *1972*: Jan., 223
Thrombocytopoiesis, ineffective, vs. thrombocytopenic purpura, *1972*: Jan., 48, 49
Thromboembolism, oral contraception and, *1970*: Jan., 168
Thromboendarterectomy, in diabetic vascular disease, *1971*: July, 1049
Thrombophlebitis, pelvic, and prolonged fever, *1970*: March, 391
Thromboplastin(s), coagulation and, *1972*: Jan., 98
Thromboplastin generation test, *1970*: July, 896
Thrombosis, arterial vs. venous, *1972*: Jan., 235–236
venous, intensive care after, *1971*: Sept., 1212
Thrush, nystatin for, *1970*: Sept., 1335
Thymectomy, is myasthenia gravis, *1972*: March, 521
Thymoma, autoimmunity and, *1972*: March, 329
Thymoma-agammaglobulinemia, *1970*: March, 297
Thymus, aplasia, *1970*: March, 286
immunologic aspects, *1972*: March, 296, 326
treatment by transfer of immunity, *1972*: March, 471
function, *1970*: March, 281; *1972*: March, 307, 310, 319–321
hyperplasia, autoimmunity and, *1972*: March, 329
immunologic deficiency disorders and, *1972*: March, 326–327
in development of immune system, *1972*: March, 319
tumors, autoimmunity and, *1972*: March, 329
Thyroid active substances, side-effects, *1970*: Nov., 1612
Thyroid gland, autoantibodies, tanned red cell agglutination test for, *1970*: Jan., 120
disorders, autoimmunity and, *1970*: Jan., 120
current concepts in management of, *1970*: Jan., **117–130**
diagnosis, laboratory tests in, *1970*: July, 1037–1047
problems in, *1972*: July, **841–848**
glucose intolerance and, *1971*: July, 1062
hypertension and, *1971*: Jan., 25
intensive care for, *1971*: Sept., 1322–1324
Thyroid gland (*Continued*)
disorders, lipid disturbances in, *1972*: July, 1014–1016
neurologic complications, *1972*: July, 1030–1033
function, lithium carbonate and, *1972*: May, **681–686**
oral contraception and, *1970*: Jan., 166
tests and scans, *1971*: May, 553
factors in interpretation, *1970*: Jan., 117–118
methods, advantages, and disadvantages, *1970*: July, 1044–1045
principles, *1970*: July, 1041–1042
needle biopsy, in Hashimoto's thyroiditis, *1972*: July, 894
physiology, *1972*: July, 841
subtotal resection, for exophthalmic goiter, *1970*: Jan., 126
Thyroid hormones, assay of, *1972*: July, **861–869**
circulating, concentration of, assay of, *1972*: July, 843
deficiency, in children, clinical manifestations, *1972*: July, **871–884**
osteoporosis and, *1970*: Jan., 148–149
plasma protein interaction, measurement of, *1972*: July, **849–860**
production ratios, abnormal, *1972*: July, 845
transport, *1970*: July, 1039–1041; *1972*: July, 841
Thyroiditis, and prolonged fever, *1970*: March, 391
Hashimoto's, *1972*: July, **885–896**
Thyrotoxicosis. See also *Hyperthyroidism*.
calcium balance in, *1970*: Nov., 1482
T_3, *1972*: May, 721–722
tremor of, *1972*: Nov., 1367
Thyrotropin, excess, in Hashimoto's thyroiditis, *1972*: July, 887, 892
tests for, *1970*: July, 1044–1045
Thyrotropin injection test, *1972*: July, 892
Thyroxine, abnormalities, metabolic changes in, *1970*: Nov., 1480
free, index, *1972*: July, 858
saturation and adsorption on charcoal, as screening test, *1972*: July, 852–854
serum, measurement of, *1970*: Jan., 118–119; July, 1044
Thyroxine-binding proteins, anomalies, *1972*: July, 844–845
measurement, *1972*: July, **849–860**
Tissue. See also specific types.
integrity, nutrition and, *1970*: Nov., 1498
Tissue typing, *1970*: Jan., 46–52
and tissue immunity, *1970*: Jan., **43–58**
Tofranil. See *Imipramine*.
Togavirus encephalitis, *1972*: Nov., 1393–1398
Tolbutamide (Orinase), anticoagulants and, *1972*: Jan., 257
for diabetes mellitus, evaluation and precautions, *1971*: July, 1073–1074
skin reactions, *1971*: July, 1026
thrombocytopenia induced by, *1972*: Jan., 66

Tolbutamide response test (TRT), intravenous, age and, *1971*: July, 844
Tolerance, immunologic, *1972*: March, 459
MLC reactivity as measure of, *1972*: March, 343
Tonsillitis, penicillins for, *1970*: Sept., 1086
Torsion dystonias, *1972*: Nov., 1328–1333
Torticollis, spasmodic, *1972*: Nov., 1329
Total body water, diuretics and, *1971*: March, 362
Tourniquet test, of platelet function, *1972*: Jan., 36
Trace elements, caries-inhibiting, *1970*: Nov., 1558
Trace minerals, current concepts, *1970*: Nov., **1509–1542**
Tracheostomy, evaluation of, *1971*: Sept., 1220–1223
Trancylpromine (Parnate), blood glucose level and, *1971*: July, 927
for parkinsonism, *1972*: Nov., 1387
Tranquilizers, blood glucose level and, *1971*: July, 927
in medical practice, *1971*: March, **485–494**
thrombocytopenia induced by, *1972*: Jan., 66
Transfer factor, *1971*: May, 774; *1972*: March, 468–470
Transfusion, for disseminated intravascular coagulation, *1972*: Jan., 187
incompatible, disseminated intravascular coagulation and, *1972*: Jan., 181
massive, coagulation defect after, *1972*: Jan., 214
thrombocytopenia after, *1972*: Jan., 88
plasma, for von Willebrand's disease, *1972*: Jan., 282
platelets, *1972*: Jan., **81–94**
dosage, *1972*: Jan., 89–91
immunologic aspects, *1972*: Jan., 91–92
in idiopathic thrombocytopenic purpura, *1972*: Jan., 58
Transient global amnesia, cerebrovascular disease and, *1970*: March, 354
Transient ischemic attacks, cerebrovascular disease and, *1970*: March, 351
therapy for, *1970*: March, 356
"Transplant lung," *1970*: Jan., 89
Transplantation. See also under specific organs and tissues.
antilymphocyte globulin in, *1972*: March, 424–428
bone marrow, rejection reaction in, *1972*: March, 436–438
donor selection in, *1970*: Jan., 79–81; *1971*: Jan., 196–200
early studies of, *1970*: Jan., 44
genetic locus in man, *1970*: Jan., 52
heart, antilymphocyte globulin in, *1972*: March, 427
hemodynamic observations after, *1970*: Jan., **107–113**
manifestations of rejection after, *1970*: Jan., 110–111
Transplantation (*Continued*)
hemorrhage and, *1972*: Jan., 212
HL-A antigens in, *1972*: March, **403–417**
immunity and, *1970*: Jan., 44–45
immunologic aspects, future of, *1972*: March, **453–464**
immunologic enhancement in, *1972*: March, 462
immunosuppression in, *1971*: Jan., 200–201
kidney, hypercalcemia and, *1972*: July, 961, 970–973
immunologic considerations, *1971*: Jan., **193–204**
patient selection and management in, *1970*: Jan., **75–94**
organ preservation for, *1971*: Jan., **205–212**
rejection reactions, graft vs. host, *1972*: March, 466
immunologic aspects, *1972*: March, 305–317, 453–455
minimizing, *1972*: March, 456, 467
pathophysiology of, *1971*: Jan., 194
Transplantation antigens. See under *Antigens*.
Trauma, dementia with, *1972*: Nov., 1416
intensive care after, *1971*: Sept., **1171–1181**
to liver, intensive care after, *1971*: Sept., 1285
Tremor, *1972*: Nov., 1337–1340
differential diagnosis of, *1972*: Nov., 1363–1375
Treponema pallidum, altered antibiotic and chemotherapeutic sensitivity, *1972*: Sept., 1062
identification, in darkfield microscopy, *1972*: Sept., 1167
serologic, *1972*: Sept., **1145–1150**
Triacetyloleandomycin, allergic reactions to, incidence of, *1970*: Jan., 63
Triazure. See *Azaribine*.
Trichomonas vaginalis, *1972*: Sept., **1203–1209**
leukorrhea of, *1972*: Sept., 1110
Tricuspid valve, stenosis of, complicating heart failure, *1970*: March, 319
Tridione. See *Trimethadione*.
Trifluoromethyl-2′-deoxyuridine, *1971*: May, 697
Triglycerides, atherosclerotic cardiovascular disease and, *1970*: Nov., 1450
medium chain, in surgical nutrition, *1970*: Nov., 1375
metabolism, abnormal, obesity and, *1970*: Nov., 1535
clinical evaluation, *1970*: Nov., 1540
in adipose tissue, *1970*: Nov., 1539
plasma, in diagnosis of hyperlipidemia, *1971*: March, 403
plasma transport, physiology of, *1970*: Nov., 1384–1386
serum, tests for, *1970*: July, **1029–1035**
Trihexyphenidyl (Artane), in parkinsonism, *1972*: Nov., 1390

Triiodothyronine, assay of, *1972*: July, **861–869**
clinical applications, *1972*: July, 867
chemical determination, *1972*: July, 864–865
radioimmunoassay, *1972*: July, 861–863
suppression test, *1972*: July, 842
uptake tests, *1972*: July, 854–858
Trimethadione (Tridione), for convulsive seizures, *1972*: Nov., 1227
thrombocytopenia induced by, *1972*: Jan., 66
Trimethaphan, for hypertensive emergencies, *1971*: March, 331
Trimethaphan camsylate (Arfonad), for pulmonary edema, *1970*: March, 322
Tripelennamine (Pyribenzamine), blood glucose level and, *1971*: July, 927
thrombocytopenia induced by, *1972*: Jan., 66
Trisulfapyrimidines (Sulfose), for urinary tract infections, advantages of, *1970*: Sept., 1078
Tropical sprue. See *Sprue, tropical.*
TRT. See *Tolbutamide response test.*
Tuberculosis, diabetes mellitus and, *1971*: July, 935
hepatic, *1970*: March, 381
miliary, without radiologic evidence, *1970*: March, 380
prolonged fever and, *1970*: March, 380–382
pulmonary, without radiologic evidence, *1970*: March, 381
treatment, ethambutol in, *1970*: Sept., 1320–1324
Tularemia, antimicrobials for, *1970*: Sept., 1192
Tumor(s), alpha-fetoprotein in, *1970*: May, **797–803**
catecholamine-secreting, *1971*: Jan., 27–31
chromosomal abnormalities in, *1970*: July, 1024–1025
gastrointestinal, cell proliferation and differentiation, *1971*: May, **601–612**
hormone-dependent, diagnosis and treatment, *1971*: May, 616
malignant, antilymphocyte serum and, *1972*: March, 424
as cause of hypercalcemia, *1972*: July, 943–944
immunity, inhibition of, *1972*: March, 494
immunologic aspects, *1972*: March, 507–508
lymphocyte in, *1972*: March, 305–317
immunologic deficiency diseases and, *1970*: March, 298–299
immunotherapy in, *1972*: March, 475–476
localization of, radionuclides in, *1971*: May, 557
viruses and, *1972*: March, 354
vs. hyperparathyroidism, *1970*: Jan., 133
prolonged fever and, *1970*: March, 386–390
Tumor immunology, future of, *1972*: May, **801–836**
Tumor-specific antibodies, disappearance with metastases, *1972*: March, 492
tests for, *1972*: March, 484–490
Turner's syndrome, chromosomal abnormality in, *1970*: July, 1018
Typhoid fever, chloramphenicol for, *1970*: Sept., 1191
L-Tyrosine, for parkinsonism, *1972*: Nov., 1380
Tyrothricin, *1970*: Sept., 1291

ULCER, gastrointestinal, complicating severe illness, *1971*: Sept., **1277–1284**
diet and, *1970*: Nov., 1357–1359
peptic. See *Peptic ulcer.*
Ulcerative colitis, diet in, *1970*: Nov., 1361
intravenous hyperalimentation for, *1970*: May, 585
Ultracentrifugation, in study of plasma lipoproteins, *1970*: Jan., 153
University Group Diabetes Program, report of study, *1971*: July, **1065–1075**
University of Chicago medical school system, *1970*: Jan., **35–40**
Urea, platelet function and, in uremia, *1972*: Jan., 227
Urea cycle, protein metabolism and, *1971*: Nov., 1382
Urea nitrogen, blood, glomerular filtration rate and, *1971*: March, 343
Uremia, bleeding in, *1972*: Jan., **221–233**
chronic, dialysis vs. transplantation for, *1970*: Jan., 77
dietary management, *1970*: March, 425–428; *1971*: March, 352, 516; Nov., 1386
calcium metabolism in, *1970*: March, 421–425; *1971*: Nov., 1387–1390
glucose intolerance in, *1971*: Nov., 1391
manifestations and treatment, *1971*: March, 350–355
mental disturbance of, *1972*: Nov., 1413
metabolic abnormalities in, *1971*: Nov., **1381–1396**
pathogenesis and treatment, newer concepts in, *1970*: March, **411–430**
polyneuritis with, *1972*: Nov., 1316
protein metabolism and, *1971*: Nov., 1381–1387
protein restriction in, *1970*: March, 425–428
red cell 2,3-diphosphoglycerate and, *1970*: May, 736
Uremic syndrome, gastrointestinal abnormalities in, *1971*: March, 351
hemolytic, *1971*: Nov., 1412
Urethra, gonococcal infection of, complications of, *1972*: Sept., **1115–1125**
Urethritis, nonspecific, *1972*: Sept., **1193–1202**
incidence, *1972*: Sept., 1060, 1061
treatment of, *1972*: Sept., 1199–1201
Uric acid lithiasis, *1972*: July, 983–984

Uridine phosphate, synthesis, defect in, *1970*: Nov., 1443
Urinalysis, *1971*: Jan., **243–266**
dipstick techniques, *1971*: Jan., 259–263
Urinary tract, infection, *1970*: March, **397–410**
ampicillin for, *1970*: Sept., 1151
chloramphenicol for, *1971*: Nov., 1450
cycloserine for, *1971*: Nov., 1451
diagnosis and treatment, *1971*: Nov., **1439–1456**
erythromycin for, *1970*: Sept., 1208
gentamicin for, *1970*: Sept., 1313
in diabetics, *1971*: July, 933
pregnant, *1971*: July, 966
in infants and children, urine findings in, *1971*: Nov., 1467
in surgical intensive care units, *1971*: Sept., 1341–1344
nalidixic acid for, *1970*: Sept., **1347–1350**
polymyxins for, *1970*: Sept., 1264
sodium colistimethate for, *1970*: Sept., 1271
sulfonamides for, *1970*: Sept., **1077–1080**; *1971*: Nov., 1450, 1452
tetracyclines for, *1970*: Sept., 1180
obstruction, causing chronic renal failure, *1971*: Jan., 139
clinical aspects, *1971*: Nov., **1417–1427**
complicating heart failure, *1970*: March, 319
management, acute, *1971*: Sept., 1255
stones, diagnosis and treatment, *1972*: July, **977–988**
Urine, bacteria in. See *Bacteriuria*.
collection of, clean-voided, *1971*: Jan., 254–256
culture techniques, *1971*: Nov., 1441
enzymes, quantitative determination, *1971*: Nov., **1493–1508**
examination, in urinary tract infection, *1970*: March, 399
in urinary tract obstruction, *1971*: Nov., 1418–1420
myoglobins in, clinical aspects, *1972*: Nov., **1233–1256**
preservation of specimens, *1971*: Jan., 259
tests, for cancer, *1971*: May, 613–622
sediment, special stains in, *1971*: Jan., 252
screening, pediatric, *1971*: Nov., **1457–1471**
Urogenital tract, nonspecific infection of, *1972*: Sept., **1193–1202**
Urography, for diagnosis of renal hypertension, *1971*: Nov., 1431
Urokinase, for pulmonary embolism, *1970*: March, 371
Uropathy, obstructive, clinical aspects, *1971*: Nov., **1417–1427**
Uveitis, anterior, nonspecific urethritis and, *1972*: Sept., 1198
VACCINIA, treatment by transfer of immunity, *1972*: March, 473
vs. herpes genitalis, *1972*: Sept., 1184, 1186
Vaginitis, monilial, in pregnant diabetics, *1971*: July, 967
senescent, *1972*: May, 792, 798
Valium. See *Diazepam*.
Valves, heart. See under *Heart* and names of valves.
Vancomycin, *1970*: Sept., **1277–1281**
allergic reactions to, incidence, *1970*: Jan., 64
Vanillylmandelic acid, urinary, in neuroblastoma, *1971*: May, 614
Vascular disease, fasciotomy for, indications, *1971*: Sept., 1211
hyperlipidemia and, *1970*: May, 660
in diabetics, control of hyperglycemia and, *1971*: July, **889–897**
prospective study, *1971*: July, **1065–1075**
peripheral, *1971*: July, **1045–1055**
prophylaxis, diet in, *1971*: July, **877–887**
surgery for, *1971*: July, 1048
intensive care for, *1971*: Sept., **1207–1215**
microscopic, in diabetics, *1971*: July, **847–860**, 894
occlusive, anticoagulation and, *1972*: Jan., 243–244
thermography in, *1970*: May, 612
Vascular reactions, inflammatory, chemical mediators of, *1972*: March, **541–556**
Vasoactive amines, in acute inflammatory reactions, *1972*: March, 544
Vasoconstriction, in migraine headaches, *1972*: Nov., 1258
Vasopressin intoxication, hypertension and, *1971*: Jan., 24
Vater, ampulla of, retrograde cannulation of, *1972*: May, **781–788**
Vein(s), insufficiency, chronic, vs. intractable heart disease, *1970*: March, 314
occlusion, massive, management, *1971*: Sept., 1212
Vena cava, interruption, pulmonary embolism and, *1970*: March, 367
obstruction, vs. intractable heart disease, *1970*: March, 315
Venereal disease. See also specific disorders.
control of, professional education and, *1972*: Sept., **1101–1104**
gonococcal, complications of, *1972*: Sept., **1115–1125**
in military, *1972*: Sept., **1087–1100**
incidence, in U. S., *1972*: Sept., **1073–1086**
increase in, causes of, *1972*: Sept., 1060–1066
penicillins for, *1970*: Sept., 1090
prophylaxis in, *1972*: Sept., **1211–1216**
symposium on, *1972*: Sept., **1057–1220**
world view of, *1972*: Sept., **1057–1071**

Venezuelan equine encephalitis, *1972*: Nov., 1395
Ventilation, assisted, for status asthmaticus, *1970*: March, 502
disturbances of, hypoxia due to, *1970*: May, 618
mechanical, *1971*: March, 451
therapy, in central nervous system disease, *1971*: Sept., 1243
in intensive care units, *1971*: Sept., 1226
Ventricular arrhythmias, in ambulatory patients, *1972*: May, 615–624
Ventricular septum, defects, cardiac catheterization in, *1970*: July, 975–976
Vertebral-basilar insufficiency, cerebrovascular disease and, *1970*: March, 354
Vibrio infections, choice of therapy for, *1970*: Sept., 1163
Vinblastine, thrombocytopenia induced by, *1972*: Jan., 66
Vinca alkaloids, in cancer therapy, dosage and side effects, *1971*: May, **683–701**
thrombocytopenia induced by, *1972*: Jan., 66
Vincristine (Oncovin), in cancer therapy, *1971*: May, 684–693
in dermatologic disorders, *1972*: May, 735
in leukemia, *1971*: May, 586, 590
neurologic complications, *1971*: May, 642
thrombocytopenia induced by, *1972*: Jan., 66
Viomycin, *1970*: Sept., **1325–1326**
Viral hepatitis, *1970*: March, **445–466**
Australia antigen and, *1970*: May, **805–817**
uncomplicated acute, treatment, *1971*: March, 374
Viral infection(s), complicating carcinoma, *1971*: May, 742
diarrhea and, *1970*: March, 446–447
immunologic aspects, *1972*: March, 327, **353–370**
neurologic disorders and, *1972*: March, 515
of kidney, *1971*: Jan., **89–106**
persistent and latent, *1971*: Jan., 99–100
Virus(es), as cause of carcinoma, *1971*: May, 656, 763; *1972*: March, 354, 365–367
connective tissue disorders and, *1972*: March, 367–368
encephalitis due to, *1972*: Nov., **1393–1404**
Goodpasture's syndrome and, *1971*: Jan., 93
Vision, See also *Eyes*.
blurred, ethambutol and, *1970*: Sept., 1319
insulin and, *1971*: July, 874
disturbed, in diabetes mellitus, *1971*: July, **989–999**
Vital signs, interpretation, sources of error, *1971*: Sept., 1242
Vitamin(s), deficiency, in liver disease, *1970*: Nov., 1459–1461
tooth development and, *1970*: Nov., 1557
enzymatic disorders and, *1970*: Nov., 1432
Vitamin B_6-dependent convulsive disorder, management, *1970*: Nov., 1444
Vitamin B_{12}, absorption, tests, in megaloblastic-macroovalocytic anemias, *1970*: May, 637
assay, in megaloblastic-macroovalocytic anemias, *1970*: May, 633
deficiency, etiology and pathogenesis of, *1970*: May, 640
mental disturbance with, *1972*: Nov., 1414
for methylmalonic acidemia, *1970*: Nov., 1444
Vitamin C, deficiency, osteoporosis and, *1970*: Jan., 145
Vitamin D, in renal osteodystrophy, *1971*: Nov., 1387–1390
intoxication, hypercalcemia and, *1972*: July, 948
therapy, for hypercalcemia, *1972*: July, 965
Vitamin D-dependent rickets, dietary management, *1970*: Nov., 1445
Vitamin K, in viral hepatitis, *1970*: Nov., 1462
Vitiligo, *1972*: July, 1044
diabetes mellitus and, *1971*: July, 1027
VLDL. See *Lipoprotein(s), very low density.*
VM-26, in cancer therapy, *1971*: May, 698
Von Willebrand's disease, *1972*: Jan., **275–284**
diagnosis, *1970*: July, 898
Vulvovaginitis, candidal, nystatin for, *1970*: Sept., 1336
gonococcal, treatment, *1972*: Sept., 1112

WALDENSTRÖM'S macroglobulinemia, electrophoresis in diagnosis, *1970*: July, 923
Water, balance, in hyperglycemia, *1970*: May, 690
body. See also *Fluids and electrolytes.*
total, diuretics and, *1971*: March, 362
deficiency, in chronic renal failure, management, *1971*: March, 346
Weanling diarrhea, *1970*: Nov., 1501–1503
Wegener's granulomatosis, *1971*: Nov., 1407
Weight, monitoring, for intensive care, *1971*: Sept., 1150–1152
body fat and, *1970*: Nov., 1369
Wernicke-Korsakoff syndrome, dementia of, *1972*: Nov., 1413

Western equine encephalitis, *1972*: Nov., 1395
WHDA syndrome, *1970*: May, 567
Whipple's disease, jejunal biopsy in, *1970*: July, 855, 856
White House Conference on Food, Nutrition and Health, recommendations, *1970*: Nov., 1592–1597
Wilms' tumor, treatment, *1971*: May, 685, 756
Wilson's disease, *1972*: Nov., 1335
  dementia of, *1972*: Nov., 1413
  tremor of, *1972*: Nov., 1372
Wiskott-Aldrich syndrome, *1970*: March, 292; *1972*: Jan., 43
  bone marrow transplantation in, *1972*: March, 445
  immunodeficiency in, *1972*: March, 328
  susceptibility to virus infection in, *1972*: March, 361
  treatment, *1972*: March, 473
Wound(s), healing, nutrition and, *1970*: Nov., 1498
    zinc and, *1970*: Nov., 1518, 1519
  infections, in surgical intensive care units, *1971*: Sept., 1337–1341
XANTHELASMA, in hyperlipoproteinemia, *1970*: Nov., 1388
Xanthinuria, *1972*: July, 982
Xanthoma, eruptive, in hyperlipoproteinemia, *1970*: Nov., 1387
  in broad-betalipoprotein disease, *1970*: Nov., 1389, 1390
Xanthurenic aciduria, management, *1970*: Nov., 1445
Xenon arc photocoagulation for diabetic retinopathy, *1971*: July, 996
X-ray. See *Radiation; Roentgen.*
d-Xylose excretion, in celiac disease, *1970*: May, 653

ZARONTIN. See *Ethosuximide.*
Zieve's syndrome, hyperlipemia and, *1971*: March, 407
Zinc, deficiency, *1970*: Nov., 1517
  nutritional significance, *1970*: Nov., 1514–1520
  toxicity, *1970*: Nov., 1520
Zollinger-Ellison syndrome, diarrhea in, *1970*: May, 573
Zyloprim. See *Allopurinol.*